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α-synuclein is an abundant and conserved presynaptic brain protein (Uversky 2007). It 
has been received extensive attention since its aggregation was identified as the main 
component of Lewy bodies and Lewy neurites, which is the pathological hallmark of 
several neurodegenerative diseases, collectively known as synucleinopathies, 
including Parkinson’s Disease (PD) (Uversky 2007). Considerable information has 
been collected about the structural properties and conformational behavior of 
α-synuclein, although the precise function is still under investigation. Metal ions such 
as copper and iron, can accelerate the aggregation and fibrillation of α-synuclein. 
Metal ions may exert their dual physiopathological properties through the interaction 
with α-synuclein, converting protein structure or/and inducing oxidative stress. In this 
study, isothermal titration calorimetry and electron paramagnetic resonance were 
used to determine the metal-binding property of the synuclein proteins, proving the 
presence of four Cu(II) binding sites per molecular of α-synuclein, with the 
coordination modes of 1N3O and 2N2O. Furthermore, α-synuclein has a catalytic 
action on the redox cycling of Cu(II), which was assessed by the application of cyclic 
voltammetry. However, this property is absent on β-synuclein and γ-synuclein, which 
belong to the synuclein family and have been suggested to be the physiological 
regulators of α-synuclein expression. In vivo, immunofluoresence studies revealed 
that Cu(II) increases the aggregates formation in mammalian doperminergic neuron 
cells overexpressing α-synuclein and the PD-associated mutants, while no aggregates 
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Chapter 1. Introduction 
1.1 α-synuclein and its family members  
1.1.1 α-synuclein 
α-synuclein (aS) was first identified as a precursor protein of a peptide termed the 
non-Aβ-component of Alzheimer’s Disease amyloid (NAC), which was discovered 
and isolated during the investigation of the composition of amyloid plaques of patients 
with Alzheimer’s Disease (AD), which is the most common form of dementia (Ueda, 
Fukushima et al. 1993; Weinreb, Zhen et al. 1996). This protein was then proven to be 
a homologue of a protein named synuclein, which was first isolated from the electric 
organ of the Pacific electric ray (Torpedo californica), where it was found in both 
nerve terminals and the nuclear envelope (Maroteaux, Campanelli et al. 1988). aS is a 
highly conserved protein, with at least three isoforms produced in humans by 
alternative splicing (Clayton and George 1998; Beyer 2006). Two of the isoforms 
aS-112 and aS-126, are produced resulting from in-frame deletion of exons 3 and 5, 
respectively (Uversky 2007). Recently, a new isoform aS-98, which lacks exons 3 and 
exons 5, has been identified as a brain-specific splice variant (Beyer, Domingo-Sabat 
et al. 2008). The best-known isoform aS-140, which is the whole and major transcript 
of the protein, is encoded by the human aS gene (SNCA or PARK1) mapping to 
chromosome 4q21.3-q22 (Chen, de Silva et al. 1995). It is a 140 amino acid protein, 
which consists of three distinct regions, namely the amphipathic N-terminal domain 
(residues 1-60), the hydrophobic region (residues 61-95) and the acidic C-terminal 
part (residues 96-140) (Eliezer, Kutluay et al. 2001)(Fig 1.1). The N-terminal domain 
of aS is characterized by four 11-amino acid imperfect repeats with a highly conserved 
hexamer motif (KTKEGV), which is responsible for the lipid binding (Perrin, Woods 
et al. 2000) and α-helical structure formation when associated with lipid micelles 
(Weinreb, Zhen et al. 1996; Davidson, Jonas et al. 1998). NMR studies have revealed 
that this domain of aS bound to lipid-mimicking detergent micelles adopts two 
separate amphipathic helices, which do not appear to interact with each other although 
the hinge region between them probably adopts a well-defined structure (Bussell and 
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Eliezer 2003; Bisaglia, Trolio et al. 2005; Bussell, Ramlall et al. 2005). In addition, 
this domain is thought to be involved in protein-protein interaction (Weinreb, Zhen et 
al. 1996; Davidson, Jonas et al. 1998) and dimerization (Jensen, Hojrup et al. 1997). 
The central hydrophobic region, comprising the NAC sequence, appears to mediate 
the conformational change of aS from random coil to β-sheet (Serpell, Berriman et al. 
2000; el-Agnaf and Irvine 2002) and further to Aβ-like protofibrils and fibrils 
(Conway, Harper et al. 1998; El-Agnaf, Jakes et al. 1998; Hashimoto, Hsu et al. 1998; 
Giasson, Uryu et al. 1999; Narhi, Wood et al. 1999; el-Agnaf and Irvine 2002). This 
part is most likely the amyloidogenic part of aS and is necessary for the aggregation of 
the protein. It shows mild sequence similarity with domains of the Prion protein and 
the β-amyloid peptide (Aβ) crucial for aggregation (El-Agnaf, Bodles et al. 1998). 
Deletion of residues 71-82 within this region prevents aS aggregation in vitro (Bodles, 
Guthrie et al. 2001; Giasson, Murray et al. 2001). The Carboxyl-terminus of aS, 
enriched in acidic residues and prolines, does not associate with either vesicles or 
micelles in solution (Eliezer, Kutluay et al. 2001), however, it is suggested to be 
primarily involved in the solubilization of the high molecular weight complexes (Park, 
Jung et al. 2002). Conversely to the hydrophobic region, this portion shows an 
inhibitory role on the aggregation of aS. Several studies have suggested that 
C-terminal truncated forms of recombinant aS assemble into filaments more readily 
than the full-length wild-type (WT) protein (Crowther, Jakes et al. 1998; Serpell, 
Berriman et al. 2000; Murray, Giasson et al. 2003; Periquet, Fulga et al. 2007). In 
addition, C-terminal part is essential for the chaperon activity of aS. aS could inhibit 
the aggregation of model substrates and protect the catalytic activity of alcohol 
dehydrogenase and rhodanese during heat stress (Kim, Paik et al. 2002) and enzyme 
activity of microbial esterases in vitro (Ahn, Kim et al. 2006), but deletion of the 
C-terminal region led to the abolishment of these chaperon activities. Moreover, 
C-terminal (residues 99-140) portion plays a signal-like role for translocation of aS 
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α-synuclein 
    Amphipathic repeat region                                    acidic region 
N                                                        C                C 
   
   1                                 61    NAC      95                     140 
Lipid binding domain         (non-Aβ-component of       Rich in proline 
                                  AD amyloid)  
 
Fig. 1.1 α-synuclein schematic representation.  
α-synuclein consists of three distinct regions, namely the amphipathic 
N-terminal domain, the hydrophobic region and the acidic C-terminal part. The 
lipid binding domain locates in the N-terminus.  
 
In vivo, aS has been demonstrated to adopt either a highly unstructured free state in the 
cytoplasm or a highly helical lipid-bound state representing the membrane- or synaptic 
vesicle-associated protein fraction (Weinreb, Zhen et al. 1996; Eliezer, Kutluay et al. 
2001). It’s likely that the two conformations are observed in vitro as well. Under 
physiological condition in vitro, aS is characterized as a natively unfolded protein 
without any secondary or tertiary structure (Uversky 2003). However, aS can self 
aggregate when incubated under certain conditions (Uversky, E et al. 2002). 
Meanwhile, aS can interact with a number of ligands and proteins, such as metals and 
enzymes, which might alter its native state conformation and lead to aS adopting 
partially folded conformation (Dev, Hofele et al. 2003). Actually, aS can adopt to a 
series of different conformations depending on the environment due to its remarkable 
conformational plasticity (Uversky 2003). 
 
1.1.2 Subcellular localization of aS 
aS is expressed in a number of neuronal and non-neuronal cell types including cortical 
neurons, dopaminergic neurons, noradrenergic neurons, endothelia cells and platelets 
(Hashimoto, Yoshimoto et al. 1997; Abeliovich, Schmitz et al. 2000; Tamo, Imaizumi 
et al. 2002). In human, aS is predominantly found in the central nervous system (CNS), 
including the cerebral cortex, the hippocampus, the amygdala and the olfactory bulb 
(Maroteaux and Scheller 1991; Iwai, Masliah et al. 1995), notably concentrated in the 
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presynaptic nerve terminals (Iwai, Masliah et al. 1995). It has been estimated that aS 
accounts for as much as 1% of the total protein in soluble cytosolic brain fractions 
(Iwai, Masliah et al. 1995). Recently, aS has also been detected circulating in human 
body fluids in a soluble form (Borghi, Marchese et al. 2000).  
 
1.1.3 Physiological function of aS 
The precise physiological function of aS remains elusive. Nevertheless, many studies 
have demonstrated that aS plays a crucial role in the regulation of membrane lipid 
component, synaptic vesicular turnover, synaptic plasticity, ubiquitin-proteasome 
processing and could act as a molecular chaperon (Dev, Hofele et al. 2003). In 
addition to binding phospholipid membranes and micelles, aS interacts stably with 
synthetic phospholipid vesicles containing negatively charged head groups (Davidson, 
Jonas et al. 1998; Jo, McLaurin et al. 2000; Ramakrishnan, Jensen et al. 2003) and 
biological membranes, such as crude brain vesicles (Jensen, Nielsen et al. 1998), and 
has a profound effect on the integrity of these bilayers, resulting in the formation of 
non-bilayer or small vesicular structures (Madine, Doig et al. 2006). These 
observations suggest that aS is involved in modulating the organization of membrane 
lipid components (Uversky 2007). In addition, it was found that when bound to the 
lipid membrane, monomeric aS can function as an antioxidant preventing the 
oxidation of unsaturated lipid in vesicles via the formation of methionine sulfoxide 
(Zhu, Qin et al. 2006). 
 
In pre-synaptic termini, monomeric aS exists in either free or plasma membrane-, 
vesicle-bound states, which are in an equilibrium (McLean, Kawamata et al. 2000). 
This association with vesicular structure has led to the hypothesis that aS might be the 
regulatory component of synaptic plasticity and this is supported by several studies: aS 
antisense oligonucleotide-treated cultures display a significant reduction in the distal 
pool of synaptic vesicles (Murphy, Rueter et al. 2000). Furthermore, songbird studies 
indicate that aS is specifically upregulated in a discrete population of presynaptic 
terminals of the songbird brain during a period of song acquisition (George, Jin et al. 
1995; Tofaris and Spillantini 2007). Specifically, aS is thought to be implicated in the 
regulation of dopamine (DA) neurotransmission, via the effects on vesicular DA 
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storage (Lotharius, Barg et al. 2002; Lotharius and Brundin 2002) and the inhibitory 
activity on tyrosine hydroxylase (TH), the rate-limiting enzyme in DA biosynthesis 
(Perez, Waymire et al. 2002). Enhanced DA release is detected at nigrostriatal 
terminals in aS knockout mice, in response to paired electrical stimuli (Abeliovich, 
Schmitz et al. 2000). Recent study has also indicated that aS regulates 
catecholaminergic neurotransmission via mediating the activity and surface 
expression of the norepinephrine transporters (NET) in a manner that is dependent on 
interaction with the microtubule cytoskeleton (Jeannotte and Sidhu 2007). Another 
function that could link aS to effects on presynaptic vesicle dynamics and synaptic 
membrane biogenesis is its inhibitory activity on phospholipase D2 (PLD2), a protein 
that hydrolyzes phosphatidylcholine (PC) to phosphatidic acid (PA) (Xia, Rohan de 
Silva et al. 1996; Jenco, Rawlingson et al. 1998). Indeed, besides its ability to bind to 
PLD2, aS appears to interact with many other proteins, including the microtubule 
associated protein Tau, 14-3-3, protein kinase C (PKC) and BAD (Dev, Hofele et al. 
2003). Based on these studies, aS has been suggested to have a profound effect on 
synaptic vesicle formation through regulation of PA metabolism, to anchor 
cytoskeletal component to plasma membrane or lipid vesicles, and to participate in 
apoptotic cell death (Eliezer, Kutluay et al. 2001). Interestingly, aS is suggested to be 
involved in the protection of nerve terminals against injury via cooperation with 
cysteine-string protein (CSP)-α and SNARE proteins on the presynaptic membrane 
interface via a downstream mechanism (Chandra, Gallardo et al. 2005). In addition, 
monomeric aS is implicated in the inhibition of proteasomal activities (Snyder, 
Mensah et al. 2005). 
 
One of the crucial functions of aS is the effect on cell survival and/or susceptibilities to 
certain insults, although the effect is still controversial. In brief, effects seem 
dependent on cell type, the kind of insult applied, and on the aS variant being 
expressed (Dev, Hofele et al. 2003). In some cases, aS acts as a neuroprotective protein. 
For example, da Costa C.A. and Lee M. (2003) have shown that overexpression of aS 
can protect neuronal cells from apoptotic stimuli and can delay cell death induced by 
serum withdrawal (Dexter, Wells et al. 1989; da Costa, Masliah et al. 2003). In other 
cases, aS displays neurotoxicity via inducing apoptosis or accelerating cell death by 
increasing the sensitivity of cells to toxic agents (Dev, Hofele et al. 2003). Expression 
of certain mutant aS forms significantly enhances the sensitivity of different cell types 
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such as PC12 and M17 neuroblastoma cell lines to the toxicity by proteasome 
inhibitors (Stefanis, Larsen et al. 2001; Tanaka, Engelender et al. 2001; Petrucelli, 
O'Farrell et al. 2002). The protective or/and toxic mechanism remains relatively 
obscure. Recent researches have shown that MAP kinase signaling pathway (Iwata, 
Maruyama et al. 2001), c-jun N-terminal kinase stress signaling pathway (Hashimoto, 
Hsu et al. 2002), the NF-kB signaling pathway (Yuan, Jin et al. 2008) and the 
extracellular signal-regulated kinase (ERK) signaling pathway (Hashimoto, 
Takenouchi et al. 2003) have been involved.  
 

















 et al (Paik, Lee et al. 1997; Souza, Giasson et 
al. 2000; Nielsen, Vorum et al. 2001; Uversky, Li et al. 2001; Golts, Snyder et al. 2002; 
Wolozin and Golts 2002; Lowe, Pountney et al. 2004; Binolfi, Rasia et al. 2006; 
Tamamizu-Kato, Kosaraju et al. 2006). This may lead to the hypothesis that aS plays a 
necessary role in the homeostasis of these metals. 
 
1.1.4 Synuclein family 
aS belongs to a class of intrinsically unstructured proteins family, which also includes 
β synuclein (bS), also known as phosphoneuroprotein 14 and γ synuclein (gS), also 
referred to breast cancer-specific gene 1 or persyn (Nakajo, Tsukada et al. 1993; Jakes, 
Spillantini et al. 1994; Iwai, Masliah et al. 1995; Polymeropoulos, Lavedan et al. 1997). 
The human β synuclein gene (SNCB), mapping to chromosome 5q35 (Spillantini, 
Divane et al. 1995), encodes a 134-amino-acid protein, while the human γ synuclein 
(SNCG) (Jakes, Spillantini et al. 1994), located on chromosome 10q23, encodes a 
127-amino-acid protein (Lavedan, Leroy et al. 1998). Concerning the structure of 
these synucleins, bS and gS show a high level of sequence homology to aS (Fig 1.2). 
Among the human family members, bS is 62% identical and 79% similar to aS, gS is 
50% identical and 74% similar to aS, and bS is 47% identical and 66% similar to gS 
(Sung and Eliezer 2006). The bS lacks 11 central hydrophobic residues within the 
middle region compared to aS and gS, while the acidic C-terminal with three 
identically placed tyrosine residues is conserved, which is missing in the gS (Buchman, 
Hunter et al. 1998; Goedert 2001).  
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1.1.5 Localization and structure of bS and gS 
The localization of bS is mostly overlapped with aS, predominantly throughout the 
brain, in the cytoplamic matrix of the presynaptic axon terminals (Nakajo, Shioda et al. 
1994). Within hippocampal neurons, bS co-localizes almost exclusively with 
synaptophysin in presynaptic terminals (Murphy, Rueter et al. 2000). In contrast, gS 
expression is more prevalent in the peripheral nervous system, but it is also expressed 
in the brain, including the substantia nigra (Buchman, Hunter et al. 1998; Lavedan, 
Leroy et al. 1998). Interestingly, it is distributed more widely throughout cell bodies 
and axons within the neuron cytoplasm than aS and bS (Lavedan, Leroy et al. 1998). 
The synucleins have been established to be present in other cell types, like bS in Sertoli 
cells of the testis and gS in the epidermis and in the breast cancer tissue (Nakajo, 
Tsukada et al. 1996; Ninkina, Alimova-Kost et al. 1998; Ninkina, Privalova et al. 
1999).  
 
Unlike aS whose structure and function properties have been extensively studied, 
relatively less investigation has been done to bS and gS. Although all three synucleins 
are expressed as natively unfolded proteins, they possess some structural variability 
and the differences between them are directly related to the variation in their primary 
amino acid sequences (Sung and Eliezer 2006). The NMR studies have demonstrated a 
high degree of homology in the N terminus of synucleins, which might be due to the 
conservation of the amino acids in this domain (Bertoncini, Rasia et al. 2007). 
However, subtle changes are observed in bS and gS compared to aS. Recent structural 
studies have reported increased α-helical conformation in this region of bS and gS 
(Bertoncini, Rasia et al. 2007), and bS possessing the highest propensity to adopt 
α-helical structure (bS>gS>aS). It is hypothesized that the absence of the central 
hydrophobic cluster in bS (Fig 1.2), which is present in aS and gS, might contribute to 
stabilize locally encoded α-helical conformation at the N terminus (Bertoncini, Rasia 
et al. 2007). At the C terminus, Carlos W. Bertoncini et al found evidence for the 
transient polyproline II conformations clustered in bS, which is stabilized by the 
presence of eight proline residues embedded in a polypeptide stretch rich in 
hydrophilic and negatively charged amino acids (Bertoncini, Rasia et al. 2007). In 
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general, bS exhibits a higher preference for random coil, whereas aS and gS are 
slightly more compact and structured (Uversky, Li et al. 2002). Both bS and gS are 
lack of the long-range contacts that observed in aS (Uversky, Li et al. 2002; Bertoncini, 
Rasia et al. 2007). 
 
      1            10            20          30             40 
(aS) MDVFMKGL  SKAKEGVVAAA  EKTKQGVAEAA  GKTKEGVLYVG  
(bS) MDVFMKGL  SMAKEGVVAAA  EKTKQGVTEAA  EKTKEGVLYVG  
(gS) MDVFKKGF  SIAKEGVVGAV  EKTKQGVTEAA  EKTKEGVMYVG  
 
 
           50              60            70            80 
SKTKEGVVHGV  ATVA  EKTKEQVTNVG  GAVVTGVTAVA  QKTVEGAGSIA  
 SKTREGVVQGV  ASVA  EKTKEQASHLG  GAVFSG-----  ------AGNIA   
 AKTKENVVQSV  TSVA  EKTKEQANAVS  EAVVSSVNTVA  TKTVEEAENIAV  
 
 






Fig. 1.2 The sequence alignment of human aS, bS, and gS.  
The imperfect 11-residue repeats are delineated by spaces. The KTKEGV 
consensus sequence within each repeat is highlighted. 
 
1.1.6 Physiological function of bS and gS 
Although the physiological role of bS and gS is not fully understood, some 
characteristic features of aS have been preserved, while others are missing. A recent 
study has confirmed the fatty acid binding property of bS, although to a less extent 
compared to aS, but suggested that gS does not share this same characteristic (Salem, 
Allsop et al. 2007). Furthermore, bS exhibits chaperon activity more efficiently than 
aS, which is supported by the observation that bS displays remarkably higher activity 
in the suppression of the heat- induced aggregation of aldolase, alcohol dehydrogenase 
and citrate sythase (Lee, Paik et al. 2004). bS has also been known to play a role in the 
antiapoptotic process and to protect neurons from neurotoxin by regulating protein 
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kinase B/Akt activity (da Costa, Masliah et al. 2003; Hashimoto, Bar-On et al. 2004). 
In addition, bS is indicated to reduce proteasomal inhibition induced by aS, through 
competing with subunit in the proteasome for binding to aS (Snyder, Mensah et al. 
2005). Unlike aS, bS does not fibrillate when incubated under the same condition, but 







pesticides (Yamin, Munishkina et al. 2005). Compared to aS and bS, very little 
information is available regarding the biological function of gS. It appears to have the 
property to fibrillate, while it is weaker than aS (Uversky, Li et al. 2002). It’s also 
shown to be involved in the proteasomal inhibition, which is not reduced by bS 
(Snyder, Mensah et al. 2005). In addition, gS participates in the heat shock 
protein-based multichaperon complex involved in estrogen receptor-α activation 
(Jiang, Liu et al. 2004). 
 
1.2 aS and Parkinson’s Disease 
Parkinson’s Disease (PD) is a common and incurable neurodegenerative disorder, 
affecting up to 2% of the population over the age of 65 years and 4-5% of those over 85 
(Eriksen, Wszolek et al. 2005). This disease is worldwide distributed, with no gender 
preference, and the risk rises steeply with advancing ages. The clinical symptoms 
include resting tremor, muscle rigidity and Bradykinesia, which refers to slowness of 
movement. Concerning the pathological features, PD is characterised by progressive 
loss of dopaminergic neurons in the substantia nigra and the development of Lewy 
bodies (LBs) observed in these neurons. LBs are the filamentous inclusions within 
neurons, which were first described in a PD brain by Dr. Friedrich H. Lewy in 1912. 
LBs in the substantia nigra typically have a characteristic spherical appearance with a 
loose radiating array of filaments in the periphery or "corona" surrounding a matted 
meshwork of filaments in the center or "core". LBs are the pathological hallmarks of 
PD and other neurodegenerative diseases including dementia associated with Lewy 
body disease (DLB), diffuse Lewy body disease (DLBD), familial forms of AD, Down 
syndrome and multiple system atrophy (MSA). These diseases, now collectively 
known as synucleinopathies (Jellinger 2003), are characterized by progressive 
neuronal cell death and the accumulation of LBs or/and LNs, which are proteinaceous 
formations in neurons. A number of proteins, such as Parkin, Hsp70 and UCH-L1, 
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have been shown to be contained in the LBs. Subsequently, fibrillar aS was found to be 
the main component of the LBs and LNs (Spillantini, Schmidt et al. 1997). 
 
The cause of PD is not clear. Substantial evidence suggests that aS is linked to the 
pathogenesis of PD in some cases. Initially, it was identified as a candidate gene for 
PD (Polymeropoulos, Higgins et al. 1996). In 1997, a missense mutation in the aS gene, 
characterized by a change from alanine to threonine at position 53, was identified in 
Italian-American and Greek families with autosomal dominant inheritance for the PD 
phenotype (Polymeropoulos, Lavedan et al. 1997). In 1998, a further mutation A30P, 
referred to alanine to proline substitution, was discovered in a German family with an 
autosomal dominant form of PD (Kruger, Kuhn et al. 1998). More recently, a third 
mutation E46K, known as glutamic acid to lysine substitution, was found in aS gene in 
a Spanish family with an autosomal dominant form of PD (Zarranz, Alegre et al. 2004). 
In addition, duplication and triplication of the aS gene, which leads to three and four 
functional copies of WT aS, also cause PD (Singleton, Farrer et al. 2003; Bonifati 
2005; Nishioka, Hayashi et al. 2006). It’s likely that aS has a crucial role in the 
pathogenesis of PD. The plasma aS levels in PD are significantly elevated compared 
with levels in controls (Lee, Lee et al. 2006), indicating a possible pathological role of 
aS. The functions of aS and its mutants have been intensely assessed in valid animal 
models using transgenic technique and viral infection. Overexpression of aS in 
Drosophila leads to the accumulation of LB-like aS aggregates in DA neurons and a 
PD-like phenotype (Feany and Bender 2000). Meanwhile, the first transgenic mice 
overexpressing human aS, generated in 2000 by Masliah et al, displayed a progressive 
accumulation of LB-like inclusions in neurons, which are associated with a loss of 
DAergic terminals in the basal ganglia and with motor impairments (Masliah, 
Rockenstein et al. 2000). Transgenic mice overexpressing the mutants including A30P 
and A53T aS, also develop many of the salient features of LB disease such as 
proteinase-K resistance, neuritic pathology and formation of aS inclusions with 
increasing age (Neumann, Kahle et al. 2002). Coincidently, in the adeno- or 
lentiviral-mediated rats models, overexpression of either WT or mutant aS led to 
cellular and axonal pathology accompanied by the loss of nigral neurons and 
significant motor impairment (Kirik, Rosenblad et al. 2002). In addition, elevated 
level of aS expression has been detected in other models of PD, including MPTP and 
1BnTIQ treatment (Shavali, Carlson et al. 2004; Purisai, McCormack et al. 2005). 
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Interestingly, down-regulation of aS expression in a viral vector modulated PD rat 
model, rescues dopaminergic cells from cell death in the substantia nigra, indicating 
the direct effects of increased level of aS to neuronal cell loss (Hayashita-Kinoh, 
Yamada et al. 2006). Based on these observations, aS is thought to play an important 
role in the disease progression. However, the precise role is still under investigation.  
 
It was suggested that the conversion of aS from soluble monomers to insoluble 
aggregates in the brain is a key event (El-Agnaf and Irvine 2000), and the aggregated 
forms of aS play a crucial role in the pathogenesis of PD. However, the molecular 
mechanisms underlying aS monomers into aggregation and further into filamentous 
inclusions remain unclear.  
 
In contrast to aS, neither bS nor gS is detected in LBs (Biere, Wood et al. 2000), and no 
mutations of either of them is identified related to familial PD (Lavedan, Buchholtz et 
al. 1998). Nevertheless, bS mutants have been found in DLB patients (Ohtake, 
Limprasert et al. 2004) and a very recent study suggests bS gene might modify the age 
at onset of PD (Brighina, Okubadejo et al. 2007), indicating bS is also linked to 
diseases. 
 
1.3 Pathological property of synucleins: 
1.3.1 α-synuclein aggregation mechanisms 
aS aggregation is thought to be a key pathogenic event in the neurodegenerative 
diseases, because the predominant composition of LBs and LNs is identified to be 
fibrillar aS (Spillantini, Schmidt et al. 1997; Spillantini, Crowther et al. 1998). aS 
inclusions are also found in several more disparate neurodegenerative diseases that are 
not commonly referred to as synucleinopathies (Dev, Hofele et al. 2003), indicating 
the pathological role of aS aggregation in various diseases. A great deal of research has 
been reported assessing the mechanism regulating aS fibril formation and the factors 
triggering this process. It is believed that the conversion of aS into insoluble fibrils is 
initiated by a conformational modification that leads to an altered structural state. This 
is particularly evident from analysis of aS in LBs from patients, where an increase in 
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β-sheet content was observed (Hashimoto, Hsu et al. 1998). It has been reported that 
aS aggregation is a nucleation-dependent phenomenon in which the initial insoluble 
seed allows the selective deposition of the inclusions (Wood, Wypych et al. 1999). The 
process initially forms oligomeric species that are relatively soluble; these oligomers 
might then self-assemble into fibrillar structures that are insoluble (Cookson and van 
der Brug 2007; Cookson and van der Brug 2008). This theory regarding aS is that aS 
has an intrinsic property to form amyloid fibrils, which is increased by raising the 
effective protein concentration (Greenbaum, Graves et al. 2005). Actually, 
recombinant aS readily assembles into filaments in vitro, which are similar to aS 
filaments extracted from diseased brains in terms of morphology, staining, and 
structure (Wright and Brown 2008). The dynamic studies indicate a multi-step process 
in the fibril formation, which involves multistate folding (Ferreon and Deniz 2007) 
and five or nine transient intermediates formation (Kamiyoshihara, Kojima et al. 2007). 
Molecular modeling and molecular dynamics simulations based on the 
micelle-derived structure of aS showed that aS homodimers can adopt nonpropagating 
(head-to-tail) and propagating (head-to-head) conformations. Propagating aS dimers 
on the membrane incorporate additional aS molecules, and lead to the formation of 
pentamers and hexamers which then form fibrils (Tsigelny, Bar-On et al. 2007). This 
observation fits well in the nucleation-dependent mechanism.  
 
Although the precise events responsible for aS aggregation are not fully understood, 
accruing evidence suggests a complex mechanism encompassing phenomena as 
diverse as structure perturbation, alternative splicing and posttranslational 
modification (Beyer 2006). 
 
1.3.1.1 Amino acid determinants 
As discussed above, aS is prone to form aggregates even in the absence of other 
proteins, suggesting this propensity is mainly related to its structure, which is directly 
correlated with its amino acid sequences. The central NAC region has been implicated 
to play a critical role in aS aggregation by several lines of evidence. As is known, NAC, 
the second major component of amyloid plaques in AD brain, readily forms ordered 
fibrils in vitro (Ueda, Fukushima et al. 1993; Han, Weinreb et al. 1995; Iwai, Masliah 
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et al. 1995). Moreover, NAC can seed Aβ amyloidogenesis and Aβ can also seed 
amyloid formation by NAC (Han, Weinreb et al. 1995). Finally, aS aggregation was 
impaired after the substitution of Ala76 with charged amino acids (either Arg or Glu) 
and was abolished after the deletion of amino acids residues 71-82 in this region 
(Giasson, Murray et al. 2001). In contrast to NAC region, C-terminus is suggested to 
play a role of intramolecular chaperon preventing aS from fibrillation. Apart from 
full-length aS, accumulated C-terminally truncated aS was found in the LBs and LNs 
in sporadic PD and LBD, as well as the glial cytoplasmic inclusions (GCIs) of multiple 
system atrophy (Baba, Nakajo et al. 1998; Gai, Power et al. 1999). Initial perikaryal aS 
accumulation also seems to be specifically constituted by aS112, a major aS isoform 
without C-terminus (Beyer, Lao et al. 2004). Several studies have revealed that 
C-terminus truncated aS constructs are more prone to fibrillate in vitro than the 
full-length protein (Crowther, Jakes et al. 1998; Serpell, Berriman et al. 2000; Murray, 
Giasson et al. 2003). According to these observations, it is clear that the C-terminus of 
aS is a negative regulator of self-assembly. Therefore, modification in this region, such 
as oxidation, nitration and phosphorylation (Hashimoto, Takeda et al. 1999; Giasson, 
Duda et al. 2000; Fujiwara, Hasegawa et al. 2002), may affect the propensity of aS to 
aggregate in vivo in a similar way to truncation. In addition, the tendency of aS to 
aggregate in vitro is proven to be accelerated by the PD-related point mutations, A30P 
and A53T, which are present in the N-terminus of aS. Both of the mutations increase 
the rate of aS oligomerization, whereas the rate of mature fibrils formation was 
increased by one (A53T) and decreased by the other (A30P) (Conway, Harper et al. 
1998; Narhi, Wood et al. 1999; Rochet, Conway et al. 2000; Li, Uversky et al. 2001; 
Uversky, Li et al. 2001; Li, Uversky et al. 2002). Detailed conformational analysis 
revealed that the two mutants possess similar structural properties with WT aS, 
remaining to be natively unfolded (Conway, Harper et al. 1998; El-Agnaf, Jakes et al. 
1998; Giasson, Uryu et al. 1999; Del Mar, Greenbaum et al. 2005). Interestingly, both 
mutations show reduced hydrophobicity in the vicinity of the substitution, which is 
assumed to be important in aggregation. Concurrently, the propensity to form α-helical 
structure was shown to be somewhat diminished in the N-terminal region of both 
mutants, whereas the internal susceptibility to form β-sheets was predicted to be 
slightly enhanced (Li, Uversky et al. 2001). Taking into account these observations it 
has been assumed that the increased tendency for A30P and A53T to form β-structure 
may not be strong enough to alter the structure of the monomeric proteins, but may 
Chapter 1. Introduction 
 29 
affect their aggregation behavior through specific stabilization of an intermolecular 
β-structure (Uversky 2007). In addition, high-resolution NMR analysis has revealed 
that A30P aS abolished a significant helical propensity in the N-terminus compared to 
WT aS, whereas A53T aS led to a preference for extended backbone conformation 
(Bussell and Eliezer 2001; Eliezer, Kutluay et al. 2001). Recently research has 
established that E46K mutation is also able to increase the propensity of aS to fibrillate, 
but to a less extent than A53T mutation (Greenbaum, Graves et al. 2005).  
 
Concerning the structure disruption, both of bS and gS inhibit aS fibril formation and 
complete inhibition was observed at 4:1 molar excess of bS and gS over aS (Uversky, 
Li et al. 2002), although the mechanism is not fully elucidated. bS inhibits the 
generation of aS aggregation in doubly transgenic mice too (Hashimoto, Rockenstein 
et al. 2001). These findings have provided important sights into the possible effects of 
structure perturbation on aS aggregation.  
 
1.3.1.2 Post-translational modifications 
There is emerging evidence showing that several conditions that are involved in 
post-translational modification of proteins are relevant in promoting aS aggregation. 
Oxidative stress appears to be one of these candidates. Free-radical generators such as 
iron and hydrogen peroxide can accelerate the generation of aS and ubiquitin-positive 
intracytoplasmic inclusions in cells overexpressing aS under certain conditions 
(Ostrerova-Golts, Petrucelli et al. 2000). Similarly, pesticide rotenone induces 
formation of aS inclusions in the substantia nigra, which closely resemble LBs, by 
inhibiting mitochondrial complex I in rats (Sherer, Betarbet et al. 2001). Reactive 
species may interact with cellular proteins, thus altering their folding properties and 
function. Abnormal phosphorylation is proven to be another factor. aS has been 
established to be selectively and constitutively phosphorylated at mainly serine 129 
within the C-terminal domain in synucleinopathy such as PD (Okochi, Walter et al. 
2000), where phosphorylation of aS stimulated fibril formation in vitro (Fujiwara, 
Hasegawa et al. 2002). It seems that aberrant protein degradation is another 
mechanism that has been implicated in the formation of LBs. This is evident from the 
marked inhibition of proteasomal activity induced by aS (Snyder, Mensah et al. 2003). 
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The reduction may lead to the potential for increased proteinaceous aggregates in the 
substantia nigra of PD patients (McNaught and Jenner 2001). Meanwhile, the role of 
lipid membranes in the conversion of WT aS to a pathogenic protein has been 
intensely investigated. Upon exposure to vesicles containing certain polyunsaturated 
fatty acid (PUFA) acyl groups, recombinant aS forms multimers in vitro (Perrin, 
Woods et al. 2001). Furthermore, exposure of mesencephalic neurons to PUFA also 
stimulates the protein to form oligomers in vivo (Sharon, Bar-Joseph et al. 2003), 
which precede the insoluble fibrilar aggregates formation. However, more recent 
research has revealed that association of aS with biological membranes can also 
impede the aggregates formation by protecting the protein from oxidation and 
nitrosylation (Trostchansky, Lind et al. 2006). Finally, several environmental 
conditions and ligands have been recognized as triggers for aS aggregation in vitro, 
such as high temperature, low pH, polyamines, and metal ions (Binolfi, Rasia et al. 
2006).  
 
1.3.2 Toxicity of aS aggregates 
The fundamental mechanism underlying the toxicity of aS and its aggregation to 
neurons is not entirely clear. A possible culprit is the transient oligomeric species 
formed along the way (Volles and Lansbury 2003). Much work has been developed to 
interpret this concept. aS oligomers are speculated to form pores on intracelluar 
membranes such as the plasma membrane based on the fact that some oligomeric 
species are annular or pore-like and aS is a lipid-associated protein (Volles and 
Lansbury 2002; Zhu, Li et al. 2003). This contention is supported by the evidence that 
aS aggregates formed ring-like structures under in vitro cell-free condition, and the 
cells expressing aS displayed increased ion current activity consistent with the 
formation of Zn
2+
-sensitive nonselective cation channels (Furukawa, 
Matsuzaki-Kobayashi et al. 2006; Tsigelny, Bar-On et al. 2007). Incubation with 
globular aS oligomers significantly inhibited autophosphorylation of p21-activated 
kinase (PAK4) (Danzer, Schnack et al. 2007), which might contribute to the neuronal 
damage. aS is reported to be involved in the neuroinflammation by up-regulating 
interleukin (IL)-6 and ICAM-1 in human astrocytes and astrocytoma cells. This is 
confirmed by the study that demonstrated early activation of microglial and 
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consequent increases in proinflammatory molecules in the model of PD (Su, 
Maguire-Zeiss et al. 2008). Finally, aS aggregating is implicated to induce formation 
of hydrogen peroxide in vitro (Turnbull, Tabner et al. 2001), which is particularly 
harmful in the elderly where the antioxidant defences are known to be deceased. 
 
1.4 Metals and synuclein 
Both redox-active metals such as copper, iron and manganese, and redox-inactive 
metals are essential in most biological reactions e.g., in the synthesis of DNA, RNA, 
and proteins, and as cofactors of numerous enzymes, particularly those involved in 
respiration. Thus their dyshomeostasis can lead to disturbances in central nervous 
system and other organ function (Sayre, Moreira et al. 2005). Elevated levels of 
several of these metals such as copper and iron, have been reported in the 
neurodegenerative diseases, including PD, which is dyshomeostasis of both 
redox-active and redox-inactive metal ions. Accruing evidence suggests that abnormal 
iron handling may be involved in the pathogenesis of PD. The first report of increased 
iron levels in the Parkinsonian substantia nigra pars compacta (SNpc) of PD was in 
1924 followed by another report in 1967 (Sayre, Moreira et al. 2005). Since then, the 
increased levels of iron in the PD midbrain have been verified by a great deal of 
research developed using several diverse methods, broadly classified as either 
postmortem or non-invasive studies. Moreover, analysis of LBs in the parkinsonian 
substantia nigra showed abnormal accumulation of iron and the presence of aluminum 
(Dexter, Carayon et al. 1991; Hirsch, Brandel et al. 1991), indicating they might be 
correlated with aS in the etiology of the disease. Similar alterations in metal 
homeostasis were observed in toxin-induced animal models of PD. 
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 
6-hydroxydopamine-induced neurodegeneration in rodents and nonhuman primates is 
associated with increased presence of iron and aS in the SNpc, which are abolished by 
iron chelators (Mandel, Maor et al. 2004). Several pieces of epidemiological and 
biochemical data has suggested that iron accumulation might be a primary event in the 
degenerative process. Occupational exposure to specific metals, especially copper, 
iron, has been established to be a risk factor for PD (Zayed, Ducic et al. 1990). Dietary 
intake of iron and manganese above median levels also conferred a nearly doubled risk 
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of PD (Sayre, Moreira et al. 2005). Meanwhile, unilateral injection or infusion of Fe
3+
 
into the SNpc of rats results in neuronal loss and progressive SNpc atrophy 
accompanied by both depletion of striatal dopamine and decreased motor function. 
These effects could be prevented by infusion of iron chelator desferrioxamine 
(Youdim, Ben-Shachar et al. 1993; Sayre, Moreira et al. 2005). In addition, altered 
levels of metal ions in bodily fluids of live patients were detected, with significant 
decreases in Al in both early and severe PD compared to controls, lower levels of Fe 
and Zn in severe PD, and higher levels of several other elements including K, Mg and 
Cu (Hegde, Shanmugavelu et al. 2004). Nevertheless, the mechanism how metals 
contribute to the pathogenesis of neurodegenerative diseases is elusive. One of the 
most popular concepts is that metals increase the levels of oxidative stress associated 




 ratio in favor of 
Fe
3+
 and a significant elevation in the Fe
3+
–binding protein, ferritin (Riederer, Sofic et 
al. 1989). Another mechanism, which indicates metals such as copper, promote aS 
aggregation either directly or via increasing levels of oxidative stress and in turn lead 
to neurodegeneration, is receiving more and more attention. In addition, Fe
2+
 was 
reported to induce DNA damage in aS transfected human neuroblastoma cells and the 
susceptibility to toxic effects of Fe
2+
 was enhanced with mutant aS associated with 
inherited forms of PD (Martin, Williamson et al. 2003).  
 
1.4.1 Metal binding 
Metals have been suggested to play a role in the pathogenesis of synucleinpathies as aS 
was identified as a metal-binding protein. There is cumulative evidence showing aS 
binds copper although the identification of the binding sites and affinities is still under 
debate (Fig 1.3). Initial studies suggested that aS binds to 5-10 copper ions with a Kd 
of 45-60 µM (Paik, Shin et al. 1999; Lee, Lee et al. 2003). However, Rasia et al 
showed that aS tightly binds to 2 copper ions per monomer with a dissociation constant 
in the range of 0.1-50 µM and is able to ligate more copper ions with significant lower 
affinity (400-500 µM) (Rasia, Bertoncini et al. 2005). Binolfi et al showed Cu(II) 
binds aS with high affinity Kd <0.1 µM (Binolfi, Rasia et al. 2006). A complete study 
using isothermal titration calorimetry technique determined the Cu(II) binding 




 M respectively, 
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and Fe(III) binding affinities to be 10
5
 M (Bharathi and Rao 2007). There is consensus 
that aS binds Fe(II), nevertheless, the binding affinities reported are different (Golts, 
Snyder et al. 2002; Binolfi, Rasia et al. 2006). The more recent study suggested that 
the affinity is around Kd ~1mM (Binolfi, Rasia et al. 2006). There is evidence showing 
aS binds other metals such as Mn(II), Co(II), and Ni(II), however, with low affinity Kd 
~1mM (Binolfi, Rasia et al. 2006). aS has also been reported to bind calcium, 
magnesium, zinc and aluminum, although the affinities are not determined yet (Paik, 
Lee et al. 1997; Nielsen, Vorum et al. 2001; Golts, Snyder et al. 2002; Lowe, Pountney 
et al. 2004).  
 
There has been some controversy in the identification of metal-binding sites. Initial 
studies claimed C-terminus of aS is responsible for copper binding (Paik, Shin et al. 
1999; Paik, Shin et al. 2000). Nevertheless, the following analysis characterized two 
distinct Cu(II)-binding motifs in aS. The high-affinity binding site encompassing a 
complex conformational array is located in the N-terminus of the protein, while the 
low-affinity site sits in the C-terminal region (Rasia, Bertoncini et al. 2005) (Fig 1.3). 
It was demonstrated that the high affinity site coordinates residues 3-9 and 49-52, 
which form a long-range interface with His50 as the anchoring residue. This 
conclusion relied on the observation that the N-terminal region is unable to interact 
with Cu(II) after modification of aS by DEPC treatment, which prevents histidine side 
chains from being able to coordinate copper. Therefore, it was reasoned that DEPC 
treatment would selectively inhibit copper binding to His50, and should not affecting 
binding to the N-terminus unless such binding required the participation of His50. 
However, a similar study reported that DEPC treatment modified the protein at 
multiple sites and eliminated copper binding to both the site around His50 and to the 
N-terminal site in full-length aS, but that it also eliminated copper binding to the 
N-terminal site in the H50A mutant, where modification of His50 is not possible (Sung, 
Rospigliosi et al. 2006). This indicates that copper-binding by aS does not involve 
long-range interaction and the N-terminus of aS and the site involving His50 are 
capable of binding copper independently of one another (Sung, Rospigliosi et al. 2006). 
This analysis suggested that although it is unlikely to occur in vivo, aS has 16 sites 
capable of binding copper because of the prevalence of negatively charged side chains, 
one histidine, and the primary amino group, particularly in the unstructured 
polypeptide. Further analysis utilizing peptides showed that Cu(II) ions appear to be 
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coordinated by the N-terminal amine group of methionine (residue 1), the amide 
nitrogen, and the β-carboxylic group of aspartic acid (residue 2) (Kowalik-Jankowska, 
Rajewska et al. 2005). They also demonstrated that copper binding is pH dependent. It 
was confirmed by a similar analysis using modified peptides, which showed that 
above pH6, the coordination of Cu(II) by His50 may involve the lateral NH2 group of 
lysine residues upstream of His50 (Kowalik-Jankowska, Rajewska et al. 2006). In 
contrast to copper, other metals appear to favour C-terminus of aS, which is more 
likely to be involved in low-affinity and nonspecific binding to metals. NMR 
spectroscopy demonstrated that many divalent metal ions such as Fe(II), Mn(II), Co(II) 
and Ni(II) bind preferentially with low affinity (millimolar) to the C-terminal domain 
of aS, the primary binding site being the motif encompassing residues 119-124, in 
which Asp121 acts as the main anchoring residue (Binolfi, Rasia et al. 2006). In 
addition, calcium was reported to bind aS and bS at the C-terminus comprising 
residues 109-140 (Nielsen, Vorum et al. 2001). So far, there is no evidence showing gS 
bind any metals.  
 
α-synuclein 
                                                          Ca(II) binding site 
              A30P   E46K  A53T 
                                                                          
N                                                                C 
1       9                 49  52    61               9                        140 
 
 
High affinity Cu(II) binding sites     Low affinity sites for Fe(II), Mn(II), Co(II) and Ni(II) 
 
Fig. 1.3 Linear representation of α-synuclein.  
The location of binding sites for various metals are indicated in the N-terminus 
and C-terminus of the protein. Three mutations A30P, E46K, A53T associated 
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1.4.2 Metals and synuclein induced neurotoxicity  
1.4.2.1  Conformational changes 
Neurodegenerative disorders possess a variety of pathological conditions, which share 
similar critical metabolic processes such as protein aggregation and oxidative stress, 
both of which are associated with the involvement of metal ions. Like other 
amyloidogenic proteins, abnormal folding of aS has been linked to the disease state. 
Several possible mechanisms for metal-stimulated fibrillation of aS can be envisaged. 
The simplest would involve direct interactions between aS and the metal, leading to 
structural changes in aS, and resulting in the enhanced propensity to aggregate 
(Uversky, Li et al. 2001). Little is currently known about how elevated levels of metals 
affect the conformational change of aS. As is known, aS is a natively unfolded protein. 
At neutral pH it is calculated to have 24 negative charges (15 of which are localized in 
the last third of the protein sequence), leading to strong electrostatic repulsion, which 
contributes to the lack of folding of aS (Uversky, Li et al. 2001). It has been assumed 
that the enhancement of fibrillation by metals can be attributed to the masking of the 
Coulombic charge-charge repulsion associated with the highly acidic C-terminus of 
the protein (Paik, Shin et al. 1999; Uversky, Lee et al. 2001). Analysis of far-UV 
circular dichroism at pH 7.5 with 35 µM aS and 2 mM metals indicated that Na(I), K(I), 
Li(I), Cs(I) and Ca(II) had no effect on the substantially unfolded nature of aS, while 
Cd(II), Zn(II), Mg(II), and Mn(II) resulted in a small increase in negative ellipticity 
around 222nm, which was a greater increase with Al(III), Fe(III), Cu(II) and Co(III), 
suggesting an increase in secondary structure change (Uversky, Li et al. 2001). This 
observation suggests that an important factor which affects polyvalent cations to 
induce aS conformational change might be the cross-linking, or bridging, between two 
or more carboxylates (Uversky, Li et al. 2001; Wright and Brown 2008), and the 
effectiveness of metal cations to induce fibrillation may be correlated with the 
increasing ion charge density and with their ability to induce fibrillation-prone 
partially folded species (Uversky, Li et al. 2001). In fact, aluminum was reported to 
participate in the pathological process in AD via the structural modifications of aS, 
which experienced the conformational alterations in the presence of aluminum such as 
the secondary structure transition to generate about 33% α-helix (Paik, Lee et al. 1997). 
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In contrast, recent study showed that Cu(II) does not affect the structural features 
inherent to the spontaneous aggregation of aS, and copper-induced fibrils exhibit the 
same morphology as those formed in the absence of the cation (Rasia, Bertoncini et al. 
2005). In addition, circular dichroism spectroscopy revealed no structural changes 
after calcium binding (Weinreb, Zhen et al. 1996; Nielsen, Vorum et al. 2001). These 
conflicts raise the idea that metal induced aS aggregation and neurotoxicity may not 
due to the conformational alteration, although it is not always necessary for metal ions 
to cause gross structural changes for functional effects to arise (Nielsen, Vorum et al. 
2001).  
 
1.4.2.2 Oxidative stress 
Redox-active transition metals such as copper and iron, may play an important role in 
the pathogenesis of neurodegenerative diseases by participating in an array of cellular 
disturbances characterized by oxidative stress and increased free radical production 
(Sayre, Moreira et al. 2005). Metal-catalyzed oxidation of proteins require metals to be 
bound to the protein and involves the reduction of metals such as Fe(III) and Cu(II), 
the reaction of Fe(II) and Cu(I) with hydrogen peroxide to generate hydroxyl radicals 
via a Fenton-like reaction, and oxidation of neighbouring amino acids (Wright and 
Brown 2008). The ability of these amino acids to form complexes with metal ions 
directly influences the susceptibility to metal-catalyzed oxidation. Oxidatively 
modified protein could increase its own tendency toward protein aggregation may due 
to the generation of reactive oxygen species (ROS). It turns soluble protein into 
insoluble form by either inhibiting intracellular proteolysis or causing unusual 
posttranslational modifications. These may then provide the covalent modifications of 
amino acid residues in proteins and formation of protein-protein cross-linkages 
(Kowalik-Jankowska, Rajewska et al. 2006). aS has been shown to be a potential 
target of intracellular oxidants by the identification of posttranslational modifications 
of synuclein within intracellular aggregates that accumulate in PD brains. It has been 
demonstrated that in the presence of copper and hydrogen peroxide, aS experienced 
Cu(II)-catalyzed oxidation and self-oligomerization, which may lead to possible 
protein aggregation and neurodegeneration (Paik, Shin et al. 2000). This could be 
almost suppressed by the addition of ascorbic acid or EDTA, indicating that 
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oligomerization was dependent upon not only metal binding but also its subsequent 
redox reaction in the presence of hydrogen peroxide (Paik, Shin et al. 2000). Similar 
effects of iron and hydrogen peroxide on aS aggregation were also observed 
(Hashimoto, Hsu et al. 1999). However, combination of copper and hydrogen peroxide 
forms soluble oligomers rather than filaments as examined by thioflavin T 
fluorescence, while iron and hydrogen peroxide led to filament formation but did not 
result in aS oligomerization (Hashimoto, Hsu et al. 1999; Cole, Murphy et al. 2005). 
This suggests that oxidation of aS can affect the aggregation and morphology of 
aggregate formed and various metals might involve different kinetics and 
modifications of the aggregate formation. In addition, the biochemically specific 
copper- or iron-mediated oxidative oligomerization was turned out to be dependent 
upon the acidic C-terminus of aS because the C-terminally truncated proteins were not 
affected by both metals and hydrogen peroxide (Paik, Shin et al. 2000). Analysis on 
Cu(II)-catalyzed oxidation of the N-terminal fragments of aS reported the cleavage of 
the peptide bond M1-D2 for all peptide studied, indicating the coordination of Met1 
and Asp2 residues to the Cu(II) ions, and the fragmentations of these peptides near the 
Lys residues, supporting the participation of this residue in the coordination of the 
metal ions (Kowalik-Jankowska, Rajewska et al. 2006). This observation to some 
extent correlates the oxidation with interaction between metal ions and synuclein 
protein.  
 
So far, no evidence has shown that bS and gS are capable of binding to metals with 







been shown to induce a partially folded conformation of bS that triggers rapid 
fibrillation (Yamin, Munishkina et al. 2005), indicating that synuclein might be 
involved in the homeostasis of metals. 
 
1.5 aS: a potential therapeutic target for PD 
The aggregated forms of aS play a crucial role in the pathogenesis of PD and the 
concept that metals substantially regulate aggregation and fibrillation of aS has been 
widely accepted, while various metals have variable effects during the process. 
Previous study showed that Cu(II) was the most effective metal ion in promoting aS 
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oligomerization (Paik, Shin et al. 1999). A recent systematic analysis examining 
effects of various metals on the kinetics of fibrillation of recombinant aS revealed that 
Al(III) was the most effective, along with Cu(II), Fe(III), Co(III) and Mn(II) (Uversky, 
Li et al. 2001). Metal ions are capable of regulating the aggregation and fibrillation of 
aS, indicating they may exert their dual pathogenic effects through the interaction with 
aS, inducing protein transformation or/and oxidative stress. Therefore, chelation 
therapy could be a valuable therapeutic approach towards the treatment of 
neurodegeneration (Gaeta and Hider 2005). In fact, initial studies suggest that 
chelators will be effective in treating PD if the neurotoxic side effects can be overcome 
(Gaeta and Hider 2005). Further research into the definition of metal-binding sites and 
the mechanism of subsequent damaging events such as oxidative stress, is required to 
provide more specific therapy. In the other hand, aS is one of the members of synuclein 
family, including bS and gS, which have been suggested to be the physiological 
regulators of aS expression. Both of bS and gS inhibit aS fibril formation and neither 
of them has been shown to bind any redox active metals for high affinities. Thus, 
determination of the physiological function of synuclein proteins may help finding the 
way to cure PD. 
 
1.6 Aim of the project 
This project tested the roles of metals in the pathological property of synuclein 
regarding to the metal-binding induced aggregation and toxicity. This work is aim to: 
1. Develop methods for the purification of recombinant synuclein proteins and their 
mutants 
2. Determine the Cu(II) binding sites and affinities on synuclein proteins by looking 
at the stoichiometry of Cu(II) binding to synuclein 
3. Investigate the coordination modes between Cu(II) and synucleins, and compare 
the differences among aS, bS and gS  
4. Explore the electrochemical properties of synuclein by analyzing the redox 
activities catalyzed by synuclein-copper complexes 
5. Characterize the effects of metals on mammalian cells stably overexpressing aS 
and PD-associated mutants 
 
Chapter 2. Materials and Methods 
Chapter 2. Materials and Methods 
2.1 Media and reagents 
All media and reagents were obtained from Sigma-Aldrich, Fisher and Melford 
Laboratories unless otherwise stated. Media and buffers which appeared in the 
following materials and methods chapter are detailed in Table 2.1. 
 
Media / Buffers Details 
LB 
LB medium: 10g tryptone, 5g yeast, 10g NaCl in 1L dH2O, 
pH7.5 and autoclaved. 
LB agar: LB medium + 1.5% (w/v) agar and autoclaved. 
Antibiotics 
Carbenicillin: 50mg/ml in dH2O, filtered through 0.22uM 




1M in dH2O, filtered through 0.22uM filter and stored at 
-20°C. 
Phenylmethylsulpho
nyl fluoride (PMSF) 
100mM in ethanol, stored at -20°C. 
deoxyribonuclease 
(DNase) 
1mg/ml in 5mM CaCl2, stored at -20°C. 
TAE buffer 
50 x stock solution: 242g Tris base, 57.1ml glacial acetic acid, 
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Media / Buffers Details 
SDS-PAGE sample 
loading buffer 
4 x stock solution: 20%  Mercaptoethanol, 40% glycerol, 
240mM Tris   pH6.8, 8%  SDS, 0.2%  Bromophenol blue 
SDS-PAGE running 
buffer 
10 x stock solution: 30.3g Tris, 188g Glycine, 10g SDS, 
dH2O to 1L, pH 8.3. 
Coomassie blue 
staining solution 
0.25g coomassie blue, 45ml methanol, 10ml glacial acetic 
acid, 45ml dH2O. 
Urea buffer 1kg urea, 23.2g NaCl, 21.1g Tris-HCl, dH2O to 2.08L, pH7.5. 
Destaining solution 100ml methanol, 140ml acetic acid, dH2O to 2L 
Transfer buffer 0.5 x Running buffer, 20% Methanol 
PBS 
20 x stock solution: 160g NaCl, 4g KCl, 4g KH2PO4,  
23g Na2HPO4, dH2O to 1L 
Buffer A 20 mM Tris-HCl, 1 mM EDTA, pH 8.0 
Buffer B 20 mM Tris-HCl, 1 mM EDTA, 2M NaCl, pH 8.0 
Buffer C 10 mM NaAcetate, 1mM EDTA, pH 4.0 
Buffer D 10 mM NaAcetate, 1mM EDTA, 2M NaCl, pH 4.0 
Buffer E          
20mM Tris-HCl pH 7.4, 2.5mM EDTA,  
100mM NaCl, 0.1% Triton X-100 
 
Table 2.1 Media and solutions 
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2.2 Plasmids and oligonucleotides used 
The constructs, pDFP1a, pDFP2, pDFP3 and pDFP4a were provided by the 
University of Lancaster. The coding sequences and amino acids sequences for human 
aS, bS, gS and their mutants are shown in appendix A. The aS and its mutant DNA 
was cloned into Xho I/Kpn I in pTrcHis vector, and bS, gS DNA was cloned into Nde 
I/Bam HI in pET15b vector. The plasmid DNA was used to transform XL-2 blue 
competent cells, from which permanent bacterial stocks were prepared in 15% sterile 
glycerol. bS and gS were subcloned into pET3a plasmid from pET15b plasmid. The 
proteins were expressed in host cells BL-21(DE). pcDNA3.1(-) plasmid was used for 
transfection in mammalian cells. The mutations were introduced into Kpn I/Xho I in 
the plasmids by using site-directed mutagenesis. Constructs pDEP4f, pDEP4g, 
pDEP4h, pDEP5e, pDEP46a, pDEP6f, pDEP6g and pDEP6i were kindly provided 
by Dr. Josephine Wright. The information about pTrcHis, pET15b, pET11a, pET3a 
and pcDNA3.1(-) vectors are indicated in appendix B. All the oligonucleotides and 
plasmids used in this project are detailed in Table 2.2 and Table 2.3.  
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of gS cDNA 
AAATATGGATCCTTACTAGTCTCCCCCACTCTG 
 
Table 2.2 Oligonucleotides 
 
 




Plasmid Description Source 
pTrcHis A 
Vector for expression of N-terminal (His)6-tag proteins 
in E.coli followed by an enterokinase cleavage site 
Invitrogen 
pET15b 
Vector for expression of N-terminal (His)6-tag proteins 
in E.coli followed by a thrombin cleavage site 
Novagen 
pET11a Vector for expression of untagged proteins in E.coli Novagen 
pET3a Vector for expression of untagged proteins in E.coli Novagen 
pcDNA 
3.1(-) 
Vector for expression of untagged proteins in 
mammalian neuroblast (SHSY5Y) cells 
Invitrogen 
pDFP1a 




































Plasmid derived from pET11a for expression of 
untagged aS H50A 
This project 
pDFP4c 
Plasmid derived from pET11a for expression of 
untagged aS△1-9 This project 
pDFP4d 
Plasmid derived from pET11a for expression of 
untagged aS△1-9 H50A This project 
pDFP4e 
Plasmid derived from pET11a for expression of 
untagged aS△119-126 This project 
pDFP4f 
Plasmid derived from pET11a for expression of 
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Plasmid Description Source 
pDFP4g 
Plasmid derived from pET11a for expression of 













Plasmid derived from pET3a for expression of 
untagged bS H65A 
This project 
pDFP5c 
Plasmid derived from pET3a for expression of 
untagged bS△1-9 This project 
pDFP5d 
Plasmid derived from pET3a for expression of 
untagged bS△1-9 H65A This project 
pDFP5e 
Plasmid derived from pET3a for expression of 









Plasmid derived from pcDNA3.1(-) for expression 




Plasmid derived from pcDNA3.1(-) for expression 
of untagged aS A30P 
This project 
pDFP6c 
Plasmid derived from pcDNA3.1(-) for expression 
of untagged aS E46K 
This project 
pDFP6d 
Plasmid derived from pcDNA3.1(-) for expression 
of untagged aS A53T 
This project 
pDFP6e 
Plasmid derived from pcDNA3.1(-) for expression 
of untagged aS H50A 
This project 
pDFP6f 
Plasmid derived from pcDNA3.1(-) for expression 




Plasmid derived from pcDNA3.1(-) for expression 




Plasmid derived from pcDNA3.1(-) for expression 
of untagged aS△119-126 This project 
pDFP6i 
Plasmid derived from pcDNA3.1(-) for expression 




Plasmid derived from pcDNA3.1(-) for expression 




Table 2.3 Plasmids 
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2.3 Site-directed mutagenesis 
The following reactions were set up in 0.5 ml thin-wall PCR tubes to introduce 
mutations: 50 ng template DNA, 1 µl of 25 µM of each primer, 2.5 µl of 25 mM of 
dNTPs, 6 µl or 8 µl MgSO4 stock solution, 5 µl of 10x buffer (without MgSO4) and 
2.5U of Pwo polymerase (Roche applied science) were added. Reactions were set up 
to a final volume of 50 µl with nuclease free water. The PCR programme, utilising a 
Thermo Hybaid PCR Sprint thermal cycler, was as follows: 1, one cycle of 95°C for 90 
seconds (separating the parental DNA); 2, 5 cycles of 95°C for 30 seconds, followed 
by 50°C for 1 minute, and then 68°C for 10 minutes; 3, 5 cycles of 95°C for 30 
seconds, followed by 55°C for 1 minute, and then 68°C for 10 minutes; 4, one cycle of 
68°C for 15 minute. Hold temperature was 4°C. Following PCR, samples were 
digested by Dpn1 at 37°C for 1 hour to remove the remaining parental DNA. 
 
2.4 Preparation of competent bacterial cells 
XL-2 Blue Ultra Competent Cells (Stratagene) and BL21 (DE3) pLysS competent 
cells (Promega) were plated on two LB agar plates and incubated overnight at 37°C. 
A single colony was inoculated into 10 ml LB medium and incubated overnight at 
37°C. The 10 ml overnight culture was added to 200 ml LB medium and incubated at 
37°C shaking at 200 rpm until the optical density at 600 nm was 0.6. The culture was 
centrifuged at 4000 rpm at 4°C for 10 minutes. Cell pellets were resuspended in 200 
ml ice cold 0.1 M sterile MgCl2 with plugged pipettes. Then the mixture was 
centrifuged as previous and the cell pellets were resuspended in 100 ml ice cold 0.1 
M sterile CaCl2. The mixture was incubated on ice for 20 minutes and centrifuged as 
previous. The cell pellets were resuspended in 10 ml ice cold 0.1 M CaCl2 with 15% 
glycerol and dispensed into 200 µl aliquots in pre-chilled 1.5 ml tubes. The cells 
were rapidly frozen and stored at -80°C. Everything was done by the flame and all 
the solution and tubes were sterilized by autoclaving.  
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2.5 Transformation 
XL-2 Blue and BL21 competent cells were used. Cells were thawed on ice and 
resuspended by gentle flicking the tube. 50 µl aliquot of cells was transferred into 
pre-chilled 1.5 ml sterile tubes. Either 50 ng of plasmid DNA or 5 µl PCR 
mutagenesis DNA digested by Dpn1 was added and the cells were then incubated on 
ice for 30 minutes. After that, cells were heat shocked for 60 seconds at 42°C, and then 
returned to the ice for 2 minutes. 300 µl LB broth was added to the cells/DNA solution 
and then incubated at 37°C shaking for 1 hour at 200 rpm. The solution was then 
centrifuged at 4000 rpm for 5 minutes. The cell pellets were resuspended in 100 µl 
supernatant and plated on LB agar plates containing 50 µg/ml carbenicillin. The plates 
were incubated at 37°C overnight.  
 
2.6 Plasmid DNA purification and quantification 
2.6.1 Mini-preps 
Three to six colonies from each of the transformation plates (XL-2 blue cells) were 
picked and added to three to six 15 ml Falcon tubes containing 5 ml LB broth with 50 
µg/ml carbenicillin. Cultures were incubated at 37°C shaking overnight at 200 rpm. 
The three to six inoculum cultures were centrifuged at 4000 rpm for 10 minutes, and 
the supernatant was discarded. Plasmid DNA was purified by using a QIAprep Spin 
Miniprep Kit according to the manufacturers protocol (QIAGEN).  
 
2.6.2 Agarose gel electrophoresis 
5 µl of the plasmid DNA from mini-prep was analyzed in the 1% agarose gel/TAE with 
0.5 µg/ml ethidium bromide to confirm the DNA purification. Gel was run at 100 volts 
for 1 hour using a BioRad mini-sub®cell GT gel tank and BioRad power pac 300. Gels 
were photographed under long wave UV light. The DNA concentration was 
determined by the absorbance at 260 nm wavelength in a UV spectrophotometer. 
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2.7 DNA sequencing 
5 µl of 100 ng/ul of purified plasmid DNA from mini-prep DNA and 5 µl of 3.2 




2.8.1 PCR amplification 
The coding sequences of bS and gS were amplified from the template DNA in 
pET15b vector by PCR in a Thermo Hybaid PCR Sprint thermal cycler. The reactions 
were set up in 0.5 ml thin-wall PCR tubes: 100 ng template DNA, 1 µl of 25 µM of 
each primer, 1 µl of 10 mM of dNTPs, 5 µl of 10x buffer (with MgSO4) and 2.5U of 
Pwo polymerase (Roche applied science) were added. Reactions were set up to a final 
volume of 50 µl with nuclease free water. The PCR programme was as follows: 1, one 
cycle of 96°C for 60 seconds; 2, 35 cycles of 96°C for 15 seconds, followed by 63°C 
for 30 seconds, and then 72°C for 90 seconds; 3, one cycle of 72°C for 5 minutes. 
Hold temperature was 4°C. Following PCR, samples were digested by restriction 
enzymes.  
 
2.8.2 Restriction enzyme digestion 
The digestion reactions were set up as follows: 3 µg of vector DNA or diagnostic 
DNA, 5 µl of 10x buffer and 0.5 µl of each restriction enzyme were transferred to a 
1.5 ml tube. MilliQ H2O was added to set up a final volume of 50 µl. The contents in 
the tube were mixed properly and centrifuged. Then the digest reaction was 
incubated at 37°C for 1 hour or overnight.  
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2.8.3 Dephosphorylation of vector DNA 
The digested vector DNA was dephosphorylated by the treatment of shrimp alkaline 
phosphatase (Roche applied science) to prevent the self-ligation of the plasmid. The 
mixture of 3 µg digested vector DNA and 2 µl shrimp alkaline phosphatase were 
incubated at 37°C for 45 minutes. The enzyme was then inactivated at 65°C for 15 
minutes.  
 
2.8.4 DNA extraction 
The digest reaction mixtures were loaded into a 1% agarose gel/TAE with 0.5 µg/ml 
ethidium bromide. Gel was run at 100 volts for 1 hour to make the DNA fragments 
separated. The DNA was visualized under a UV transilluminator and the fragments 
of interest were cut off from the gel by a clean, sharp razor blade. The DNA was 
extracted from the gel slices by using the QIAquick Gel Extraction Kit according to 
the manufacturers protocol (QIAGEN). The purified DNA was stored at -20°C. 
 
2.8.5 Ligation 
2 µl of the purified vector DNA and insert DNA was loaded into a 1% agarose 
gel/TAE with 0.5 µg/ml ethidium bromide to estimate the relative concentration of 
the DNA. The ligation reaction was carried out in a 1.5 ml tube by adding vector 
DNA and insert DNA in a ratio of 1:3. 1 µl T4 DNA ligase (Promega), 2 µl 10x 
ligase buffer and MilliQ H2O were added to make a final volume to 20 µl. The 
reaction was incubated at room temperature for 1 to 3 hours. 
 
2.9 Induction of protein expression 
A single colony of BL21 (DE) cells transformed with plasmid DNA was used to 
inoculate 25 ml of LB broth supplemented with 50 µg/ml carbenicillin in a 50 ml 
Falcon tube. The culture was incubated at 37°C overnight shaking at 200 rpm, and 
Chapter 2. Materials and Methods 
 49 
then was used to inoculate 1 L of LB broth supplemented with 50 µg/ml carbenicillin 
in a sterile 2 L conical flask. The culture was grown at 37°C shaking at 200 rpm in an 
incubator until OD600 reached 0.4-0.6 (about 2-3 hours). A 1 ml sample was taken out 
of the culture for the uninduced control in polyacrylamide gel. Then IPTG from 1 M 
stock was added to make a final concentration of 1 mM. The cultured was induced 
for a further 3-5 hours and 1 ml sample was removed to check the level of protein 
expression in polyacrylamide gel. These samples were centrifuged at 6000 rpm for 5 
minutes. The cell pellets were resuspended in 2% (w/v) SDS and heated at 100°C for 
5 minutes, 5 µl of which was then mixed with SDS-PAGE sample loading buffer and 
heated at 100°C for 5 minutes before being loaded into a SDS gel for analysis. At the 
end of induction, the cells were harvested by centrifuged at 6000 rpm for 10 minutes 
and resuspended in appropriate buffers before being stored at -80°C. 
 
2.10 Polyacrylamide gel electrophoresis 
A 10% or 12% (w/v) polyacrylamide separating gel was made by pouring the 
acrylamide solution into the gap between the glass plates. After polymerization, a 4% 
(w/v) polyacrylamide stacking gel solution was poured above the separating gel. For 
gradient gels, a 5% acrylamide solution and a 20% acrylamide solution were mixed 
individually in the Pouring Stand before they were mixed together and poured into the 
gap between the glass plates. The plates were fixed in a tank. The SDS-PAGE running 
buffer was placed between the plates and at the bottom of the tank. Protein samples 
were mixed with 4x loading buffer and dH2O to make a total volume of 20 µl. Protein 
samples were heated at 100°C for 5 minutes and loaded into the stacking gel. The gels 
were run at constant current 35 mA per gel until the dye reached the bottom of the gels. 
Under denaturing conditions, proteins in the gels were separated by molecular weight 
while the negatively charged proteins migrated towards the anode. Protein fractions 
were observed by either Coomassie blue staining or western blotting. Recipes to make 
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dH2O 2.6 2.1 3.6 2.25 0 
30% 35.1:1 bis 
acrylamide 
2.7 3.2 0.63 0.75 3 
1 M Tris pH8.8 2.6 2.6  1.45 1.45 
1 M Tris pH6.8   0.63   
10% SDS 0.08 0.08 0.05 0.045 0.045 
10% APS 0.024 0.024 0.03 0.008 0.008 
TEMED 0.01 0.01 0.005 0.0045 0.0045 
 
Table 2.4 Recipes for acrylamide gels 
 
2.11 Coomassie blue staining 
Coomassie blue staining is based on the binding of the dye Coomassie Brilliant Blue, 
which binds nonspecifically to virtually all proteins via physisorption to arginine, the 
aromatic amino acids, and histidine. Any dye that is not bound to protein diffuses out 
of the gel during the destain steps. Generally, the polyacrylamide gels were soaked in 
the coomassie staining solution and gently rocked for 5 minutes or overnight 
(depending on the freshness of the coomassie staining solution) after heated in 
microwave for 15 seconds. Then the staining solution was poured out and the gels 
were soaked in the destaining solution, which was then gently rocked until the blue 
bands were visualized against a clear background. The gels were then photographed.  
 
2.12 Western blotting 
Western blotting, also referred to be immunoblotting, is an analytical technique used 
to detect specific proteins in a given sample of protein fractions or tissue homogenate. 
It uses gel electrophoresis to separate denatured proteins by the molecular weight. 
Then the proteins are transferred to a membrane (typically nitrocellulose or PVDF), 
where they are probed by using polyclonal or monoclonal antibodies specific to the 
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target proteins.  
 
2.12.1 Protein transfer 
PVDF membrane (Millipore) was activated through immersing in 100% methanol 
solution for 15 seconds. The SDS gel was placed with the membrane between filter 
papers to form a sandwich structure. All of these were carried out in the transfer buffer. 
The “sandwich” was placed in a Trans-Blot®Semi-Dry transfer machine (Biorad). The 
transfer was run at 50 mA per gel for 1.5 hours or 12 mA per gel 6 volts constant 
overnight for big proteins transferring.  
 
2.12.2 Antigen detection 
The membrane was blocked by incubating in 5% milk in PBS-0.1% Tween20 at room 
temperature for 1 hour or at 4°C overnight. The membrane was then incubated in 
primary antibody diluted in 1:1000 in 1% milk in PBS-0.1% Tween20 for 2 hours at 
room temperature or overnight at 4°C. This was followed by 3 times of washing in 
PBS-0.1% Tween20 for 15 minutes each time. Horseradish peroxidase (HRP) 
conjugated secondary antibody was diluted 1:3000 or 1:4000 in 1% milk in TBS-0.1% 
Tween20 and incubated with membrane for 1 hour at room temperature. The 
membrane was then washed 3 times as before. The membrane was treated with ECL 
PLUS Western blotting detection kit (Amersham Pharmacia Biotech) for 5 minutes 
and exposed to film. 
 
2.13 Purification of (His)6-synuclein by Immobilised metal 
affinity chromatography (IMAC) 
Cell lysate was prepared as below: cell pellets were resuspended in urea buffer by 
shaking at 37°C for 1 hour and cells were broken down by sonication. The cell lysate 
was centrifuged at 12000 rpm for 20 minutes at 4°C and the supernatant was retained. 
The supernatant was filtered through a 0.45 µM filter (Millipore) before it was loaded 
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into the column.  
 
IMAC Column with 5-6 ml metal chelating sepharose was washed with MilliQ H2O, 
saturated with 0.3 M nickel sulphate and equilibrated with urea buffer. The cell lysate 
was loaded into the column at a speed of 1.2 ml/minute, followed by 100 ml urea 
buffer with 25 mM imidazole washing at a speed of 4 ml/minute. Then protein was 
eluted with urea buffer with 100 mM or 300 mM imidazole.  
 
2.14 Purification of synuclein by Ion exchange 
chromatography (IEC) 
IEC is a process that allows the separation of ions and polar molecules based on the 
charge properties of the molecules. It retains analyte molecules based on coulombic 
interactions and can be subdivided into cation exchange chromatography and anion 
exchange chromatography. In cation exchange chromatography, positively charge 
ions bind to a negatively charged resin, while in anion exchange chromatography the 
binding ions are negative and the resin displays a positively charged functional group. 
Once the solutes are bound, the column is washed to equilibrate in the starting buffer, 
which should be of low ionic strength, and then the bound molecules are eluted off 
using a gradient of a second buffer which steadily increases the ionic strength of the 
eluent solution. Proteins have numerous functional groups that can have both 
positive and negative charges. IEC separates proteins according to their net charge, 
which is dependent on the composition of the starting buffer. By adjusting the pH or 
the ionic concentration of the buffer, various proteins molecules can be separated.  
 
2.14.1 Anion exchange chromatography (AEC) 
Cells pellets were resuspended in buffer A with 1 mM PMSF and 50 µg/ml DNase 
and shaked at 37°C for 15 minutes. The cells were lysed by sonication (3x 1 minute) 
and 1% (w/v) of streptomycin sulfate was added to precipitate the ribosomal proteins. 
The cell lysate was centrifuged at 8000 g for 20 minutes at 4°C and the supernatant 
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was retained. 30% (w/v) ammonium sulfate was added and stirred at 4°C for at least 1 
hour to precipitate the protein. The mixture was then centrifuged at 10000 g for 20 
minutes at 4°C and the pellets were retained. Briefly, the pellets were resuspended in 
buffer A and filtered through a 0.45 µM filter (Millipore) before it was loaded onto a 
pre-equilibrated Q-Sepharose Fast Flow column connected to a fast protein liquid 
chromatography (FPLC) system (Amersham Bioscience). Bound proteins were 
eluted by a linear gradient of buffer B. Fractions containing proteins were identified 
from the UV chromatogram and analyzed by SDS-PAGE.  
 
2.14.2 Cation exchange chromatography (CEC) 
Cells pellets were resuspended in buffer C with 1 mM PMSF and 50 µg/ml DNase 
and shaked at 37°C for 15 minutes. The cells were lysed by sonication (3x 1minute). 
The cell lysate was centrifuged at 8000 g for 20 minutes at 4°C and the supernatant 
was retained. The semi-purified cell lysate was filtered through a 0.45 µM filter 
(Millipore) before it was loaded onto a pre-equilibrated Hitrap SP HP column (GE 
healthcare) connected to a fast protein liquid chromatography (FPLC) system 
(Amersham Bioscience). Bound proteins were eluted by a linear gradient of buffer D. 
Fractions containing proteins were identified from the UV chromatogram and 
analyzed by SDS-PAGE.  
 
2.15 Dialysis of protein fractions 
The dialysis tubing (Medicell) was prepared as follows: boiled in 2% (w/v) NaHCO3 
with 1 mM EDTA for 5 minutes and rinsed in dH2O. Protein samples were dialyzed 
in the tubing (MW12-14K for (His)6-synuclein, MW3K for untag synuclein) against 
chelex treated MilliQ H2O pH 7. 1 g of chelex was added to 5 liters of MilliQ water 
and stirred for 1 hour. Then the water was filtered through filter papers to get rid of 
the chelex, and adjusted to pH 7. Chelex is a styrene-divinylbenzene resin containing 
iminodiacetic acid groups. It binds metals via ionic interaction.  
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2.16 Maintenance and growth of mammalian cells 
SH-SY5Y (human neuroblastoma) cells were cultured in 50% (v/v) Dulbecco’s 
Modified Eagle Media and 50% (v/v) Ham’s F-12 supplemented with 10% (v/v) fetal 
bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM 
glutamine. All the media and reagents were obtained from Biowhittaker Lonza. 
Growth conditions were maintained at 37°C and 5% CO2 in a humidified incubator. 
 
2.17 Transfection 
Transfections were performed using FuGene 6 transfection reagent (Roche applied 
science). For stable transfections, 6-well plates were used and cells were plated at 50% 
confluency the day before the transfection. To perform the transfection 50 µl of serum 
free media was transferred into a micro-centrifuge tube; 3 µl of the FuGene 6 reagent 
was then added directly to this and mixed by gentle flicking. The mixture was 
incubated for 5 minutes at room temperature. For each cell line, 1 µg of DNA was then 
added to the mixture, mixed as before, and incubated at room temperature for 15 
minutes. After this the transfection mixture was added to the cells, the 6-well plate 
swirled and returned to the incubator overnight. Cells were selected with 400 µg/ml 
G418 sulfate (Calbiochem) 24 hours after transfection, and maintained in 100 µg/ml to 
keep the plasmid in the cells.  
 
2.18 Immunofluorescence 
Coverslips (Scientific laboratory supplies), which were sterilized in 100% ethanol 
beforehand, were put at the bottom of the wells of 6-well plates. The coverslips were 
covered in Poly-L Lysine for 10 minutes and rinsed with PBS. Cells were cultured on 
the coverslips overnight and treated with metals for 48 hours. Coverslips were rinsed 
in Hanks and fixed in 4% paraformaldehyde/PBS for 30 minutes at room temperature. 
Coverslips were transferred to a new dish and washed 3 times in PBS with 5 minutes 
each time. Cells were permeabilised by incubating in 0.1% Triton X-100 in PBS for 10 
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minutes, followed by washing 3 times as before. Coverslips were then incubated in 1% 
glycine in PBS for 10 minutes, and washed by PBS to remove the excess glycine. Cells 
were blocked in 10% FBS in PBS for 30 minutes and washed with PBS. Cells were 
then incubated in primary antibody overnight at 4°C and washed 3 times as before, 
then incubated with secondary antibody for 1 hour in dark at 37°C and washed as 
before. Cells were then mounted in mounting media (Vector Lab) on a clean slide and 
viewed under the Laser Scanning Microscope LSM510 (Zeiss). The data was 
analyzed by the software LSM510 image examiner provided by the company.  
 
2.19 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay 
MTT assay is a colorimetric assay used to determine cytotoxicity. MTT is a yellow 
tetrazolium salt that is reduced to form dark blue formazan crystals. The reduction is 
dependent on the mitochondrial enzyme-succinate dehydrogenase and therefore only 
occurs in viable cells.  
 
Cells were cultured on 96-well plates with same densities overnight and treated with 
different concentrations of copper in chelexed media for 48 hours. MTT was 
prepared to 2.5 mg/ml in Dulbecco’s Modified Eagle Media/Ham’s F-12 and filtered. 
Then media was removed from the plates and 50 µl of MTT was added per well. 
Cells were incubated for 30 minutes at 37
o
C with 95% O2 and 5% CO2. MTT was 
removed carefully before 100 µl propanol was added per well to dissolve crystals 
and incubated for at least 30 minutes. The absorbance of this colored solution was 
quantified by measuring at a wavelength of 570 nm by FLUOstar Omega (BMG 
Labtech). Each treatment was conducted in triplicate. 
 
Chapter 2. Materials and Methods 
 56 
2.20 Protein concentration determination  
2.20.1 Bradford assay 
Bradford assay was used to determine the protein concentration of cell lysate. 5 fold 
Biorad protein assay reagent (Biorad) was diluted 1:5 with dH2O. Bovine serum 
albumin (BSA) protein standards were prepared ranging from 0-4 mg/ml from a 
stock of BSA at 4 mg/ml in dH2O. 2 µl of BSA standard or cell lysate and 198 µl 
diluted protein assay reagent were mixed in a 96-well plate and incubated at room 
temperature for 15 minutes. The absorbance of each well was measured at 595 nm 
and recorded in a micro-plate reader (FLUOstar Omega). The protein concentration 
of the cell lysate was determined by analyzing the data in Excel software.  
 
2.20.2 UV absorbance 
This method was used to determine the concentration of recombinant proteins. 
Protein samples (100 µl) and appropriate buffer (900 µl) were transferred to a quartz 
cuvette and mixed properly. The absorbance at 280 nm was measured in a Cary 50 
Bio UV-visible spectrophotometer (Varian) before it was zeroed using the same 
buffer. Protein concentrations were calculated by using the principles of 
Beer-Lamberts law:             A280 = log10(P0 / P) = abc 
where, A280 = absorbance at 280 nm, P0 = the incident light intensity, P= the 
emergent light intensity, a = the molar absorption coefficient (M/cm), b = the path 
length of the protein sample (cm) and c = the solute concentration (M). The 
theoretical molar absorption coefficients were determined by the amino acid 
sequences of the proteins (us.expasy.org/tools/protparam.html).  
 
2.21 Isothermal Titration Calorimetry (ITC) 
ITC experiments were carried out in a Microcal titration calorimeter (Microcal 
VP-ITC). Protein samples and metal solutions were adjusted to an appropriate 
concentration in chelex-treated MilliQ H2O or 10 mM MES buffer pH 7. All solutions 
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were filtered through a 0.22 µM filter and degassed before use. All reactions and 
measurements are performed in an enclosed cell maintained at 25°C. A time course of 
30 injections of 4 µl or 8 µl metal solution was titrated into a cell containing protein 
stirring at 300 rpm. Injections were separated by 120 seconds to allow temperature 
equilibration. The instrument measured the heat change, generated or absorbed, as 
metals reacted with protein. The data presented as a binding isotherm by the 
instrument was expressed in terms of the heat change per mole of metal solutions 
titrated into protein sample against the metal to protein molar ratio. The binding 
affinities, the change in enthalpies and the change in entropies were obtained by 
analyzing the data through the Origin 5.0 software from MicroCal.  
 
When analyzing the data, a base-line correction was applied. For each experiment, the 
data was subtracted from a series of injections of metal solutions into a buffer blank 
relating to the heat of dilution of the metal into protein samples. After that, a nonlinear 
least squares method was used to minimize χ
2
 values and acquire best fit parameters 
for the binding constants, Ka and heating change, ∆H°. In all experiments, the optimal 
values were obtained in the sequential binding sites model, whereby the numbers of 
binding sites were determined to fit in a sequential manner by the user. In all cases, 1 to 
10 binding sites model were tried to ensure that the best-fit model was obtained.  
 
2.22 Electron paramagnetic resonance spectroscopy (EPR) 
EPR, also referred to electron spin resonance (ESR), is a technique for studying 
chemical species that have one or more unpaired electrons, including organic free 
radicals and transition metal ions. In the presence of an external magnetic field with 
strength B0, the electron possesses two energy states. The separation between the 
lower energy state and the upper state is ∆E = geµBB0, where ge is the electron's 
so-called g-factor. An unpaired electron can move between the two energy levels by 
either absorbing or emitting electromagnetic radiation of energy ε = hν such that the 
resonance condition, ε = ∆E, is obeyed. Substituting in ε = hν and ∆E = geµBB0 leads to 
the fundamental equation of EPR spectroscopy: hν = geµBB0. 
 
Structural information can be determined by investigating the transition metal ions 
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and radicals in proteins. Synuclein protein samples were prepared at a concentration 
of 100 µM in 20 mM N-ethylmorpholine (EM) buffer pH 7.4. Different equivalents 
of Cu(II) were added into protein samples before they were transferred into the 3 mm 
internal diameter quartz EPR tubes and frozen in liquid nitrogen. The experiments 
were performed in a Bruker continuous wave EPR spectrometer at temperature of 20 
K. All the spectra were operated at X-band with 100 kHz magnetic field modulation, 
with modulation amplitude of 0.5 mT and microwave power of 2 W. The data was 
analyzed and plotted in Peisach-Blumberg plots to assign the structure of 
copper-binding sites in synuclein proteins.  
 
2.23 Cyclic Voltammetry (CV) 
All measurements were conducted in a 50 ml three-terminal cell consisting of a 3 mm 
diamond boron-doped diamond working electrode (Diafilm
TM
, Windsor Scientific, 
UK), a platinum foil counter electrode and a reference electrode saturated with 
potassium chloride (SCE, REF401, Radiometer). The working electrode was polished 
on a fresh micro cloth (Buehler, UK) with alumina slurry (1 micron, Buehler, UK) 
followed by thoroughly rinsing with dH2O. Then the diamond electrode was immersed 
into the protein solution for 1 minute to allow the protein deposit on the electrode. 
 
All of the electrochemical measurements were carried out at room temperature in 10 
mM MES buffer pH 7.0, which stabilized the reaction solution. Prior to the 
experiments, solutions were degassed with high-purity nitrogen to deaerate the system, 
and a continuous flow of nitrogen was conducted to prevent air from coming in to 
contaminate the reaction solution.   
 
The voltammetric measurement was manipulated by a µ-Autolab III potentiostat 
system (Eco Chemie, The Netherlands) connected to a personal computer. A current 
was introduced into the reaction system by the counter electrode. Electrons were 
absorbed or released from the protein-diamond electrode surface, resulting in the 
reduction or oxidation reactions, which can be detected by the computer system. All 
the cycles were scanned within the potential range –0.5 V-0.5 V (step potential 0.0042 
mV). The data obtained was analyzed with the Autolab software. 
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2.24 Mass spectroscopy 
Mass spectroscopy is an analytical technique that identifies the chemical composition 
of a compound or sample based on the mass-to-charge ratio of charged particles. A 
sample undergoes chemical fragmentation forming charged particles (ions). The ratio 
of charge to mass of the particles is calculated by passing them through electric and 
magnetic fields in a mass spectrometer. Synuclein proteins were made at a 
concentration of 50 µM in chelex treated MilliQ H2O pH 7. All the experiments were 
carried out in the Quadrupole time-of-flight (Q-TOF) or matrix-assisted laser 
desorption ionization (MALDI) mass spectrometers in the University of West 
England.  
 
2.25 Nuclear magnetic resonance spectroscopy (NMR) 
NMR is a powerful technique for studying the structures of proteins in solution. It is 
a property that magnetic nuclei have in a magnetic field and applied electromagnetic 
pulse. The nuclei absorb energy from the electromagnetic pulse and radiate this energy 
back out. The energy radiated back out is at a specific resonance frequency which 
depends on the strength of the magnetic field and other factors. This allows the 
observation of specific quantum mechanical magnetic properties of an atomic nucleus. 
Chemical shift is used to probe the chemical structure of molecules which depends on 
the electron density distribution in the corresponding molecular orbitals. Synuclein 
protein samples from different purification methods were prepared at a concentration 
of 1 mM in chelex treated MilliQ H2O pH 7. The experiments were performed in the 
Bruker 600 MHz spectrometer at room temperature by Dr Jill Madine in the 
University of Liverpool.  
 
2.26 Circular dichroism spectroscopy (CD) 
CD spectroscopy measures differences in the absorption of left-handed polarized light 
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versus right-handed polarized light which arise due to structural asymmetry. 
Secondary structure can be determined by CD spectroscopy in the "far-uv" spectral 
region (190-250 nm). At these wavelengths the chromophore is the peptide bond, and 
the signal arises when it is located in a regular, folded environment. aS protein 
samples from different purification methods were prepared at a concentration of 50 
µM in chelex treated MilliQ H2O pH 7. The samples were transferred to cuvettes 
with 1 mm path length. The CD spectra were measured from 180 nm to 270 nm at 
room temperature. Two scans were averaged and the buffer background was 
subtracted.  
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Chapter 3. Expression and Purification of 
aS 
3.1 Introduction 
aS and bS were first discovered in the cytosolic extract of human brain by western 
blotting with anti-tau antibody (Jakes, Spillantini et al. 1994). While their precise 
function and biochemical features are still not fully understood, there is cumulative 
evidence showing that aS is a metal-binding protein. In this study, recombinant 
His-tagged and untag synucleins were used to investigate their metal-binding 
characteristics. aS was first overexpressed as Hig-tag fusion proteins in E.coli and 
purified by immobilised metal affinity chromatography (IMAC). 
 
IMAC is a common technique used for the purification of recombinant proteins. It is 
based on the specific co-ordinate covalent binding of amino acids, particularly 
histidine, to metals. This technique works by allowing proteins with an affinity for 
metal ions to be retained in a column containing immobilized metal ions, such as 
cobalt, nickel, copper, zinc, or iron ions. (His)6-tags in the fusion proteins have an 
affinity for nickel or cobalt ions which are co-ordinated with a chelator for the 
purposes of solid medium entrapment. The protein of interest is eluted either by 
changing the pH or by adding a competitive ligand such as imidazole. In this study, 
His-tag proteins were applied to a Ni(II) charged HiTrap chelating HP column and 
eluted with a gradient concentration of imidazole.  
 
Untag synucleins were also purified in this project. Presently, two major purification 
methods are used in other research groups working on aS. The first one, which is the 
most common one, is to use a boiling step to semipurify the cell lysate during 
purification. This is based on the heat stability of aS demonstrated by Weinreb et al. 
(1996), where circular dichroism (CD) spectroscopy indicated that the structural 
properties of aS were unchanged post boiling (Weinreb, Zhen et al. 1996). 
Nevertheless, a more recent research by Uversky et al. (2001) showed that 
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conformational transition in aS from natively unfolded state to a partially folded 
intermediate with β–sheet is induced by high temperatures (Uversky, Lee et al. 
2001). Moreover, the rate of aS fibrillation was shown to be accelerated by high 
temperatures. This might be due to theβ–sheet in the partially folded intermediate, 
which forms the major part of the secondary structure in aS fibrils (Uversky, Li et al. 
2001). The second method involves an acid precipitation step before loading the cell 
extract onto an ion exchange column during purification. The pH was decreased to 
precipitate some of the contaminant proteins in the cell lysates; however, it was later 
shown that acidic conditions influence the structure of proteins (Salt D.J. et al. 1982). 
In this study, a new, gentler method, involving only ion exchange chromatography 
(IEC), was designed to purify synucleins. Three various methods were compared in 
this study.  
 
3.2 Expression and purification of His-tagged aS 
Plasmid pDFP1a (Table 2.3), a derivative of pTrcHis A in which the ORF of aS was 
cloned into Xho I/Kpn I (appendix B), was transformed into BL21(DE) cells to 
overexpress (His)6-aS. BL21(DE) cells carrying this plasmid were grown in batch 
culture to OD600 of 0.4-0.6, followed by inducing the protein with 1 mM IPTG.. After 
3 hours of induction, the cells were harvested by centrifugation, re-suspended in urea 
buffer and frozen at -20
o
C. The cell lysate was prepared as discussed before in 
chapter 2 and loaded onto an IMAC column. (His)6-aS was eluted with 100 mM 
imidazole/urea buffer. Samples from each fraction were analyzed by 12% 
SDS-PAGE (Fig 3.1) and western blots.  
 
As can be seen in Fig 3.1, the majority of the protein was washed off from the 
column in the presence of 25 mM imidazole, whilst a smaller amount of protein 
remained bound and began eluting at 100 mM imidazole. The protein was present in 
the eluted fractions but not in the flow-through. The molecular weight of the 
(His)6-aS is about 18.6 kDa.  
 
 






Fig. 3.1 Purification of (His)6-aS and analyzed in 12% SDS-PAGE gel.  
Lane a, molecular weight standards (kDa); lane b and c, cellular proteins before 
and after (3hours) induction with IPTG; lane d, soluble proteins in urea buffer; 
lane e, protein flow through the IMAC column; lane f, flow through column 
after 25 mM imidazole wash; lane g-l, fractions eluted with 100 mM imidazole. 
 
All fractions containing the target proteins were pooled and dialyzed against 
chelex-treated water and 2-6 µg of each sample was applied to SDS-PAGE to check 




Fig. 3.2 Purified aS was separated on a 12% SDS-PAGE gel.  
Lane a, molecular weight standards (kDa); lane b, (His)6-aS. 
 
                (His)6- aS      
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3.3 Expression and purification of untag aS  
Presently, two main strategies are employed for the purification of synuclein; one 
involves high temperature while the other involves lowering the pH of the cell lysate.   
As demonstrated, however, these two conditions can potentially cause damage to 
protein structures, rendering these purification methods less than ideal for the 
purpose of purifying synuclein. In this study, a milder method was introduced and 
compared with the two strategies discussed above, where the most approrpaite 
method was selected for the purification of all proteins used in this project.  
 
3.3.1 Three different purification methods 
Plasmid pDFP4a was transformed into BL21(DE) cells to overexpress aS. BL21(DE) 
cells were grown in batch culture to OD600 of 0.4-0.6 where the protein was induced 
with 1 mM IPTG. After 3 hours of induction, the cells were harvested by 
centrifugation. The cell lysates were prepared differently using different methods.  
 
3.3.1.1 Boiling and precipitation (Volles and Lansbury 2007) 
100 ml of induced cell culture was harvested by centrifuging at 8000 g for 6 minutes. 
The cell pellets were re-suspended in 750 µl TEN (50 mM Tris pH 8, 10 mM EDTA, 




The eppendorf was placed directly into a boiling water bath, boiled for 7 minutes and 
centrifuged at 21000 g for 4 minutes at room temperature. The yellowish supernatant 
was removed and placed into a 1.5 ml tube, followed by the addition of 136 µl of 
10% streptomycin sulfate. 228 µl glacial acetic acid was then added per ml of 
supernatant and mixed before it was centrifuged at 21000 g for 2 minutes to 
precipitate the ribosomal proteins and nucleic acid. The yellowish supernatant was 
decanted into a 2 ml tube and mixed with the same volume of saturated ammonium 
sulfate (prepared in MilliQ water at 4
o
C). The aS protein was precipitated by 
centrifugation at 21000 g for 2 minutes. The protein pellet was washed with 50% 




C) by vortexing and centrifugation to get rid of the residual 
acetic acid. Finally, the protein was re-suspended in 20 mM Tris-HCl pH 8 buffer and 
dialyzed in chelex-treated MilliQ water for further analysis. Due to the solubility of 
protein, only the purified aS from last few steps of analysis was analyzed on 12% 
SDS-PAGE (Fig 3.3). The molecular weight of untag aS is about 14.5 kDa.  
 






Fig. 3.3 Purified aS was analyzed on a 12% SDS-PAGE.  
Lane a, molecular weight standards (kDa); lane b, aS resuspended in Tris-HCl 
pH 8 buffer; lane c-d, aS after dialysis in chelex treated MilliQ water. 
 
3.3.1.2 Acid precipitation (Conway, Harper et al. 1998) 
1 L of induced cell culture of aS was harvested by centrifuging at 8000 g for 6 
minutes. The cell pellets were lysed mechanically by sonication in 10 mM NaAcetate, 
1 mM EDTA pH 4 (buffer C) with 1 mM PMSF and 50 ug/ml DNase. The cell lysate 
was spun for 1 hour at 25000 g and the pellets were discarded. The supernatant was 
acid precipitated on ice by adjusting the pH to 4 using 10% acetic acid. The 
suspension was stirred on ice for 30 minutes before it was spun for 1 hour at 25000 g. 
The supernatant was retained and loaded on the 5 ml cation exchange HiTrap SP HP 
column equilibrated with 2 CV buffer C. The column was then washed with 2 CV 
buffer C, and a broad gradient elution (10 CVs) from 0 – 60% 10 mM NaAcetate, 1 
mM EDTA, 2 M NaCl pH 4 (buffer D) was performed to elute aS. The program was 
shown in appendix D. As was shown in the UV chromatogram, a peak was observed 
as semi-purified cell lysate was loaded onto the column (Fig 3.4A). A broad low peak 
appeared during the flow of a low concentration of buffer D, while a tight high peak 
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corresponded to the eluted fractions of aS (Fig 3.4A), analyzed on a 12% SDS-PAGE 

















Fig. 3.4 Purification of aS by cation exchange chromatography.  
A: UV chromatogram showing the process of protein loading and elution. B: 
Eluted aS fractions analyzed on a 12% SDS-PAGE. Lane a, molecular weight 
standards (kDa); lane b-j, eluted aS fractions.  
 
The purified aS was then buffer exchanged to 20 mM Tris-HCl pH 8 buffer through 
PM10 membrane (Millipore) and dialyzed against chelex treated MilliQ water for 
further analysis. 
 
3.3.1.3 Anion exchange chromatography 
1 L of induced cell culture of aS was harvested by centrifuging at 8000 g for 6 
minutes. The cell pellets were lysed mechanically by sonication in 10 mM Tris-HCl, 
1 mM EDTA pH 8 (buffer A) with 1 mM PMSF and 0.5 mg/ml DNase. The cell 
A 
B 




a  b  c d  e  f  g  h  i  j 
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lysate was spun for 1 hour at 25000 g and the pellets were discarded. The supernatant 
was loaded on the 50 ml anion exchange Q sepharose column equilibrated with 2 CV 
buffer A. The column was then washed with 2 CV buffer C and a broad gradient wash 
(2 CVs) from 0 – 11% 10 mM Tris-HCl, 1 mM EDTA, 2 M NaCl pH 8 (buffer B) was 
performed followed by 2 CVs of 11% buffer B wash. aS was eluted by 11%-50% 
buffer B (4 CVs). The program was shown in appendix D. As was shown in the UV 
chromatogram, a peak was observed as semi-purified cell lysate was loaded onto the 
column (Fig 3.5A). A broad low peak appeared during the flow of a low 
concentration of buffer B, while a tight high peak corresponded to the eluted 



















Fig. 3.5 Purification of aS by anion exchange chromatography.  
A: UV chromatogram showing the process of protein loading and elution. B: 
Eluted aS fractions analyzed on a 12% SDS-PAGE. Lane a, molecular weight 
standards (kDa); lane b, cell lysate; lane c-d, flow through; lane e-v, eluted aS 
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Fractions containing aS were pooled and filtered through a PM30 membrane 
(Millipore), where most of the contaminants were trapped above the membrane while 
the protein passed through the filter (Fig 3.6A). Finally, the purified aS was 











Fig. 3.6 Purified aS by PM30 membrane analyzed on a 12% SDS-PAGE. 
A: Lane a, molecular weight standards (kDa); lane b, pooled fractions from 
anion exchange chromatography; lane c, aS passed through PM30 membrane. B: 
Lane a, molecular weight standards (kDa); lane d, concentrated aS.  
 
3.3.2 Comparison of aS from different purification methods 
Matrix Assisted Laser Desorption Ionisation (MALDI) mass spectrometry indicated 
that the aS purified from the three methods was of the right size at 14460 dalton and 
was more than 95% pure (Fig 3.7). Due to the limitation of the technique, no 










Fig. 3.7 Mass spectrometry of purified aS.  
A: aS purified using boiling and precipitation method. B: aS purified using acid 
precipitation and cation exchange chromatography. C: aS purified using anion 
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Interestingly, two-dimensional nuclear magnetic resonance (NMR) spectroscopy 
demonstrated slight differences in the structure of aS from the different purification 
strategies used (Fig 3.8), where the precise changes were unknown because the 
protein was un-labled on nitrogen, carbon or hydrogen atoms. As seen in Fig 3.8D, 
few variation in conformations between the two proteins were observed when the 
data of aS from acid precipitation preparation and anion exchange chromatography 
were overlayed and compared. The concentration of aS used in this experiment was 1 
mM. However, it appeared that the concentration of aS from the boiling and 
precipitation strategy was much lower in comparison to the other two strategies used 
(Fig 3.8A). This might have been due to the aggregation of the protein according to 
the raw data due to the observation of very few crosspeaks in the 2D spectrum. This 
conclusion was confirmed by loading the sample to a size exclusion column linked 
with a multiangle light scattering (Fig 3.9). Multiangle light scattering is a technique 
for measuring, independently, the absolute molar mass and the average diameter of 
particles in solution, by detecting how it scatters light. The intensity of light scattered 
at different discrete angles is measured simultaneously by either a single detector on a 
goniometer, a series of detectors or an array of detectors. Three peaks were detected 
for aS obtained using the boiling method, whereas two peaks were detected for the 
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Fig. 3.8 NMR spectroscopy of purified aS.  
A: aS purified using boiling and precipitation method. B: aS purified using acid 
precipitation and cation exchange chromatography. C: aS purified using anion 
exchange chromatography. D: overlayed data of aS from acid precipitation (red) 























Chapter 3. Expression and Purification of aS 
 73 
aS (Boil)  
 
 
aS (Acid prep) 
 
aS (Anion exchange) 
 
 
Fig. 3.9 Data from light scattering analysis for Comparison of aS purified with 
boiling, acid prep and anion exchange methods.  
Three peaks are indicated for aS from boiling method. Peak 1 indicates aS 
aggregates. Green: UV absorbance; Blue: differential refractive index data; Red: 
count rate. 
 
1 2 3 
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Similarly, far-UV circular dichroism (CD) spectroscopy showed that the structures of 
aS purified using acid precipitation and anion exchange chromatography were similar, 
and were also different from that of the more compacted structure of aS prepared by 
boiling and precipitation (Fig 3.10). aS obtained from the boiling method 
demonstrated a more negative value of [θ]222 nm than the protein purified by anion 
exchange chromatography and acid precipitation methods (Fig 3.10), suggesting that 
aS contained a higher degree of helical secondary structure due to boiling. This 
explained why the protein sample from the boiling method was more prone to 




Fig. 3.10 Comparison of far-UV CD spectra on aS from different methods.  
Measurements were carried out at 25°C. At least three scans were carried out 
for each experiment.  
 
Considering the results from MALDI mass spectrometry, NMR spectroscopy, light 
scattering and far-UV CD spectroscopy, aS purified from acid precipitation and anion 
exchange chromatography techniques were of similar conformation, while the 
protein that undergone a high temperature resulted in a more compact structure. 
Consequently, the two methods involving cation exchange and anion exchange 
chromatography were found to be more reliable, and were used in subsequent 
purification of the protein. 
 
Chapter 3. Expression and Purification of aS 
 75 
3.4 Discussion 
His-tagged proteins firstly used in the study as fusion protein were widely used in the 
aS research (Uversky, Lee et al. 2001; Choi, Sung et al. 2002) and the histag showed 
no adverse effect on copper binding to the prion protein (Thompsett, Abdelraheim et 
al. 2005). However, the induction of the His-tagged protein was too low for 
purification. The matter was further complicated by the presence of extra amino 
acids, excluding the (His)6 tag, in the N-terminus region of the target protein. This 
may be problematic if the protein was to be used for characterization analyses, as the 
presence of extraneous amino acids may affect protein features with regard to copper 
binding. As a consequence, untagged version of the protein was introduced to avoid 
this potential problem.   
 
Until recently, the most common forms of purification of aS involve either a boiling 
step or acid precipitation during the preparation of the cell extracts (Jakes, Spillantini 
et al. 1994; Weinreb, Zhen et al. 1996; Giasson, Uryu et al. 1999; Narhi, Wood et al. 
1999; Hoyer, Antony et al. 2002; Lee, Paik et al. 2004). The protein extraction was 
prepared at high temperature owing to the protein’s apparent heat stability (Weinreb, 
Zhen et al. 1996). However, Uversky et al. (2001) demonstrated that aS experienced 
a transition from a natively unfolded state to a partially folded conformation with 
some β–sheet, forming the main component of secondary structures in aS fibrils. 
Whilst the rate of aS aggregation was accelerated by high temperature, the structural 
changes induced by heating were found to be reversible (Uversky, Lee et al. 2001). 
In this study, conformation variations were detected by CD, NMR spectroscopy and 
light scattering for aS produced by the boiling protocol. More secondary structures 
were observed in the protein compared to those from the other two purification 
protocols (Fig 3.8, Fig 3.9 and Fig 3.10), suggesting that the accumulation of aS 
might be due to the more compacted structure. This explained the reason for protein 
aggregation observed in NMR spectroscopy. However, far-UV CD spectra 
demonstrated an essentially unfolded polypeptide chain for aS, including the
 
characteristic minimum in the vicinity of 196 nm and the absence
 
of bands in the 
210-230 nm region (Uversky, Li et al. 2002). In that experiment, aS was extracted 
from the human brain tissue and purified by boiling and chromatography system. In 
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this study, the negative peak of the far-UV spectra for aS purified by the boiling 
protocol was around 208 nm and the [θ]222 nm intensity was much higher, illustrating 
a higher degree of secondary structure. This may be due to the freezing and 
re-thawing of the protein, making it more prone to assembly as boiling may have 
caused an alteration to protein conformation. Having said this, the structure was even 
more unfolded straight after purification. This hypothesis was confirmed by the 
observation from NMR analysis. NMR chemical shifts were frequently applied to 
investigate the propensity of natively unfolded proteins to probe the different regions 
of conformational space (Eliezer, Kutluay et al. 2001; Bertoncini, Rasia et al. 2007; 
Sung and Eliezer 2007). The distribution of the dots in the 2D plot (Fig 3.8) was in 
close agreement with that demonstrated by other groups (Eliezer, Kutluay et al. 2001; 
Wu, Kim et al. 2008). As the majority of studies employing the boiling step in 
protein purification were mainly concerned with the investigation of synuclein 
aggregation, this may explain why the changes in protein properties causing 
aggregation were not realized during these studies. (Giasson, Uryu et al. 1999; Narhi, 
Wood et al. 1999; Hoyer, Antony et al. 2002). Interestingly, aS purified using acid 
precipitation showed a similar structure to that of aS prepared by anion exchange 
chromatography, a very common and mild technique for protein purification.  
 
In the protocol for anion exchange chromatography, PM30 membranes (Millipore) 
were used in the last step to trap the high molecular contaminants. Gel filtration 
chromatography was initially used to separate aS from the contaminant species but 
was unsuccessful. aS was shown to behave abnormally on FPLC gel-filtration 
chromatography with the apparent molecular mass of 70 kDa, which might due to its 
unfolded structure (Paik, Lee et al. 1997). This provides an explanation as to why 
some molecules of 35-45 kDa in size always eluted with the target protein during gel 
filtration chromatography. These molecules were retained by the PM30 membrane 
while the synucleins were filtered through; this is most likely due to the differences 
in cellulose material between the membrane and the gel filtration mechanism.  
 
To maintain the results in this project in a comparable manner, acid precipitation and 
cation exchange chromatography were utilized to purify most of the proteins in this 
study. Additionally, the anion exchange chromatography was found not to be 
practical for the purification of some of the proteins, such as aS1-100 and aS1-100 
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H50A, due to the high isoelectric points (pI). The pI of synuclein proteins purified 












Chapter 5. Metal-binding properties of synucleins measured by ITC 
Chapter 4. Cu(II) binding modes of 
synucleins determined by EPR spectroscopy 
4.1 Introduction 
Several possible mechanisms for metal-stimulated fibrillation of aS can be envisaged. 
The simplest would involve direct interactions between aS and the metal, leading to 
structural changes in aS, and resulting in the enhanced propensity to aggregate 
(Uversky, Li et al. 2001). Analysis of far-UV CD at pH 7.5 with 35 µM aS and 2 mM 
metals indicated that Cu(II) resulted in a large increase in negative ellipticity around 
222 nm, suggesting an increase in secondary structure change (Uversky, Li et al. 2001). 
In contrast, a recent study showed that Cu(II) does not affect the structural features 
inherent to the spontaneous aggregation of aS, and copper-induced fibrils exhibit the 
same morphology as those formed in the absence of the cation (Rasia, Bertoncini et al. 
2005). These conflicts create the necessity for the examination of aS-Cu interaction. 
NMR mapping revealed that there are two affected regions in the protein when 
binding to copper. The first one is located in the N-terminus, comprising residues 3-9 
and the histidine within sequence 48-52, while the second region which is less 
effective is within the C-terminus of aS involving residues 119-124 (Binolfi, 
Lamberto et al. 2008). Later EPR spectroscopy studies showed that aS binds Cu(II) 
via two N-terminal binding modes at physiological pH (Drew, Leong et al. 2008). 
The controversy of copper coordination to the regions of aS deserves a more detailed 
study to elucidate the degree of contribution of the individual motifs to the overall 
binding modes. Currently it is still unclear about the mechanism of how copper 
increases aS aggregation. The details of the binding specificity of Cu(II) to aS, i.e., 
the identity of the binding sites and the nature of the anchoring domain, may provide 
important and practical insights into the process. Unlike aS, its homologue bS does 
not fibrillate when incubated under the same condition, but it can be forced to fibrillate 






) and pesticides (Yamin, 
Munishkina et al. 2005). In addition, both of bS and gS inhibit aS fibril formation and 
complete inhibition was observed at 4:1 molar excess of bS and gS over aS (Uversky, 
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Li et al. 2002), although the mechanism is not fully elucidated. In this chapter, Cu(II) 
binding modes of the full length synucleins and their mutants were deconvoluted by 
spectroscopic analyses at physiological pH through the Continuous-Wave (CW) EPR 
technique. It provides an understanding of the role of Cu(II) on the altered structural 
states of aS associated with disease. 
 
4.2 Cu(II) binding modes of aS, bS and gS at pH 7.4 
Synuclein proteins were expressed and purified as described before (Chapter 3) and 
the purity was checked in SDS-PAGE (appendix E). All the protein samples were 
prepared at a concentration of 100 µM in 20 mM N-ethylmorpholine (EM) buffer pH 
7.4. Different equivalents of Cu(II) were added into protein samples before they were 
transferred into the 3 mm internal diameter quartz EPR tubes and frozen in liquid 
nitrogen. Fig 4.1 showed the CW-EPR spectra of aS, bS and gS with 0, 1, 2, 3 and 4 









Fig. 4.1 Continuous-wave EPR of Cu(II) binding to WT aS, bS and gS.  
EPR spectra at pH 7.4 of (A): aS; (B): bS; and (C): gS bound to 0-4 mol 
equivalents of Cu(II). Two Cu(II) binding modes were indicated for three 
proteins. The experiments were performed in a Bruker CW-EPR spectrometer 
at temperature of 20 K. All the spectra were operated with 100 kHz magnetic 






Chapter 4.Cu(II) binding modes of synucleins determined by EPR spectroscopy 
 81 
All three proteins appeared to have similar binding complexes (Fig 4.1). It was 
evident that the hyperfine peaks were very wide, which corresponds to two binding 
modes for each protein, referred as mode 1 and mode 2. The two modes were present 
at all Cu(II) concentrations, at the same ratio throughout the titration, with mode 1 
always the predominant one. Quantification of Cu(II) binding by double integration 
of the EPR spectra revealed that the proportions of Cu(II) bound by mode 1 and 
mode 2 in aS were 75% and 25% respectively. Both signals of the parallel hyperfine 
splitting for the two forms grew upon further addition of Cu(II). The EPR spectra of 
both modes were typical of type II Cu(II) centers with N and O lignds in a 
square-planar or tetragonal environment (Peisach and Blumberg 1974). The 
coordination structure was determined by the A∥ and g∥ parameters which were 
plotted using Peisach-Blumberg diagrams, suggesting 2N2O and 1N3O coordination 
spheres for all three proteins (Table 4.1).  
 
 A∥ (mK) g∥ Coordination 
Mode 1 14.0 2.29 2N2O 
aS 
Mode 2 13.0 2.33 1N3O 
Mode 1 13.9 2.29 2N2O 
bS 
Mode 2 12.9 2.33 1N3O 
Mode 1 14.1 2.29 2N2O 
gS 
Mode 2 13.2 2.33 1N3O 
 
Table 4.1 Spin Hamiltonian parameters of Cu(II) binding modes for human 
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4.3 Comparison of Cu(II) binding modes of aS and its 
mutants at pH 7.4 
To investigate the contributions of N-terminus and His50, aS∆1-9 and H50A mutant 
in which histidine was replaced by alanine were examined. To indentify the residues 
in aS which were involved in the Cu(II) coordination modes, domain-truncated 
models of aS were utilized in the EPR experiments. aS and its mutants were 
expressed and purified as described before (Chapter 3) and the purity was checked in 
SDS-PAGE (appendix E). All the protein samples were prepared at a concentration 

























Fig. 4.2 Continuous-wave EPR of Cu(II) binding to aS and its mutants.  
EPR spectra at pH 7.4 of (A): aS and the N-terminus mutants; (B): aS and the 
C-terminus mutants bound to 1 mol equivalent of Cu(II). Two Cu(II) binding 
modes were indicated for the proteins. The experiments were performed in a 
Bruker CW-EPR spectrometer at temperature of 20 K. All the spectra were 
operated with 100 kHz magnetic field modulation, with modulation amplitude 
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Fig 4.2 shows the comparisons for the titration of aS and its mutants with 1 mol 
equivalent Cu(II) followed by CW-EPR at pH 7.4. As reported for aS, at least two 
different Cu(II) species can be obtained from the EPR spectra for each of the aS 
mutants on the basis of their A∥ and g∥ parameters. In Fig 4.2A, two identical 
coordination species (mode 1 and mode 2) were detected in aS mutants H50A aS, 
aS△1-9 and aS△1-9 H50A. The A∥ and g∥ values obtained for the main species 
fell between the range of values associated with Cu(II) complexs with a 2N2O 
coordination and the values of the other one fell in the range associated with a 1N3O 
binding mode comparing to the previous data (Binolfi, Lamberto et al. 2008; Drew, 
Leong et al. 2008) (Table 4.2). A large increase in the proportion of mode 2 was 
observed in aS△1-9 H50A as the relative signal intensity was stronger (Fig 4.2A). In 
Fig 4.2B, EPR spectra showed that the g ∥  values decreased in aS mutants 
aS△119-126, aS△1-9 H50A △119-126 and aS10-100 H50A when binding to Cu(II), 
and it favoured the 3N1O coordination in the Paisach-Blumberg program comparing 
to the previous data (Drew, Leong et al. 2008) (Table 4.2). This might be due to the 
mutation in the C-terminal region of the protein which is responsible for the donation 
of an oxygen ligand (Rasia, Bertoncini et al. 2005). The proportion of the second 
mode was much higher in aS△1-9 H50A △119-126 and aS10-100 H50A compared 
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 A∥(mK) g∥ Coordination 
Mode 1 14.0 2.29 2N2O 
aS 
Mode 2 13.0 2.33 1N3O 
Mode 1 13.9 2.29 2N2O 
H50A 
Mode 2 12.9 2.33 1N3O 
Mode 1 13.9 2.29 2N2O 
aS△1-9 
Mode 2 12.9 2.33 1N3O 
Mode 1 14.2 2.29 2N2O 
aS△1-9 H50A 
Mode 2 12.7 2.33 1N3O 
Mode 1 16.4 2.23 3N1O 
aS△119-126 
Mode 2 15.9 2.26 3N1O 
Mode 1 16.2 2.22 3N1O aS△1-9 H50A
△119-126 Mode 2 15.1 2.27 3N1O 
Mode 1 16.4 2.23 3N1O 
aS10-100 H50A 
Mode 2 16.5 2.26 3N1O 
 
Table 4.2 Comparison of spin hamiltonian parameters of Cu(II) binding modes 
for aS and its mutants at pH 7.4.  
 
4.4 Comparison of Cu(II) binding modes of bS and its 
mutants at pH 7.4 
As the homologue of aS, bS was assumed to behave in a similar way while binding 
copper. Thus, similar site-directed and truncated mutants were designed in this 
experiment. bS mutants were expressed and purified as described before (Chapter 3) 
and the purity was checked in SDS-PAGE (appendix E). All the protein samples were 
prepared at a concentration of 100 µM in 20 mM EM buffer pH 7.4. Different 
equivalents of Cu(II) were titrated into protein samples before they were transferred 
into the 3 mm internal diameter quartz EPR tubes and frozen in liquid nitrogen. Fig 
4.3 shows this data. 
 




Fig. 4.3 Continuous-wave EPR of Cu(II) binding to bS and its mutants.  
EPR spectra at pH 7.4 of bS and its mutants bound to 1 mol equivalent of 
Cu(II). Two Cu(II) binding modes were indicated for WT bS. The experiments 
were performed in a Bruker CW-EPR spectrometer at temperature of 20 K. All 
the spectra were operated with 100 kHz magnetic field modulation, with 
modulation amplitude of 0.5 mT and microwave power of 2 W. 
 
Two binding components were indicated in Fig 4.3 for WT bS and H65A bS, which 
suggested that the mutation of His65 had little effect on the change of coordination 
modes. However, the ratio of mode 2 increased in H65A bS compared to that in WT 
bS. Two modes were observed for all the mutants although the A∥ and g∥ values 
were slightly different (Table 4.3). The estimation for the structure coordination 
showed two 3N1O components for bS△1-9 H65A and bS10-100 H65A. It seemed 
that the shift from 2N2O in bS to 3N1O in the mutants was produced by the 







Chapter 4.Cu(II) binding modes of synucleins determined by EPR spectroscopy 
 87 
 A∥(mK) g∥ Coordination 
Mode 1 13.9 2.29 2N2O 
bS 
Mode 2 12.9 2.33 1N3O 
Mode 1 14.4 2.29 2N2O 
H65A 
Mode 2 12.9 2.33 1N3O 
Mode 1 14.7 2.23 3N1O 
bS△1-9 H65A 
Mode 2 15.1 2.27 3N1O 
Mode 1 15.0 2.23 3N1O 
bS10-100 H65A 
Mode 2 13.8 2.27 3N1O 
 
Table 4.3 Comparison of spin hamiltonian parameters of Cu(II) binding modes 




EPR spectroscopy has been widely used for determining the interaction between 
Cu(II) and proteins (Klajnert, Cangiotti et al. 2007; Bruschi, De Gioia et al. 2008; 
Gaggelli, Jankowska et al. 2008; Gralka, Valensin et al. 2008). This study showed 
how EPR parameters could help in assigning the most favorable structure of Cu(II) 
complexes in synuclein proteins. EPR spectroscopy identified at least two Cu(II) 
binding modes for human recombinant aS, bS and gS proteins at physiological pH. 
Despite the slight differences in the amino acid sequences between synuclein 
proteins, the three homologues displayed the same Cu(II) binding modes. This result 
was unexpected, because gS lacks the C-terminal region compared to aS while the 
carboxylate-rich C-terminal region was originally thought to drive copper binding. 
  
The predominant mode found for aS was 2N2O (mode 1), which was consistent with 
the study assigning it as｛NH2, N-, β-COO-, H2O｝, involving coordination of the 
N-terminal amine of Met1 and the deprotonated backbone amide and carboxylate 
side chain of Asp2 (Drew, Leong et al. 2008). Based on the A∥ and g∥ parameters, 
the second mode was estimated to correlate well with 3N1O coordination, involving 
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the nitrogen from the imidazole group of His50 (Binolfi, Lamberto et al. 2008). The 
EPR spectrum of H50A aS indicated identical binding modes with WT aS. This 
suggested that the coordinating ligand from the His50 could be replaced by that from 
other amino acid for the Cu(II) coordination mode 2. An analysis using modified 
peptides showed that above pH 6, the coordination of Cu(II) may involve the lateral 
NH2 group of lysine residues upstream of His50 (Kowalik-Jankowska, Rajewska et al. 
2006). EPR spectra showing similar coordination components were also observed in 
both aS△1-9 in which residues 1-9 were knocked out and aS△1-9 H50A aS, 
although mode 2 was more intense for the double mutant (Fig 4.2A). This implied 
that Asp2 might be substituted by Glu13 which could also provide a nitrogen and an 
oxygen ligand in Cu(II) binding modes (Rasia, Bertoncini et al. 2005).  
 
It showed that there was a decrease in the g∥ values for aS△119-126, in which 
residues 119-126 were deleted. The spin Hamiltonian parameters suggested two 3N1O 
coordination components. This implied that amino acids 119-126 contributed to the 
Cu(II) binding event and the involved amino acids could be substituted because the 
relative signal intensity was identical to WT aS (Fig 4.2B). This was confirmed by the 
observation of two identical EPR spectra of aS△1-9 H50A △119-126 and aS10-100 
H50A (Fig 4.2B). It was evident that the ratio of second binding species was much 
higher than that for WT aS, which suggested that the replacement of the amino acids 
in Cu(II) coordination modes might diminish the binding affinities. Based on these 
findings, it implied that when binding to copper, synuclein proteins might not act like 
other type II copper binding proteins such as the prion protein where copper binding 
sites were assigned to certain amino acids, the binding sites disappeared when certain 
amino acids missing or mutated (Klewpatinond, Davies et al. 2008). The 
inconsistence from the other studies might due to the different features of the 
synuclein proteins, which were purified through different methods. As was shown in 
chapter 3, the high temperature enhanced the property of aS to aggregate by altering 
the protein conformation, which could ultimately affect the Cu(II)-binding modes. To 
further elucidate the details of Cu(II) coordination with aS, more work needs to be 
done. Future research could focus on studies on model peptides by employing 
thermodynamic and spectroscopic techniques such as ITC, NMR et al.  
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The EPR parameters of the bS-Cu(II) complexes estimated at least two different 
Cu(II) binding modes which were identical to those for aS (Table 4.1). This might be 
due to the similarity of the amino acid sequences involved in copper coordination, 
including the Met1, Asp2 and His65. Although two identical binding species were 
found in H65A bS, the ratio of second mode was increased compared to bS. This 
implied that substitution of histidine in the coordination made the main mode less 
significant. Interestingly, the EPR spectra were fairly similar for bS△1-9H65A and 
bS10-100 H65A apart from a slight reduction on the signal intensity for bS10-100 
H65A (Fig 4.3), which implied the contribution of the C-terminus of bS to Cu(II) 
binding. However, the A∥ and g∥ values fell in the range associated with two 3N1O 
coordination modes, which could be due to the lack of donation of oxygen ligand 
from Asp121 or Glu125 (Rasia, Bertoncini et al. 2005). This also confirmed that 
residues 1-9 played a role in the copper-binding event as H65A bS displayed two 














Chapter 6. Electrochemistry of Cu(II) bound synuclein proteins 
Chapter 5. Metal-binding properties of 
synucleins measured by ITC 
5.1 Introduction 
Within the last decade, the functional characterization of aS has progressively 
become an area of extensive study; however, the precise function of aS remains very 
much elusive. A significant number of studies have demonstrated that aS plays a 
crucial role in the regulation of membrane lipid component, synaptic vesicular 
turnover, synaptic plasticity, ubiquitin-proteasome processing and could act as a 
molecular chaperon (Dev, Hofele et al. 2003). One of the most crucial functions of aS 
is the effect on cell survival and/or susceptibilities to certain insults involving the 
co-operation of copper. The idea that aggregated aS is responsible for the 
pathogenesis of many neurodegenerative diseases where copper acts as an accelerant 
in the aggregation process is on its way to becoming a universally accepted concept.   
 
Whilst there is cumulative evidence showing that aS binds copper, the identification of 
the binding sites and affinities is still under debate. Initial studies suggested that aS 
binds to 5-10 copper ions with a Kd of 45-60 µM (Paik, Shin et al. 1999; Lee, Lee et al. 
2003). However, Rasia et al showed that aS tightly binds to 2 copper ions per monomer 
with a dissociation constant in the range of 0.1-50 µM and is able to ligate more copper 
ions with significant lower affinity (400-500 µM) (Rasia, Bertoncini et al. 2005). 
There is consensus that aS binds Fe(II); nevertheless, the binding affinities reported 
are different (Golts, Snyder et al. 2002; Binolfi, Rasia et al. 2006).  
 
There has been some controversy in the identification of metal-binding sites. Initial 
studies claimed that the C-terminal region of aS is responsible for copper binding. 
Nevertheless, the following analysis showed the characterization of two distinct 
Cu(II)-binding motifs in aS. The high-affinity binding site encompassing a complex 
conformational array is located in the N-terminal region of the protein, while the 
low-affinity site sits in the C-terminal region (Rasia, Bertoncini et al. 2005). Further 
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analysis utilizing peptides showed that Cu(II) ions appear to be coordinated by the 
N-terminal amine group of methionine (residue 1), the amide nitrogen, and the 
β-carboxylic group of aspartic acid (residue 2) (Kowalik-Jankowska, Rajewska et al. 
2005). They also demonstrated that copper binding is pH dependent. This was 
confirmed by a similar analysis using modified peptides, indicating that at a pH above 
6, the coordination of Cu(II) by His50 may involve the lateral NH2 group of lysine 
residues upstream of His50 (Kowalik-Jankowska, Rajewska et al. 2006). In contrast to 
copper, other metals appear to favour the C-terminus region of aS, which is more 
likely to be involved in low-affinity and non-specific binding to metals. Although a 
considerable amount of evidence has been provided for the mechanism of copper 
binding, there remain several unknowns in this process. The unreliability of many of 
these studies has also been proven (Thompsett, Abdelraheim et al. 2005), and there 
exists limited avaibility with regard to information on the study of full length 
proteins.  
 
In this chapter, isothermal titration calorimetry (ITC) was applied to assess metal 
affinity for recombinant synuclein proteins. ITC can provide direct information about 
the thermodynamics of metal-protein interactions. ITC can be used to measure 
enthalpy and free energy of a reaction and to quantify stoichiometry and affinity; for 
this reason, it allows quantification of complete metal binding thermodynamics. This 
is done by directly measuring the energy associated with a chemical reaction when two 
components are mixed. This is complicated by numerous factors such as heat of 
dilution, heat from redox, precipitation and hydrolysis. Competition for the metal ion 
with the buffer and any chelator must be taken into account (Zhang, Akilesh et al. 
2000).   
  
5.2 Copper binding to His-tagged synucleins 
To test the capability of ITC in analyzing the binding affinities and binding sites of 
aS to copper, His-tagged synucleins were utilized in the experiment. His-tagged 
proteins were expressed and purified as described before (Chapter 3) and the purity 
was checked in SDS-PAGE (appendix E). The complications involved in the study of 
the coordination chemistry of transition metal ions were taken into account. At pH 
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7.0, Cu(II) is insoluble due to the formation of oxide species which can alter the 
protein forms because of their redox activities. It is also important to differentiate 
between specific binding and non-specific binding. Therefore, copper chelators were 
applied to chelate the copper ions until they were transferred to the target molecule 
during the experiments. The coordination of copper with a ligand is physiologically 
appropriate as metal always appears in chelated form and not free in solution under in 
vivo conditions. 
 
Glycine was proven to be the best chelator in this experiment, which has also been 
used as a ligand to study copper binding to the prion protein (Thompsett, 
Abdelraheim et al. 2005). Moreover, the well characterized interaction between 
glycine and Cu(II) must also be taken into account during data analysis. Cu(II) forms 
a bis glycine complex, Cu(Gly)2, in the presence of excess copper. Copper: glycine 
was used in ratio of 1:4 unless otherwise stated. The presence of excess glycine 
ensured that redundant copper titrated was either chelated or bound to the protein to 
avoid the inhibition of reaction due to free copper in the solution. Moreover, the excess 
glycine performed as a competitor to nonspecific protein-copper incorporation. When 
analyzing the data, the chelator can be taken into account by directly modifying the 
equations used to fit the data. Alternatively, the chelator can be accounted for post 
analysis (Zhang, Akilesh et al. 2000; Wells, Jackson et al. 2006), as the chelator only 
affects the absolute enthalpy change and not the number of binding sites. In this 
study, data was analyzed using Origin 5.0 with the Microcal software patch installed. 
Each experimental condition had a blank run with protein present in the chamber 
replaced with buffer. This data was then subtracted from the run with protein present 
to take into account any energy of dilution reaction (Davies, Marken et al. 2009). The 
binding isotherm which fit the data with the lowest X
2
 value was taken as the best fit 
model. From this model, values for Ka and ∆H were calculated along with the most 
likely number of binding sites involved. The Ka values were then adjusted to factor in 
the affinity of copper for glycine. Glycine has been shown to bind two atoms of 








 with β2 




 at pH 7.0 (Davies, Marken et al. 2009). The relative contribution of 
each of these species at the prevalent pH was then used in the final equilibrium to fully 
account for the effect of the chelate. The true Kd values of each copper binding events 
at pH 7.0 were calculated using equation (1), where Kd(app) was the measured 
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apparent dissociation constant by using Origin 5.0 software, Kd
1
 (Gly) and Kd
2
 (Gly) 
were the stepwise dissociation constants for formation of a Cu(Gly)2 complex at pH 




His-tagged bS was used in comparison with aS to investigate whether there were any 
differences in copper binding properties when the amino acid sequences were 
partially changed. The disease-related mutants, His-tagged A30P, E46K and A53T, 
were also used for the assessment of their copper binding properties in relation to 
causing increased aggregation of aS in the presence of copper. All the protein samples, 
different synucleins and the mutant aS proteins were adjusted to a concentration of 20 
µM, proven to be the optimal concentration of His-tagged protein for the experiments. 
All the experiments were performed at pH 7.0 in chelex treated distilled water at room 
temperature. The metal solution of Cu(Gly)4 was titrated into all of the protein samples. 
The final ratio of protein to copper in the reaction cell after each experiment was 1:5. 
The energy change in molar ratio was indicated by dots in the plots of ITC data (Fig 
5.1 and Fig 5.2). All the data has been subtracted from the buffer run, due to heat 
released from the dilution of metal into the buffer. Each experiment was repeated at 
least three times, and where possible, separately prepared protein was used. The 
isotherms obtained from ITC representing the interaction between His-tagged 



















































































      
 

























Fig. 5.1 ITC analysis of copper binding to His-tagged aS and His-tagged bS.  
The panel shows heat change on addition of the ligand (kcalories/mol). (A) 
Cu(Gly)4 (1mM: 4mM) titrated into 20 µM (His)6-aS. Three different models 
were tried. (B) Cu(Gly)4 (1mM: 4mM) titrated into 20 µM (His)6-bS.  
 
(A) His-tagged aS-Cu   
(B) His-tagged bS-Cu 
Two sets of sites         one set of sites         Four sequential sites 
X
2
 = 4218               X
2
 = 63689            X
2
 = 7166 
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The data was tried to fit all possible models by using the fitting program. Fig 5.1(A) 
compared the fitting of three models for His-tagged aS. X
2
 value is equal to the sum 
of the squares of the deviations of the theoretical curves from the experimental points 
divided by the number of degrees of freedom. The two sets of sites model gave the 
lowest X
2
 value and the errors which were less than 10%. The ‘two sets of sites’ 
model uses regression to fit a binding isotherm model that assumes two groups of 
single or multiple independent sites of similar affinity and enthalpy. Table 5.1 
showed the stoichiometry and stability constants for the His-tagged aS and 
His-tagged bS at pH 7.0, where logK values were adjusted to account for the 
contribution of the chelator species to the overall equilibrium at pH 7.0.  
 
 n1 logK1 n2 logK2 
His-tagged aS 1.92±0.03 6.76 3.30±1.29 3.11 
His-tagged bS 2.03±0.08 5.90 5.60±1.72 3.02 
 
Table 5.1 Comparison of log stability constants and number of binding sites for 
copper between His-tagged aS and His-tagged bS.  
The experiments were carried out at pH 7.0 at 25
0
C. n1 and n2 represent the 
number of sites detected within each group of binding sites. Therefore the total 
number of sites was n1 and n2.  
 
The number of sites from the second group (n2) varied for His-tagged aS and 
His-tagged bS and the errors were more than 30% for both of them. K values were 
calculated from the mean of at least two independent experiments, with errors less 
than 10% for K1 and more than 10% for K2. This observation implied that the second 
group of sites was likely located in the His tag with low affinities. The variation in 
number of sites and high errors might be due to the mobility and the instable 
coordination of His tag. There were two copper binding sites (n1) in both His-tagged 
aS and His-tagged bS, where His-tagged bS showed lower binding affinity compared 
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Fig. 5.2 ITC analysis of copper binding to PD-related mutants at pH 7.0.  
The panel shows heat change on addition of the ligand (kcalories/mol). (A) 
Cu(Gly)4 (1mM: 4mM) titrated into 20 µM (His)6-A30P aS. (B) Cu(Gly)4 (1mM: 
4mM) titrated into 20 µM (His)6-A53T aS. (C) Cu(Gly)4 (1mM: 4mM) titrated 
into 20 µM (His)6-E46K aS.  
 
   (A) His-tagged A30P aS-Cu          (B) His-tagged A53T aS-Cu 
(C) His-tagged E46K aS-Cu              
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Again, the two sets of sites model gave the lowest X
2
 value and the errors were less 
than 10%. Table 5.2 showed the stoichiometry and stability constants for the 
His-tagged aS and the disease mutants at pH 7.0. LogK values were adjusted to 





n1 logK1 n2 logK2 
aS 1.92±0.03 6.76 3.30±1.29 3.11 
A30P 3.40±0.01 3.21 0.94±0.11 7.16 
E46K 1.93±0.06 6.19 6.79±0.05 3.76 
A53T 0.97±0.08 5.97 4.11±0.16 2.45 
 
Table 5.2 Comparison of log stability constants and number of binding sites for 
copper between His-tagged aS and the mutants.  
The experiments were carried out at pH 7.0 at 25
0
C. n1 and n2 represent the 
number of sites detected within each group of binding sites. Therefore the total 
number of sites was n1 and n2.  
 
There was a group of sites with high stability constants, representing the copper 
binding sites on the protein. The other group with low log stability represented the 
nonspecific interaction between His tag and copper. The number of sites in this group 
varied in each mutated protein and the errors for K values were more than 20%. 
According to the observation, it seemed that the analysis using the Origin 5.0 
software could only separate the two groups in terms of the binding events caused by 
the disruption of His tag during its interaction with copper in the ITC experiment. 
Therefore, untagged proteins were used in the next experiment.  
 
5.3 Copper binding to untagged aS and bS at pH 7 
Recombinant aS and bS proteins were expressed and purified as described in Chapter 
3 and the purity was checked on SDS-PAGE. Cu(Gly)2 was titrated into the protein 
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solution with 10 mM MES as buffer. Fig 5.3 showed the thermodynamic data for aS 
and bS following subtraction of buffer energies of dilution.  
 












































Fig. 5.3 Thermodynamic plots of synuclein titrated with Cu/Gly at pH 7, 25
0
C. 
Data was after subtraction of the buffers. 10 mM MES was used to stabilize the 
pH throughout the experiment. (A) Plot of aS-Cu reaction. (B) Plot of bS-Cu 
reaction.  
 
The data fitted well into the sequential binding model which assumes that sites are 
filled sequentially and each site is affected by the previous binding event. The 
sequential binding model was used under circumstances where sites within a group 
of sites were not identical, leading to the degeneracy within the two sites (Zhang, 
Akilesh et al. 2000). The model was supplied in the Origin software by Microcal and 
the chelator effect was factored to the overall equilibrium and potentially error prone 
according to equation (1). This was previously demonstrated to be a feasible model 
for the studies of Prion protein (Davies, Marken et al. 2009). Table 5.3 compared the 
values from aS and bS analyzed by a sequential binding model. The means of three 
independent experiments were calculated, with errors between K values not 
exceeding 10%.  
(A) aS - Cu (B) bS - Cu 
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 logKa ∆Gº (kcal/mol) 
K1 7.022 -5.618 
K2 7.274 -5.934 
K3 6.661 -5.441 
aS 
K4 7.356 -4.411 
K1 7.749 -6.649 
K2 7.869 -6.800 
K3 8.033 -7.018 
bS 
K4 7.998 -6.972 
 
Table 5.3 Comparison of log stability constants and number of binding sites for 
copper binding to aS and bS at pH 7.0, 25
0
C. 
Sequential binding model was applied to fit the data. LogK values have been 
adjusted to account for the relative contribution of the chelator species to the 
overall equilibrium. Errors between K values were not exceeding 10%.  
 
Four binding events were detected for both aS and bS with three events of similar 
affinity constants. The binding sites on bS showed higher affinity than those on aS.  
 
5.4 Copper binding to aS mutants 
To investigate the details of copper binding to aS, site-directed and domain-truncated 
mutants were applied for the ITC analysis. The recombinant proteins were expressed 
and purified as described in Chapter 3. The experiments were conducted as before. 
Fig 5.4 showed thermodynamic data for aS mutants following subtraction of buffer 
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(A) aS∆1-9-Cu (B) H50A aS-Cu 
(C) aS∆1-9 H50A-Cu (D) aS1-100-Cu 
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Fig. 5.4 Thermodynamic plots of aS mutants titrated with Cu/Gly at pH 7, 25
0
C. 
Data was after subtraction of the buffers. 10 mM MES was used to stabilize the 
pH throughout the experiments. (A) Plot of aS∆1-9-Cu reaction. (B) Plot of 
H50A aS-Cu reaction. (C) Plot of aS∆1-9 H50A-Cu reaction. (D) Plot of 
aS1-100-Cu reaction. (E) Plot of aS10-100 H50A-Cu reaction. 
 
Again, the data fitted well using the sequential binding model. The chelator effect 
was factored to the overall equilibrium and potentially error prone as before. Table 
5.4 compared the values from aS and its mutants analyzed by the sequential binding 
model. The means of three independent experiments were calculated, with errors 









(E) aS10-100 H50A-Cu 
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 logKa ∆Gº (kcal/mol) 
K1 7.022 -5.618 
K2 7.274 -5.934 
K3 6.661 -5.441 
aS 
K4 7.356 -4.411 
K1 7.340 -6.514 
K2 7.817 -7.167 
K3 6.802 -5.784 
aS∆1-9 
K4 7.073 -6.152 
K1 7.520 -5.134 
K2 5.750 -4.998 
K3 7.070 -5.526 
aS H50A 
K4 7.460 -5.333 
K1 6.980 -4.720 
K2 6.320 -4.962 
K3 6.830 -5.009 
aS ∆1-9 
H50A 
K4 6.910 -5.142 
K1 6.340 -4.600 
K2 6.180 -4.409 
K3 7.040 -5.391 
aS 1-100 
K4 6.410 -5.004 
K1 6.320 -5.371 
K2 6.320 -5.304 
K3 5.910 -4.949 
aS 10-100 
H50A 
K4 6.490 -5.581 
 
Table 5.4 Comparison of log stability constants and number of binding sites for 
copper binding to aS and its mutants at pH 7.0, 25
0
C. 
Sequential binding model was applied to fit the data. LogK values have been 
adjusted to account for the relative contribution of the chelator species to the 
overall equilibrium. Errors between K values were not exceeding 10%. 
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Table 5.4 demonstrated that the affinity value of the second binding site was 1.5 
magnitudes less when the His50 was replaced with alanine. In contrast, the affinity 
constants of the first and third events were slightly increased. However, the number 
of sites remained the same, indicating the involvement of His50 in the interaction 
with copper. The amino acid vicinity might substitute the histidine for the binding to 
copper and affect the copper coordination of the other sites in H50A aS mutant. It 
seemed that the log stability constants of the last three binding events were 
diminished in the double mutant aS∆1-9 H50A, although the number of binding sites 
remained to be four. This suggested that the amino group and His50 were both 
responsible for the copper coordination. Similarly, for aS1-100, the log stability 
constant was enhanced for the third binding site and decreased for the other three and 
the affinity values were reduced for all four sites in aS10-100 H50A. This implied 
that the C-terminal region of aS contributed to the interaction with copper.  
 
5.5 Copper binding to bS mutants 
To investigate the details of copper binding to bS, site-directed and domain-truncated 
mutants were applied for the ITC analysis. The recombinant proteins were expressed 
and purified as described in Chapter 3. The experiments were conducted as before. 
Fig 5.5 showed thermodynamic data for bS mutants following subtraction of buffer 
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Fig. 5.5 Thermodynamic plots of bS mutants titrated with Cu/Gly at pH 7, 25
0
C. 
Data was after subtraction of the buffers. 10 mM MES was used to stabilize the 
pH throughout the experiments. (A) Plot of bS∆1-9-Cu reaction. (B) Plot of 
H65A bS-Cu reaction. (C) Plot of bS∆1-9 H65A-Cu reaction. (D) Plot of 
bS10-100 H65A-Cu reaction. 
 
The data was analyzed by using a sequential binding model. The chelator effect was 
(A) bS∆1-9-Cu (B) H65A bS -Cu 
(C) bS∆1-9 H65A -Cu (D) bS10-100 H65A -Cu 
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factored to the overall equilibrium and potentially error prone as before. Table 5.5 
compared the values from aS and its mutants analyzed by a sequential binding model. 
The mean of three independent experiments were calculated, with errors between K 
values not exceeding 10%.  
 
 logKa ∆Gº (kcal/mol) 
K1 7.749 -6.649 
K2 7.869 -6.800 
K3 8.033 -7.018 
bS 
K4 7.998 -6.972 
K1 7.100 -6.149 
K2 5.830 -4.811 
K3 7.050 -6.309 
bS∆1-9 
K4 7.290 -6.576 
K1 7.600 -5.771 
K2 6.450 -5.201 
K3 7.890 -5.766 
bS H65A 
K4 6.960 -5.900 
K1 7.810 -6.981 
K2 7.640 -6.733 
K3 5.100 -4.591 
bS∆1-9 
H65A 
K4 6.210 -5.755 
K1 7.230 -6.590 
K2 5.350 -4.777 
K3 5.170 -4.349 
bS10-100 
H65A 
K4 Not detected Not detected 
 
Table 5.5 Comparison of log stability constants and number of binding sites for 
copper binding to bS and its mutants at pH 7.0, 25
0
C. 
Sequential binding model was applied to fit the data. Errors between K values 
were not exceeding 10%. 
Chapter 5. Metal-binding properties of synucleins measured by ITC 
 106 
Four binding events were observed in the WT bS and the N-terminal mutants, while 
the affinity constants varied. The logK values of the second and third binding sites 
were two and one magnitude less, respectively, when residues 1-9 were knocked out. 
This occurred on the second and fourth site when the His65 was substituted with 
alanine. However, this variation was shifted to the third and fourth site for the double 
mutant bS∆1-9 H65A. One binding site was missing when the C-terminus was 
deleted and the affinities of the first and second site were decreased. According to 
these observations, residues 1-9, His65 and the C-terminal region were all involved 
in copper coordination.   
 
5.6 Discussion 
The role of metal binding in the physiological and pathological function of aS has 
been the focus for a number of studies on aS protein. However, there have been some 
inconsistencies with regard to previous publications on the copper binding sites and 
affinities for aS (Paik, Shin et al. 1999; Lee 2003; Rasia, Bertoncini et al. 2005). In 
this chapter, a thorough thermodynamic study of copper binding to aS was presented 
to explain the fundamental knowledge of copper binding stoichiometry for the 
metalloprotein.  
 
In order to examine the feasibility of ITC on assessing the aS-Cu interaction, 
(His)6-tag proteins were applied first. It appeared that there was a huge variation on 
the number of binding sites that was most likely contributed by the His tag. This 
could be due to the mobility and instability of the His tag. In addition, there was a 
disadvantage for the use of His-tagged synucleins. The purified protein contained 
additional amino acids at the N-terminus region even when the His-tag was cleaved 
by specific proteinases. This might interrupt the copper interaction as the amino acids 
might be potential factors in stopping copper binding. However, ITC was proven to 
be a feasible method for exploring copper binding to aS despite the inaccuracy in the 
number of binding events caused by the presence of the His tag.  
 
There were four independent copper binding sites detected on untagged aS at pH 7, 
25
o
C through the application of ITC. The logK values were in the range of 6.66-7.36 
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which was in close agreement with current literature (Rasia, Bertoncini et al. 2005; 
Binolfi, Lamberto et al. 2008). Previous studies by other groups have claimed that 
three regions are associated with metal binding to aS: the N-terminus, a region near 
the C-terminus and a histidine at position 50 (Murray, Giasson et al. 2003; Rasia, 
Bertoncini et al. 2005; Sung, Rospigliosi et al. 2006). In this study, single amino acid 
mutated and domain-truncated recombinant proteins were produced and examined by 
ITC for copper binding properties. Four binding events were observed in all the aS 
mutants including aS10-100 H50A at pH 7. This result was unexpected because it 
was previously suggested that copper bound exclusively to the negatively charged 
C-terminal region (Paik, Shin et al. 1999; Uversky, Li et al. 2001). Subsequent 
studies indicated the involvement of the N-terminus and His50 with the high-affinity 
binding site assigned to the N-terminal region (Rasia, Bertoncini et al. 2005). 
However, the affinity constants varied when the amino acid was mutated or deleted 
and the affinity values of four sites were reduced in the absence of the three regions 
(Table 5.4 and Table 5.5). According to this observation, the three domains were 
responsible but not essential for copper incorporation. In their absence, other residues 
became dominant and replace them in the coordination with copper; this explained 
the presence of four binding sites with variable logK constants. The finding on the 
significant reduction in the affinity of second binding site on H50A aS indicated that 
His50 was assigned for the high-affinity anchoring site on aS. A CD and EPR 
spectroscopic analysis using modified peptides showed that above pH6, the 
coordination of Cu(II) may involve the lateral NH2 group of lysine residues upstream 
of His50 (Kowalik-Jankowska, Rajewska et al. 2006), showing that lysine could act 
as a copper anchoring site in the absence of histidine. While the majority of the 
literature suggest for the presence of at least two copper binding sites on aS, there is 
no strong, solid evidence for such inference. CD spectra revealed that aS was not 
saturated even with four equivalents of Cu(II), and spectra of the aS1-108-Cu 
complex was similar to that of the WT protein (Rasia, Bertoncini et al. 2005). In 
addition, the purification of aS from other studies involved the high temperature, 
which was proven to alter the protein conformation in this study. This explained why 
only two binding sites were detected in those researches (Rasia, Bertoncini et al. 
2005). In the recent study showing two Cu(II)-binding sites on aS, no chelators were 
used in the ITC experiment when copper was titrated into the protein solution at pH 7 
(Bharathi and Rao 2007). As is known, at pH 7.0, Cu(II) is insoluble due to the 
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formation of oxide species which can alter the protein forms because of their redox 
activities. This could affect the copper-protein interaction.  
 
Unlike aS, its homologue bS has attracted less attention and the metal-binding 
features have remained largely unexplored. It was reported for the first time that bS 
binds two copper atoms per monomer with the Kd in the range of 0.2-50 µM (Binolfi, 
Lamberto et al. 2008). In this study, four binding sites with higher affinities than aS 
were detected by analyzing the ITC data for bS-Cu interaction. Similarly, residues 
1-9 and His65 were involved in the copper binding but they were not essential as the 
number of sites remained unchanged without their participation. However, one site 
was missing in the absence of the C-terminal region (Table 5.5), indicating that it is 
the only essential contributor for one binding site. The affinity constants were altered 
when any of the three regions was mutated or deleted. This suggested that the three 
regions contributed to the copper binding event. Moreover, there was a manifest 
decrease in the affinity on second binding site on bS∆1-9, implying that the 
higher-affinity site on bS was allocated on the residues 1-9 not on histidine. This 
finding was in close agreement with the literature showing the higher-affinity site 
was assigned to the N-terminal amino group of Met1 (Binolfi, Lamberto et al. 2008). 
In general, the four sites on bS displayed higher affinity for copper than aS (Table 
5.5). The evidence presented here might provide some insight into the mechanism by 
which bS inhibit aS aggregation. This study implied that the preventive effect of bS 
on aS aggregation might be related to the higher affinities for copper. In that case, bS 
competes with aS for copper binding and acts as a copper-sequestering protein, 
playing the role of a copper chelator, hence preventing or attenuating the subsequent 
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Chapter 6. Electrochemistry of Cu(II) 
bound synuclein proteins 
6.1 Introduction 
Accumulating evidence has demonstrated that metals, especially copper, are one of 
the triggers for the aggregation of aS (Atwood, Moir et al. 1998; Paik, Shin et al. 
1999; Shin, Lee et al. 2000; Uversky, Li et al. 2001). Redox-active transition metals 
such as copper and iron, may play an important role in the pathogenesis of 
neurodegenerative diseases by participating in an array of cellular disturbances 
characterized by oxidative stress and increased free radical production (Sayre, Moreira 
et al. 2005). Metal-catalyzed oxidation of proteins require metals to be bound to the 
protein and involves the reduction of metal ions such as Fe(III) and Cu(II). Fe(II) and 
Cu(I) can react with hydrogen peroxide to generate hydroxyl radicals via a Fenton-like 
reaction, and oxidation of neighbouring amino acids (Halliwell and Gutteridge 1986; 
Wright and Brown 2008). The ability of these amino acids in the protein to form 
complexes with metal ions directly influences the susceptibility to metal-catalyzed 
oxidation. Oxidatively modified protein could increase its own tendency toward 
protein aggregation due to the generation of reactive oxygen species (ROS), which 
exert pro-aggregatory effects and turn soluble protein into insoluble forms by either 
inhibiting intracellular proteolysis or causing unusual posttranslational modifications. 
These may then provide the covalent modifications of amino acid residues in proteins 
and formation of protein-protein cross-linkages (Kowalik-Jankowska, Rajewska et al. 
2006).  
 
aS has been shown to be a potential target of intracellular oxidants by the identification 
of posttranslational modifications of synuclein within intracellular aggregates that 
accumulate in PD brains. It has been demonstrated that in the presence of copper and 
hydrogen peroxide, aS experienced Cu(II)-catalyzed oxidation and 
self-oligomerisation, which may lead to possible protein aggregation and 
neurodegeneration (Paik, Shin et al. 2000). This could be almost suppressed by the 
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addition of ascorbic acid or EDTA, indicating that oligomerisation was dependent 
upon not only metal binding but also its subsequent redox reaction in the presence of 
hydrogen peroxide (Paik, Shin et al. 2000). Similar effects of iron and hydrogen 
peroxide on aS aggregation were also observed (Hashimoto, Hsu et al. 1999). 
Therefore, it is important to explore the biochemical features of the protein-metal 
complex, which might shed light on the molecular basis of the aS aggregation. There 
have been no attempts to directly characterise the redox chemistry of as so far. 
Electrochemical analysis was employed for the first time to investigate the amyloid 
formation of aS (Palecek, Ostatna et al. 2008). In traditional electrochemical system, 
protein is analyzed in free solution within a three electrode cell where the effect of 
protein migration through the solution on the electrode potential has to be corrected. 
In addition, the signal from the copper bound protein might be buried due to the high 
background. In this study, a new electrochemical method cyclic voltammetry (CV) 
was designed to describe the electrochemistry properties of copper charged synuclein 
proteins.  
 
Recombinant bS and gS were utilized to compare the redox activities with aS by the 
application of CV experiments. Among the human family members, bS is 62% 
identical and 79% similar to aS, gS is 50% identical and 74% similar to aS (Sung and 
Eliezer 2006). Both bS and gS inhibit aS fibril formation and complete inhibition was 
observed at 4:1 molar excess of bS and gS over aS (Uversky, Li et al. 2002), although 
the mechanism is not fully elucidated. The electrochemical properties investigation of 
bS and gS might provide a better understanding for the effects of the homologues on 
aS aggregation. 
 
6.2 Electrochemical system  
The CV system was set up and all measurements were conducted in a 50 ml 
three-terminal cell consisting of a 3 mm diamond boron-doped diamond working 
electrode (Diafilm
TM
, Windsor Scientific, UK), a platinum foil counter electrode and a 
reference electrode saturated with potassium chloride (SCE, REF401, Radiometer) as 
described before in chapter 2. 10 mM MES buffer was used to stabilize the system at 
pH 7 as this was proven to make minimal background to the voltammagram. The 
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working electrode was prepared as previously described in chapter 2 and immersed 
in the voltammetric cell for recording background signal. The electrode was then 
immersed in apo protein or copper-bound protein samples for one minute before 
being rinsed thoroughly in buffer to eliminate any loosely bound protein. Synuclein 
proteins were shown to be able to adhere strongly to the negatively charged surface 
of the working electrode due to the positively charged regions on the proteins 
(http://mobyle.pasteur.fr/cgi-bin/portal.py). The distribution of charges on synuclein 
proteins were presented in appendix F. All the protein samples were prepared at a 
concentration of 100 µM at pH 7. The electrode was then placed in the CV cell and 
the voltage ramped from 450 mV to -450 mV. Each experiment was scanned at least 
twice and the data represented the second scan. Fig 6.1 shows a typical cyclic 
voltammogram of WT aS bound to copper recorded at a scan rate of 60 mVs
-1
.  














Fig. 6.1 Representative cyclic voltammogram of WT aS bound to copper 
recorded at scan rate of 60 mVs
-1
.  
Blue line indicates that reduction and re-oxidation of aS-Cu complex absorbed 
on the 3 mm diamond boron-doped diamond working electrode. Red line 
represents the background signal of aS without copper bound. The experiment 
was conducted in 10 mM MES buffer pH 7. The step potential was 0.0042 mV.  
 
The background current in Fig 6.1 (red line) was obviously different from the signal 
of aS-Cu complex. A stable redox cycle (blue line) was observed over the 
background. This suggested that the reduction and re-oxidation processes were 
assigned to the copper centres in the aS-Cu complex. Each experiment was scanned 
twice and the signal remained the same, implying the processes were reversible and 
reproducible. The voltammograms were recorded at different scan rates to examine 
the reliability of the redox process (Fig 6.2).  
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Fig. 6.2 Comparison of voltammograms of aS-Cu complex at five different scan rates. 
A. Comparison of voltammograms of aS-Cu obtained at different scan rates. B. 
Plot of the peak current versus the scan rate. C. Plot of the peak potentials 
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Fig 6.2 showed the comparison of voltammetric data of aS-Cu complex at five 
different scan rates and the peak current and potential were plotted against the scan 
rates. Fig 6.2 B presented a linear relationship between peak current and scan rate. 
Ipa and Ipc indicated the peak current of oxidation and reducation respectively. This 
confirmed a permanently surface bound protein and electron transfer directly into the 
protein bound copper (Davies, Marken et al. 2009). This proved that the adsorption 
of the protein was stable and the current responses were highly reproducible and 
reversible. Fig 6.2 C demonstrated the effect of scan rates on the peak potentials. Epa 
and Epc indicated the peak potential of oxdaiton and reduction respectively. Emid 
was the average of Epa and Epc. The characteristic logarithmic dependence was 
consistent with an electron transfer rate limited process, which was represented by 
the equation (Davies, Marken et al. 2009),  
                     
(R, gas constant; T, temperature; n, number of electrons transferred; F, Faraday 
constant; O, oxide on the electrode surface; R reducer on the electrode surface). 
 
It suggested that the peak potential was related to the midpoint potential, the number 
of transferred electrons and the protein-copper complex.  
 
6.3 Redox activities of synuclein-copper complexes 
Synuclein proteins were expressed and purified as described before (Chapter 3) and 
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Fig. 6.3 Voltammograms of synuclein-Cu obtained at scan rate of 60 mVs
-1
.  
The experiments were conducted in 10 mM MES buffer pH 7. The step potential 
was 0.0042 mV. 
 
Fig 6.3 demonstrated different copper centres in three synuclein proteins showing 
different midpoint potentials (Table 6.1). The different copper centres on each protein 
might be electronically distinct but coupled and therefore might not be individually 
resolved. Nevertheless, there was a second small oxidation peak of gS-Cu complex, 
which might indicate an individual copper centre. The midpoint potentials were 
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Midpoint potential Emid (V vs SCE) 
 
1st 2nd 
aS 0.130±0.003 Not detected 
bS 0.140±0.007 Not detected 
gS -0.045±0.005 0.065±0.006 
 
Table 6.1 Comparison of the midpoint potentials from aS, bS and gS.  
 
The midpoint potentials of aS and bS were quite close and were quite different from 
that of gS (Table 6.1). The peak current of oxidation and reduction was nearly 
identical for aS (Fig 6.1), which suggested that the redox cycling was fully reversible. 
However, the current response of reduction was less than the oxidation peak for bS 
and gS (Fig 6.3). This indicated two possibilities: the oxidation was not reversible 
and part of the copper or protein might be oxidized permanently; the reduced Cu(I) 
fell off due to the weak binding to protein. Two oxidation peaks were detected for 
gS-Cu, suggesting the existence of two independent redox process. 
 
6.4 Comparison of electrochemical features of synucleins 
and their mutants 
6.4.1 aS and its mutants 
Previous studies by other groups have suggested three specific regions are associated 
with metal binding to aS. These include the N-terminus, a region near the C-terminus 
and a histidine at position 50. In order to explore the dependence on copper for the 
protein’s apparent redox state, aS mutants lacking the candidate residues for copper 
binding were applied to the cyclic voltammetry experiments. The voltammograms of 
these mutants-Cu complexes were obtained at scan rate of 60 mVs
-1
 and compared 
with WT aS-Cu in Fig 6.4. 
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Fig. 6.4 Comparison of voltammograms of site-directed and domain-truncated 
aS mutants-Cu with WT aS-Cu obtained at scan rate of 60 mVs
-1
. 
The experiments were conducted in 10 mM MES buffer pH 7. The step potential 
was 0.0042 mV. 
 
The voltammograms in Fig 6.4 were obtained from the proteins with the same 
equivalents of copper added. In Fig 6.4 A, the voltammograms exhibited a second 
oxidation peak for the mutant aS△1-9 and H50A, which suggested that the coupled 
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the double mutant aS△1-9 H50A showed similar redox potential to that for WT aS. 
The fact that mutation of either of the regions on aS caused a redox shift without the 
loss of this redox centre strongly suggests that both regions were involved in copper 
coordination without being the main binding residue for redox chemistry. This may 
also point towards a fundamental change in protein structure when these coordinating 
ligands were not present and therefore when copper bound to the protein. The 
midpoint potentials and integrated current peak charges were compared in Table 6.2.  
 
To explore the effect of C-terminus on the copper-dependent redox properties of aS, 
the cyclic voltammetry signals of C-terminal mutated or truncated mutants were 
presented in Fig 6.4 B and C. The oxidation and reduction peaks were eminently 
reduced on aS10-100 H50A and aS1-100, where C-terminus was deleted. Meanwhile, 
the redox peak for aS△119-126 was much higher compared to these two mutants. In 
addition, the redox potential was shifted when the 119-126 residues were knocked 
out, which suggested that this region was involved in copper coordination. The redox 
peak charges were compared in Table 6.2. The plots for the comparison of 
voltammetric data of aS10-100 H50A-Cu complex at different scan rates are shown 
in appendix F, confirming a permanently surface bound protein and electron transfer 
directly into the protein bound copper (Davies, Marken et al. 2009). This proved that 
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aS 0.130±0.003 Not detected 3592±222 -3638±85 
H50A -0.030±0.008 0.089±0.006 2839±140 -1167±89 
aS△1-9 -0.044±0.007 0.077±0.004 3788±314 -2408±71 
aS△1-9 
H50A 
0.103±0.002 Not detected 4082±91 -4195±155 
aS△
119-126 
-0.063±0.005 Not detected 2500±318 -1241±56 




0.092±0.003 Not detected 4775±47 -2971±24 
aS10-100 
H50A 
0.032±0.002 Not detected 668±12 -110±3 
 
Table 6.2 Comparison of the midpoint potentials and integrated peak charges 
from aS and its mutants. 
 
The voltammograms showed without doubt that WT aS was capable of cycling 
electrons when bound to copper. However, when the His50 was replaced with alanine, 
which was proven not to bind copper, the integrated oxidation peak charge was 
diminished by 20% and the reduction peak charge was reduced by nearly 70% (Table 
6.2). There was no obviously change of oxidation peak for aS△1-9, while the 
reduction was about half of the oxidation charge. It was interesting to note that the 
redox activity was restored on the double mutant aS△1-9 H50A (Table 6.2).  
 
Similarly, the oxidation peak charge was slightly reduced on aS△119-126, while the 
reduction was only half of the oxidation charge. Nevertheless, for the C-terminus 
truncated mutants aS1-100 and aS10-100 H50A, only 1007±29 nC and 668±12 nC 
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of responsive oxidation charge was observed respectively, and the reduction peak 
was almost eliminated (Table 6.2). These findings indicated that although the copper 
centres were combined, some of them were not redox reversible or some copper was 
lost from the protein when it was reduced. 
 
6.4.2 bS and its mutants 
The physiological function of bS still remains to be elucidated. Nevertheless, bS has 
been found to inhibit the aggregation of aS and the formation of aS protofibrils 
(Hashimoto, Rockenstein et al. 2001; Park and Lansbury 2003), indicating that bS may 
be an internal regulator of aS. The electrochemistry of bS and its mutants lacking 
candidate residues for copper binding were applied to the CV experiments. The 
voltammograms of these mutant-Cu complexes were obtained at scan rate of 60 
mVs
-1
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Fig. 6.5 Comparison of voltammograms of site-directed and domain-truncated 
bS mutants-Cu with WT bS-Cu obtained at scan rate of 60 mVs
-1
. 
The experiments were conducted in 10 mM MES buffer pH 7. The step potential 
was 0.0042 mV. 
 
It seemed that the redox activity of bS was enhanced when the His65 was substituted 
with alanine, while no increase was detected when residues 1-9 were knocked out 
although the peak potential was shifted (Table 6.3). The ability of bS to exchange 
electrons in the electrode system was greatly decreased when the C-terminal region 
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Midpoint potential Emid 









bS 0.140±0.007 Not detected 1719±89 -931±45 
H65A bS 0.117±0.002 Not detected 2417±74 -2389±13 
bS△1-9 -0.083±0.007 Not detected 1208±67 -307±50 
bS△1-9 H65A -0.055±0.006 0.066±0.002 3113±106 -1178±49 
bS10-100 
H65A 
-0.135±0.001 Not detected 1454±44 -184±4 
 
Table 6.3 Comparison of the midpoint potentials and integrated peak charges 
from bS and its mutants. 
 
It seemed that only half of the copper centres on bS-Cu complex were redox 
reversible because the integrated reduction peak value was about 50% of oxidation 
charge. His65 might inhibit the redox activity especially the reduction of bS-Cu 
because the H65A bS mutant showed reversible electron cycling (Table 6.3). The 
reduction peak was greatly diminished for bS△1-9, indicating amino acids 1-9 
contributed to the reduction process. It was interesting that the oxidation intensity 
was regained for the double mutant bS△1-9 H65A, while the calculated reduction 
charge was not. This finding further confirmed that His65 inhibited the redox activity 
while the region 1-9 activated it. The lack of C-terminus on bS10-100 H65A led to a 
further descend in redox activity especially in reduction process compared to bS△
1-9 H65A, suggesting the C-terminus of the protein was involved in the 
electrochemistry. The calculated charge response in oxidation was 1454±44 nC for 
bS10-100 H65A, which was about half of that for bS△1-9 H65A (3113±106 nC). 
This suggested that C-terminus contributed to half of the electron transfers in the 
process.  
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6.5 Discussion 
The voltammograms showed that aS was capable of exchanging electrons when 
bound to copper. The electrochemistry was completely dependent on the interaction 
with copper because no redox signal was detected on the apo protein. The redox 
cycling was fully reversible (Table 6.1), suggesting that the protein was unaffected 
by continuous oxidation and reduction. However, this was not the case for bS and gS, 
where the reduction peaks were much less than the oxidation peaks (Table 6.1).The 
finding indicated that some of the copper or protein might be oxidized permanently, 
which could prevent the protein from aggregating or Cu(I) was not stable on the 
protein and was lost during the change in oxidation state. Interestingly, there were 
two independent redox centres on gS, while only one was detected on aS or bS 
(Table 6.1). Regarding the decreased reduction peak, one of the copper centres might 
be reduction silent. This implied that bS and gS could act as internal regulators for aS 
aggregation by oxidative and reductive modifications rather than structural 
interruption. This observation may open new avenues for the research on bS and gS 
functions. 
 
The electrochemical property of aS was further examined by investigating the 
mutants lacking potential proposed copper-binding sites. Only one oxidation and 
reduction peak was observed for the WT aS-Cu species, suggesting the copper 
centres were electronically coupled as ITC data in chapter 5 showed that there were 
more than one copper bound. The imidazole ring of His50 was believed to be 
involved in the copper coordination (Kowalik-Jankowska, Rajewska et al. 2006). 
However, the midpoint potential and responsive current peak during the redox 
process on the mutant aS△1-9 H50A was quite close to that for WT aS, indicating 
the amino acids in the proximity might fill in the position and form the identical 
coordination geometry which is consistent with the EPR data in chapter 4. There is 
evidence showing that lysine residues upstream of His50 could act as a copper 
anchoring site in the absence of histidine (Kowalik-Jankowska, Rajewska et al. 2006). 
Similarly, Asp2 might be substituted by Glu13 which could also provide nitrogen and 
oxygen ligand in Cu(II) binding mode (Rasia, Bertoncini et al. 2005). It was 
interesting that the single mutation caused the split of the copper centres and one of 
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them lost the reductive feature, because two oxidation peaks were obtained on H50A 
aS and aS△1-9 but the number of electrons transferred during reduction process 
were about half of that during oxidation (Table 6.2). Similarly, aS△119-126 showed 
slightly decreased oxidative activity but large diminished reductive response (Table 
6.2). This implied that the electrochemistry was mostly dependent on the feature but 
not on the number of the copper centres, because some of the copper centres were 
redox-silent when the original copper-binding sites were replaced. According to the 
observation, the redox capability of aS was contributed by copper bound to the 
residues 1-9, His50 and the C-terminus. The integrated reduction peak charge was 
enormously reduced on aS1-100, indicating the presence of the C-terminal region of 
aS was essential for the reductive electrochemistry, which might be involved in the 
mechanism of inhibition of aS aggregation, providing evidence showing C-terminus 
of aS is a negative regulator of self-assembly. The protein might be partially oxidized 
permanently without the C-terminal region, which could lead to self-oligomerization 
and hence possible protein aggregation and neurodegeneration (Paik, Shin et al. 2000). 
It fits the hypothesis that C-terminus truncated aS constructs are more prone to 
fibrillate in vitro than the full-length protein (Crowther, Jakes et al. 1998; Serpell, 
Berriman et al. 2000; Murray, Giasson et al. 2003). This is confirmed by a recent 




motif in aS can modulate DA inhibition of aS 




 motif (residues 1-124) 
could still form soluble oligomers (Leong, Pham et al. 2009). In addition, the 
biochemically specific copper- or iron-mediated oxidative oligomerization was turned 
out to be dependent upon the acidic C-terminus of aS because the C-terminally 
truncated proteins were not affected by both metals and hydrogen peroxide (Paik, Shin 
et al. 2000). 
 
In contrast to aS, mutation of His65 on bS enhanced the redox activity especially the 
reduction current, producing reversible electron cycling (Table 6.3). This 
demonstrated that His65 was responsible for the inhibition of the electrochemical 
activity of the protein. This was contrast to aS, where His50 contributed to the redox 
activity especially the reduction response which was thought to inhibit the protein 
aggregation (Table 6.2). In addition, there was research showing the mutation on 
His50 could slow down the copper induced aS aggregation. The difference of the 
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electrochemical features on the two proteins indicated two distinct mechanisms for 
the protein aggregation, as no study has reported inhibition of aggregation on the 
His65 mutant. The reductive response was enormously diminished for bS△1-9 and 
bS10-100 H65A, indicating the involvement of residues 1-9 and the C-terminus on 
the redox activity. Little has been investigated about bS, this new technique might 
provide new insight into the role of bS on the inhibition of aS aggregation.    
 
This is the first time CV is employed to investigate the electrochemical property of 
aS. More work needs to be done to confirm some of the hypothesis and uncertainties. 
For example, Cu(I)-aS could be used in the experiment to see if the signal is still 
detectable as Cu(I) was speculated to fall off the protein when Cu(II) was reduced. In 
addition, the number of redox active coppers could be calculated by using the 
integrated oxidation peak charge and weighing the electrode with protein-Cu bound. 
In that case, the electrochemistry of the protein could be investigated in a 
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Chapter 7. Characterization of metal effects 
on synuclein aggregation in mammalian 
cells 
7.1 Introduction 
Two neuropathological hallmarks of PD are LBs and LNs that can occur in the 
dopaminergic neurons of the substantia nigra. These are intracytoplasmic protein 
inclusions whose main components are implicated to be aggregated aS (Goedert 
1999). The etiology of PD is still unknown. The concept that aS aggregation is 
involved in the pathology of PD is widely accepted. LB-like inclusions and neuronal 
cell loss were found in some transgenic, adenoviral, lentiviral-based animal models 
overexpressing aS (Masliah, Rockenstein et al. 2000; Kirik, Rosenblad et al. 2002; 
Lee, Stirling et al. 2002; Lo Bianco, Ridet et al. 2002; Martin, Pan et al. 2006), and 
the dopaminergic cell death was resuced with down-regulation of aS expression in 
the substantia nigra of a PD rat model (Hayashita-Kinoh, Yamada et al. 2006). 
However, the mechanism by which the amyloid-like aggregated aS is formed and 
causes cell death remains unclear. Three potential factors which may contribute to 
the formation of aS aggregates in cells have been identified. First of all, most in vitro 
studies using recombinant proteins suggest that three different missense mutations in 
the aS gene lead to increases in aS aggregation because of an increase in the rate of 
aggregation of mutant proteins compared with WT aS (Conway, Harper et al. 1998; 
Takeda, Hashimoto et al. 1998; Giasson, Uryu et al. 1999). These mutations include 
A30P, E46K and A53T substitutions in aS identified in autosomal dominantly 
inherited, early onset PD (Polymeropoulos, Lavedan et al. 1997; Kruger, Kuhn et al. 
1998). These findings indicate that the mutations of aS might be involved in the 
mechanisms of aS aggregation. Secondly, transition metals are another possible 
trigger involved in the pathogenesis of aS misfolding. There is a great increase in the 
accumulation of aS aggregates and vulnerability to toxicity induced by iron in 
BE-M17 neuroblastoma cells overexpressing aS (Ostrerova-Golts, Petrucelli et al. 
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2000). Binolfi A et al. demonstrated that Cu(II) binds specifically to aS and triggers 
its aggregation by establishing a hierarchy in aS-metal ion interaction. Nevertheless, 
whether the metals promote aS aggregation directly by binding and inducing structure 
change or via increasing levels of oxidative stress is still obscure. Finally, aS is a 
protein which can self aggregate under certain conditions, especially when the 
cellular concentration of aS increases which appears in both familial and sporadic 
forms of PD (Wu, Kim et al. 2008). Thus, it is a key challenge for neuron cells to 
maintain the intracellular levels of aS in a steady state and below the critical 
concentration. Consequently, this brings up the importance of protein transport and 
localization, which has not been intensely investigated. Abnormal accumulation of 
aS in specific cellular organelles may increase local concentration of this protein, 
which may induce the protein self-aggregation, even without altering the total level. 
For example, paraquat treatment promotes nuclear localization of aS and amino acids 
134-139 of aS seem to be responsible for this localization (Goers, Manning-Bog et al. 
2003; Yu, Li et al. 2007). Additionally, translocation of aS to the mitochondria was 
shown to be caused by exposure of cells to various stresses (Cole, Dieuliis et al. 2008; 
Parihar, Parihar et al. 2008; Shavali, Brown-Borg et al. 2008).  
 
The survival of neurons with intracellular LBs shows that intracytoplasmic aS 
aggregates are not toxic to all cells (Spillantini, Schmidt et al. 1997). Considerable 
evidence suggests the loss of homeostasis of the redox active transition metals 
copper and iron plays a role in many neurodegenerative diseases. High levels of iron 
are found in the substantia nigra (Dexter, Wells et al. 1989) and high levels of copper 
in the CSF in PD brains (Pall, Williams et al. 1987). In addition, aS was shown to 
bind to copper and iron (Golts, Snyder et al. 2002; Rasia, Bertoncini et al. 2005; 
Binolfi, Rasia et al. 2006) and aS aggregation is stimulated in the presence of these 
metals (Uversky, Li et al. 2001; Rasia, Bertoncini et al. 2005). These findings 
suggest that the examination of the links between intracellular synuclein proteins and 
metals is desirable.  
 
In this chapter a cell culture system was used to investigate intracellular synuclein 
aggregation in the presence or absence of metals. Aggregates in mammalian 
dopaminergic neuron cells overexpressing synucleins or their mutants were detected 
and assessed by western blotting and confocal microscopy. Cells stably transfected 
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with mutant forms of aS were also created to investigate the potential amino acid 
determinants involved in the translocation of aS. Cell toxicity induced by synuclein 
overexpression was examined in the presence of copper.  
 
7.2 Creation of cell lines overexpressing aS and bS 
SH-SY5Y cells were stably transfected with pcDNA3.1(-) (control), pcDNA3.1(-) aS 
and bS as described in chapter 2. The overexpression of aS and bS was detected by 
western blotting (Fig 7.1). 
 
                                          
 
 
Fig. 7.1 Western Blotting of cells overexpressing aS and bS. 
Lane 1 and 3, cells transfected with pcDNA3.1(-). Lane 2 and 4, cells transfected 
with pcDNA3.1(-) aS. Lane 5, cells transfected with pcDNA3.1(-) bS. aS and bS 
were detected using the mouse primary aS antibodyB (Zymed Laboratories Inc.) 
and the mouse primary bS antibody (Upstate) respectively. 
 
 










1    2    3    4      5 
aS bS 
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    pcDNA3.1(-)            bS                 aS 
   
 
Fig. 7.2 Immunofluorescence of SHSY5Y cells expressing vector, aS and bS. 
aS and bS were detected using the mouse primary aS antibodyB (Zymed 
Laboratories Inc.) and the mouse primary bS antibody (Upstate) respectively, 
and visualized with a secondary Rhodamine Red-x goat anti-mouse antibody 
(Invitrogen). aS aggregate was indicated.  
 
7.3 Quantitative analysis of aS aggregates in cells 
7.3.1 Immunofluorescence 
The major axis length of the aggregate was more than approximately one-twenty 
fifth of the cell nucleus diameter. As shown above, aggregates were formed in cells 
overexpressing aS but not in cells overexpressing pcDNA3.1(-) or bS. To investigate 
the role of metals in the induction of aggregates, cells were treated with different 
concentrations of copper and iron before they were visualized under confocal 
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Fig. 7.3 Immunofluorescence of SHSY5Y cells expressing pcDNA3.1(-) aS. 
aS was detected using the mouse primary aS antibodyB (Zymed Laboratories 
Inc.), and visualized with a secondary Rhodamine Red-x goat anti-mouse 
antibody (Invitrogen). Images were captured using a Zeiss LSM 510 confocal 
microscope. Cells were treated with six different conditions: A. nontreated 
media, B. chelex treated media (CM), C. CM+10 µM CuCl2, D. CM+300 µM 
CuCl2, E. CM+10 µM FeSO4 F. CM+300 µM FeSO4, for 48 hours. Scale bar 
represents 10 µm. Two images were presented for each treatment: the left for 
single cell and right for group cells. 
 
The aggregates formed under different conditions were quantified by counting the 
number of cells with aggregates in at least three groups of cells with each group of at 
least 30 cells. Table 7.1 represents the percentage of cells with aggregates in different 
conditions.  
 
 Percentage of cells with aggregates 
Nontreated media 12.7% ± 2.7% 
Chelexed media (CM) 3.8% ± 0.3% 
CM + 10 µΜ CuCl2 9.8% ± 0.8% 
CM + 300 µΜ CuCl2 37.7% ± 1.8% 
CM + 10 µM FeSO4 3.6% ± 0.5% 
CM + 300 µM FeSO4 4.5% ± 0.6% 
 
Table 7.1 High concentration of Cu(II) accelerates the formation of aS 
aggregates. 
Data were expressed as the mean ± standard error (S.E.). Statistical analyses 
were conducted using a two-tailed t-test. Among these conditions, 300 µΜ CuCl2 
induced aggregation most efficiently (p < 0.001 ).  
 
7.3.2 Proteinase K (PK) resistance of aS aggregates  
In this study, PK resistance of aS aggregates was analyzed by using western blotting 
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as a new quantitative technique. Briefly, cells were split into 6-well plates at a density 
of 2 x 10
5
 per well. To investigate the metal triggered aS aggregation, cells were 
treated with 10 µM CuCl2, 10 µM FeSO4 and 1 mM FeSO4 in chelex treated media for 
48 hours. Cells were harvest in buffer E (Table 2.1) and homogenized with 26G 
needles and centrifuged at 14000 rpm for 10 minutes at 4
o
C. Cells overexpressing aS 
were lyzed and the cell lysate concentration was determined by Bradford assay. 20 
µg of cell lysate was digested with different concentrations of PK at 37°C for 1 hour 
and applied to western blotting. Fig 7.4 presents the data of western blotting against aS. 
The experiments were repeated at least three times. It seems the aggregates were 
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Fig. 7.4 PK resistance of aS aggregates.  
A, control cells; B, cells treated with 10 µM CuCl2; C, cells treated with 10 µM 
FeSO4; D, cells treated with 1 mM FeSO4. PK concentrations were between 0 
and 1 µg/ml.  
 
Because the aggregates were retained in the stacking gels, it was very difficult to 
judge how resistant of the aggregate is to PK. To solve this problem, gradient gels 
were used instead of normal SDS gels. The cells and cell lysates were prepared as 
before. Fig 7.5 presents the data of western blotting against aS. The experiments were 
repeated at least three times. There were no obvious aggregates observed (Fig 7.5).  
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A. Control    B. 10uM CuCl2         C. 10uM FeSO4 D. 1mM FeSO4




Fig. 7.5 PK resistance of aS aggregates. 
A, control cells; B, cells treated with 10 µM CuCl2; C, cells treated with 10 µM 
FeSO4; D, cells treated with 1 mM FeSO4. PK concentrations were between 0 
and 1 µg/ml. 
 
Comparing these two methods, it seems neither of them has successfully 
demonstrated the PK resistance of aS aggregates formed under different 
concentrations of metals. Based on this, the method referring to immunofluorescence 
described above was employed in the following studies.  
 
7.4 Effects of metals on synuclein aggregation 
7.4.1 Generation of cell lines overexpressing mutated aS 
To investigate whether the potential metal-binding regions of aS are involved in the 
effects of metal accelerated aS aggregation or whether copper increases the aS 
aggregation by binding directly to the protein or not, several cell lines overexpressing 
the related proteins in which the potential copper or iron binding sites were mutated 
or truncated, were employed. SH-SY5Y cells were stably transfected to generate cell 
lines overexpressing H50A aS, aS△1-9 H50A, aS△1-9 and bS. The overexpression 
of proteins in cells was detected and visualized under the confocal microscopy (Fig 
7.7).  
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7.4.2 Quantitative analysis of synuclein aggregates in cells 
The overexpression of protein in the stable cell lines were also confirmed by using 
immunofluorescence under confocal microscope (Fig 7.6). Expression of 
pcDNA3.1(-) alone served as negative control. Cells overexpressing aS were shown 
in Fig 7.3. Only images representing single cells were shown in Fig 7.6, images 
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Fig. 7.6 Immunofluorescence of SHSY5Y cells overexpressing aS mutants.  
A: aS was detected using the mouse primary aS antibodyB (Zymed 
Laboratories Inc.), and visualized with a secondary anti mouse antibody 
(Invitrogen); B: aS was detected using the sheep primary aS antibodyA (abcam) 
directed against amino acids 11-26 of aS sequences, and visualized with a 
secondary anti sheep antibody (Molecular probes). Images were captured using 
a Zeiss LSM 510 confocal microscope. Shown are six cell lines treated with six 
different conditions: nontreated media, chelex treated media (CM), CM+10 µM 
CuCl2, CM+300 µM CuCl2, CM+10 µM FeSO4 CM+300 µM FeSO4, for 48 
hours. Scale bar represents 10 µm. 
 
Aggregates were only observed in cells overexpressing H50A aS and aS△1-9 H50A 
but not in cells overexpressing other mutant forms of aS with or without copper. No 
aggregates were detected in cells overexpressing aS△1-9, aS△1-9 H50A, aS1-100 
or aS10-100 H50A when treated with iron. The aggregates in different cell lines and 
different conditions were quantified by counting the number of cells with aggregates 
in at least 3 groups of certain amount of cells. The images of cells were captured 
under Zeiss LSM 510 confocal microscope. Fig 7.7 represents the differences of 













Fig. 7.7 The percentage of cells with aggregates in SHSY5Y cells overexpressing 
H50A aS and aS△1-9 H50A is decreased and there is no aggregates found for 
cells overexpressing aS△1-9, aS1-100 and aS10-100 H50A. 
The cells were treated with four different conditions: nontreated media, chelex 
treated media (CM), CM+10 µM CuCl2, CM+300 µM CuCl2 for 48 hours. Data 
were expressed as the mean ± standard error (S.E.). Statistical analyses were 
conducted using a two-tailed t-test. Among cells overexpressing aS, H50A aS 
and aS△ 1-9 H50A, 300 µΜ CuCl2 induced aggregation most efficiently 
compared to the other conditions (p < 0.001 ).  
 
For cells overexpressing aS, the percentage of cells with aggregates was nearly 
tripled with treatment of 300 µΜ copper compared to physiological concentration. 
However, the effect of high concentration of copper was impaired in cells 
overexpressing H50A aS and aS△1-9 H50A, because the percentage decreased to 
16% and 17% respectively compared to 30% in cells overexpressing aS. It seemed 
that the aggregation was impeded in the absence of metals because the cells with 
aggregates were significantly decreased in chelex treated media (Fig 7.7). However, 
the number of cells was restored when 10 µM CuCl2 was added. No aggregates were 
detected in cells overexpressing aS△1-9, aS1-100, or aS10-100 H50A with or 
without metal treatments.  
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7.5 Effects of metals on the aggregation of PD-associated aS 
mutants 
Apart from metals, alterations in the amino acid sequences of aS contribute to the 
formation of aggregates without the presence of excess metals. It was proven that the 
tendency of aS to aggregate in vitro is accelerated by the PD-related point mutations, 
A30P and A53T, which are present in the N-terminus of aS. In this study, 
immunofluorescence was employed to detect and quantify the aggregates under 
confocal microscope. Cells overexpressing A30P aS, E46K aS and A53T aS were 
used to investigate if the three mutations have a role in the metal regulated 
aggregation.  
 
7.5.1 Creation of cell lines overexpressing PD-associated mutants 
SH-SY5Y cells were stably transfected to generate cells overexpressing A30P, E46K 
and A53T aS. The cells were harvested as before, and the cell extract was applied to 
western blotting for the confirmation of protein overexpression (Fig 7.8). The 
concentration of cell extract was determined by Bradford assay. Equal amount of 
















Fig. 7.8 Western blotting of cells overexpressing aS and the disease mutants. 
Lane 1, cells transfected with pcDNA3.1(-). Lane 2, 3, 4 and 5, cells 
overexpressing WT aS, A30P aS, E46K aS and A53T aS. aS antibody B (Zymed 
Laboratories Inc.) was against the C-terminus of aS. 
 
7.5.2 Quantitative analysis of synuclein aggregates in cells 
The overexpression of protein in the stable cell lines were also confirmed by using 
immunofluorescence under confocal microscope (Fig 7.9). Cells overexpressing aS 
were shown in Fig 7.3. Fig 7.9 represents the images of cells overexpressing 
PD-associated aS mutants A30P, E46K, A53T under different conditions. Only 
images representing single cells were shown in Fig 7.9, images representing groups 
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Fig. 7.9 Immunofluorescence of SHSY5Y cells expressing PD-related aS mutant. 
aS was detected using the mouse primary aS antibodyB (Zymed Laboratories 
Inc.), and visualized with a secondary Rhodamine Red-x goat anti-mouse 
antibody (Invitrogen). Images were captured using a Zeiss LSM 510 confocal 
microscope. Shown are three cell lines treated with six different conditions: 
nontreated media, chelex treated media (CM), CM+10 µM CuCl2, CM+300 µM 
CuCl2, CM+10 µM FeSO4 CM+300 µM FeSO4, for 48 hours. Scale bar 
represents 10 µm. 
 
The aggregates in different cell lines and different conditions were quantified by 
counting the number of cells containing aggregates in at least 3 groups of certain 
amount of cells. The images of cells were captured under Zeiss LSM 510 confocal 
microscope. Fig7.10 represents the differences of percentages of cells with 


















Fig. 7.10 The percentages of cells containing aggregates in SHSY5Y cells 
overexpressing aS, A30P aS, E46K aS and A53T aS were significantly increased 
in the presence of 300 µM CuCl2 but not FeSO4. 
A: Comparison of cells with aggregates in different cell lines treated with 
nontreated media, chelex treated media (CM), CM+10 µM CuCl2, CM+300 µM 
CuCl2 for 48 hours; B: Comparison of cells with aggregates in different cell lines 
treated with nontreated media, chelex treated media (CM), CM+10 µM FeSO4 
CM+300 µM FeSO4 for 48 hours. Data was expressed as the mean ± standard 
error (S.E.).Statistical analyses were conducted using a two-tailed t-test. Among 
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There was not an obvious increase of percentages of cells with aggregates in the cells 
overexpressing A30P, E46K and A53T aS in physiological condition compared to 
cells overexpressing aS (Fig 7.10). However, the percentages were three times and 
twice fold higher respectively with the increasing of concentration of copper, which 
suggested high concentration of copper had a stonger effect on the aggregation of aS 
mutants. Interestingly, no increase on the percentage of cell with aggregates was 
observed when iron was added to the chelex treated media (CM) (Fig 7.10). For cells 
overexpressing WT aS, E46K and A53T aS, the aggregation with treatment of 300 
µM FeSO4 was even less than that in control media. 
 
When cells were treated with chelexed media in which metals were removed by 
binding to the chelex, most of the overexpressed proteins were bound to the cell 
membranes (Fig 7.3 and Fig 7.10), and this phenomenon disappeared when copper or 
iron were added back to the media. It indicates that aS might be the physiological 
copper or/and iron transporters, which insert into the membranes and form influx 
channels to keep the homeostasis of metals.  
 
7.6 Localization of aS in mammalian cells regulated by 
different amino acid regions 
The distribution of aS in cells is of great importance because abnormal accumulation 
of aS in specific cellular organelles may increase local concentration of this protein, 
which may induce the protein self-aggregation, and finally fibrillization. Cells 
overexpressing aS mutants in which suspicious copper or/and iron binding sites were 
mutated or truncated, were employed to investigate if these regions were responsible 
for the transport or/and location of the proteins. Fig 7.11 represents the location of 
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              aS               H50A            aS△1-9 
   
          aS△1-9 H50A         aS1-100         aS10-100 H50A  
                                     
 
Fig. 7.11 Comparison of location of aS mutants in SHSY5Y cells overexpressing 
aS, H50A aS, aS△1-9, aS△1-9 H50A, aS1-100 and aS10-100 H50A. 
aS was detected using the mouse primary aS antibodyB (Zymed Laboratories 
Inc.) for aS, H50A aS, aS△1-9 and aS△1-9 H50A or sheep primary aS 
antibodyA (abcam) for aS1-100 and aS10-100 H50A. Scale bar represents 10 
µm. 
 
Cells were observed under non-fluorescence first and the location of nuclei was 
defined. Overexpressed WT aS and H50A aS was distributed all over the whole cells. 
In cells overexpressing aS△1-9 and aS△1-9 H50A, aS△1-9 and aS△1-9 H50A 
was concentrated in the nucleus (Fig 7.6 A). This implied the amino acid sequences 
of 1-9 in aS were responsible for the translocation of aS. Similarly, this happened to 
the C-terminus truncated protein aS1-100. The overexpressed protein was 
concentrated in the nuclues (Fig 7.6 B). Nevertheness, aS10-100 H50A was mostly 
located in the cytoplasm under all conditions (Fig 7.6 B). This suggests that the 
residues 1-9 and C-terminal domain of aS were both involved in the transport of aS 
in mammalian cells. However, the precise amino acid sequences have not been 
determined yet.  
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7.7 Synucleins and copper induced cytotoxicity 
Overexpressed aS and copper induced aS aggregates were thought to be toxic to cells. 
In this experiment, MTT assay was employed to analyze the cell toxicity induced by 
synuclein proteins. Fig 7.12 shows the percentages of survived cells among different 
cell lines treated with different concentrations of copper in CM for 48 hours. 











Fig. 7.12 Copper induced cell toxicity is enhanced in cells overexpressing aS and 
PD-related mutants. 
SHSY5Y cells were treated with different conditions in CM: 10 µM, 50 µM, 100 
µM, 200 µM, 300 µM, 350 µM, 400 µM, 450 µM, 500 µM and 600 µM CuCl2 for 
48 hours. A: Comparison of cells overexpressing pcDNA3.1(-) and aS; B: 
Comparison of cells overexpressing pcDNA3.1(-), aS, A30P aS, E46K aS, A53T 
aS; C: Comparison of cells overexpressing pcDNA3.1(-), aS, H50A aS and 
aS 11△ 9-126; D: Comparison of cells overexpressing pcDNA3.1(-), aS, aS 1△ -9 
and aS 1△ -9 H50A. Each experiment was repeated at least 3 times. Data was 
expressed as the mean ± standard error (S.E.). Statistical analyses were 
performed by one-way ANOVA. There was a significant increase in cell toxicity 
for cells overexpressing aS compared to cells overexpressing pcDNA3.1(-), H50A 
aS, aS 119△ -126, aS 1△ -9 and aS 1△ -9 H50A ( p < 0.001).  
C 
D 
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It seemed physiological concentration of copper favours the growth of all the cells, 
while it was toxic when the concentration increased to 300 µM or more. 40% of cells 
death was observed in cells overexpressing aS when treated with 300 µM CuCl2 in 
CM (Fig 7.12A). This might be due to the disadvantages of this experiment because 
the floating cells were not counted. More cell death was detected for cells 
overexpressing the PD-related mutants compared to control cells when treated with 
high concentration of CuCl2 (Fig 7.12B). However, there was nearly no cell death in 
cells overexpressing aS mutants where some copper binding sites were mutated or 
truncated when treated with 300 µM CuCl2 in CM, and there was 10% increase of 
cell growth for cells transfected with pcDNA3.1(-) vector (Fig 7.12C), which means 
the copper-aggregate complex might be toxic to the cells. There is no obvious 
difference in the cell death for cells overexpressing PD-related aS mutants, compared 
to cells overexpressing WT aS.  
 
7.8 Discussion 
aS is a small protein currently regarded to play a role in the pathogenesis of PD. The 
physiological function of this protein remains unknown. What is known is that point 
mutations or increased levels of expression of WT aS causes PD. A great deal of 
literature supports the hypothesis that aS is neurotoxic because it is inherently prone 
to aggregation and the small oligomers are damaging to neuron cells. In this study, a 
series of methods were designed and applied to investigate the factors which promote 
the aggregation and the neurotoxicities induced.  
 
The cell culture system was applied and a method was designed to quantify the 
aggregates in neuron cells overexpressing aS by analyzing the PK resistance. No 
obvious difference was observed when treated with different metals (Fig 7.4), and it 
seemed that the aggregates were retained in the stacking gel due to their stickiness 
and insolubility. This problem was not solved even in gradient gels (Fig 7.5). Another 
possibility is that the proportion of the oligomers and monomers is too low that the 
oligomers could not be detected when certain amount of total protein was loaded. 
This was proven by Dr Josephine in our lab when she successfully separated the 
aggregates from the monomeric aS (Wright, Wang et al. 2009).  
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In this study, immunofluorescence was used to determine the aggregation in 
synuclein overexpressing cells. As discussed above, aS is prone to form aggregates 
and aggregates were observed in cells overexpressing aS (Fig 7.3). No aggregate was 
detected in bS overexpressing cells (Fig 7.2), which might due to the lack of NAC 
region that is implicated in aS aggregation (Ueda, Fukushima et al. 1993; Han, 
Weinreb et al. 1995; Iwai, Masliah et al. 1995).  
 
Redox-active metal ions such as Cu(II) and Fe(III) are known to enhance aS 
fibrillogenesis (Uversky, Li et al. 2001). Nearly 40% of aS overexpressing cells 
containing aggregates were detected when treated with 300 µM CuCl2 (Table 7.1), 
while only 12.7% of them was seen in cells in nontreated media. It seemed that Fe(II) 
has no effect on the formation of aS aggregates (Table 7.1). Copper and iron showed 
differential binding pattern toward aS revealed by fluorescence (Bharathi and Rao 
2008), which might induce the differences in the morphology of aggregates in 
immunofluorescence. In addition, Fe(III) is more chemically active than Fe(II), 
which could accelerate the protein aggregation by increasing the levels of oxidative 
stress.  
 
Intriguingly, in cells transfected with H50A aS, there were only 7.1% of cells 
including aggregates in nontreated media and 16.3% in 300 µΜ CuCl2 treated media 
(Fig 7.6A and Fig 7.7). The percentages were much less than those for cells 
overexpressing WT aS (12.7% and 37.7% respectively). Again, 17.3% of cells 
overexpressing aS△1-9 H50A treated with 300 µΜ CuCl2 were obversed containing 
aggregates, while none was detected in cells overexpressing aS∆1-9 or aS10-100 
H50A (Fig 7.6 and Fig 7.7). This finding was surprising, as the three regions of aS 
including residues 1-9, His50 and C-terminus were demonstrated to be responsible 
for copper binding (Sung, Rospigliosi et al. 2006), which was suggested to promote 
aggregation. This led to the conclustion that copper mediated aS aggregation was not 
only relied on direct binding to the protein as four binding sites were detected on all 
the proteins according to ITC analysis in chapter 5. This indicated that the other 
hypothesis that metals enhance aS aggregation by increasing the levels of oxidative 
levels is possible. This hypothesis was further confirmed by CV data in chapter 6 
showing fully reversible redox process on copper bound aS and aS∆1-9 H50A, but 
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much less reduction peak charge for aS∆1-9 and aS10-100 H50A, in which case the 
protein or the metal might be oxidized permenantly. 
 
The PD-related point mutations, A30P and A53T, increase the propensity of aS to 
aggregate in vitro (Conway, Harper et al. 1998; Narhi, Wood et al. 1999; Rochet, 
Conway et al. 2000; Li, Uversky et al. 2001; Uversky, Li et al. 2001; Li, Uversky et al. 
2002). In this study, more aggregates were visualized in cells overexpressing A30P, 
E46K and A53T when treated with 300 µΜ CuCl2 (Fig 7.10). Specifically, the 
percentages of cells increased by 10%, 3% and 6% respectively compared to that in 
cells overexpressing WT aS (Fig 7.10A). This is consistant with the literature 
establishing that E46K mutation is able to increase the propensity of aS to fibrillate, 
but to a less extent than A53T mutation (Greenbaum, Graves et al. 2005). Nevertheless, 
there were only slight increased aggregates in cells overexpressing A30P when 
treated with 300 µΜ iron, no obvious increase in cells overexpressing E46K and 
A53T aS was observed (Fig7.10B). This implied that iron mediated aggregation 
could involve different mechanisms compared to copper. Fe
2+
 was reported to induce 
DNA damage in aS transfected human neuroblastoma cells and the susceptibility to 
toxic effects of Fe
2+
 was enhanced with mutant aS associated with inherited forms of 
PD (Martin, Williamson et al. 2003).  
 
In chelex treated media where metals were removed by binding to the chelex, most 
of the overexpressed proteins were bound to the cell membranes (Fig 7.3 and Fig 
7.6). The proteins were distributed over the cell when copper or iron was added back 
to the chelex treated media (Fig 7.3 and Fig 7.6). This implies that aS might be one 
of the copper or/and iron transporters and it is translocated to the membrane when 
the concentrations of copper or/and iron were different in and out of cells. In addition, 
immunofluorescence revealed that most of the protein was distributed in the nuclei in 
cells overexpressing aS△1-9, aS△1-9 H50A and aS1-100 (Fig 7.11). In contrast, 
most of the proteins were transported to the cytoplasm in cells overexpressing 
aS10-100 H50A (Fig 7.11). These observations suggested that both of the amino 
acids 1-9 and the C-terminus were the domains on aS responsible for the transport of 
protein between the cytoplasm and the nucleus, although the mechanism is still 
unknown. 
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The copper induced cytotoxicity was assessed by MTT assay which revealed that 
overexpressing cells were less resistant to high concentrations of copper than control 
cells (Fig 7.12). 59% of viabilities were observed in cells overexpressing aS with 300 
µΜ CuCl2 (Fig 7.12A), which might due to the disadvantage of this technique, 
because floating cells could not be counted in this experiment. No toxicity was 
observed in the absence of copper in all the cell lines, suggesting that overexpression 
of synuclein protein was not toxic. This corresponds with that intracytoplasmic aS 
aggregates are not toxic to cells (Spillantini, Schmidt et al. 1997). It seemed that cells 
overexpressing WT aS and the PD-related mutants displayed the higher degree of 
cell death than control cells when treated with high concentration of copper (Fig 
7.12B), indicating that the copper-aggregate complex played a role in the cytotoxicity. 
However, no toxicity was detected in cells overexpressing the aS mutants in which 
some of the copper-binding sites were mutated or truncated when treated with 300 
µΜ CuCl2, indicating the overexpression of these mutants was not toxic even in the 
presence of high concentration of copper when there was no aggregate. These 
findings revealed that overexpression of WT and PD-related aS mutants enhanced 
Cu(II)-induced neurotoxicity in SHSY5Y cells and copper could mediate the toxicity 
by interacting with the protein directly which led ultimately to aggregation which 
triggered cell death. In PD patients, there is increased expression of aS and high 
levels of copper in the CSF (Pall, Williams et al. 1987). This study collates these 
observations by suggesting that the combination of increased aS expression and 
copper levels causes increased toxicity to neuronal cells.  
 
Previous studies have shown that aging A30P or A53T aS increases their toxicity 
(El-Agnaf, Salem et al. 2006). Accordingly, this study showed that the toxicity of 
aggregated aS mutants was significantly increased in the presence of high 
concentration of copper (Fig 7.12B). However, there was no significant difference in 
the effect of the aS mutants compared to WT aS (Fig 7.12B), which corresponds with 
the observation that there is no significant difference between the ability of WT aS 
and aS mutants to bind copper (Bharathi and Rao 2007). In addition, no significant 
difference was observed in the morphology of fibrils formed from WT aS or mutants, 
which were the toxic species to cells (Wright, Wang et al. 2009). 
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Chapter 8. Disscussion 
PD is a chronic and progressive neurodegenerative disorder, affecting approximately 
2% of the population by the age of 65 years, and up to 4% to 5% of the population by 
the age of 85 years (Eriksen, Wszolek et al. 2005). This disease is worldwide 
distributed, with no gender preference, and the risk rises steeply with advancing ages. 
It is expected by the World Health Organisation that PD, along with other 
neurodegenerative diseases, will surpass cancer as the second most common cause of 
death by the year of 2050. As far as we know, there is no cure for PD although 
medications or surgery can provide transient relief from the symptoms. Furthermore, 
it is yet unclear about the mechanisms how the abnormal protein deposits are formed 
and what causes the neuronal cell death in the brain. Therefore, it is important to 
characterize the proteins which are implicated in the development of the disease, as 
these may provide potential therapeutic targets.  
 
The clinical symptoms of PD include resting tremor, muscle rigidity and Bradykinesia, 
which refers to slowness of movement. Neuropathologically PD is characterized by 
progressive loss of dopaminergic neurons in the substantia nigra and the development 
of LBs and LNs observed in these neurons (Tofaris and Spillantini 2007). The fact 
that aS has been linked to PD is based on two observations: the identification of point 
mutations and gene duplication and triplication of aS in the families with 
autosomal-dominant early-onset PD and the discovery that the fibrillar form of aS is 
the major component of LBs (Tofaris and Spillantini 2007). Later on, its homologues 
bS and gS, were shown to be able to inhibit the aS fibril formation (Uversky, Li et al. 
2002), although the mechanism is not fully elucidated. The precise function of aS is 
unknown. However, there is increasing evidence showing that the process of aS 
aggregation is the key step during the progression of neurodegeneration. Metals such 
as copper and iron were proven to be factors accelerating aS fibrillation (Paik, Shin 
et al. 1999; Uversky, Li et al. 2001), although the mechanisms are not fully 
understood. There are several hypotheses about the mechanisms for metal-stimulated 
fibrillation of aS. The simplest would involve direct interactions between aS and the 
metal, leading to structural changes in aS, and resulting in the enhanced propensity to 
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aggregate. Another one indicates redox-active transition metals such as copper and 
iron, may exert their pathogenic effects by participating in an array of cellular 
disturbances characterized by oxidative stress and increased free radical production 
(Sayre, Moreira et al. 2005). The aim of this thesis was to further our understanding 
of the role of synuclein proteins and metals in the pathogenesis of PD by 
investigating the copper-binding properties of aS and copper induced aggregation 
and neurotoxicity in doperminergic neuron cells. 
 
To date, there are mainly two strategies for synuclein purification, involving high 
temperature and acidic condition in the cell lysate preparations respectively. Previous 
recombinant aS has been purified on the basis that the protein is heat resistant (Jakes, 
Spillantini et al. 1994; Weinreb, Zhen et al. 1996; Giasson, Uryu et al. 1999). 
However, high temperature has been shown to cause conformational alteration in aS 
(Uversky, Lee et al. 2001; Bertoncini, Jung et al. 2005). In this study, three 
purification protocols including boiling, acid precipitation and anion exchange 
chromatography, were introduced and compared in chapter 3. The proteins from each 
protocol were examined by MALDI mass spectrometry, far-UV CD, 2D NMR 
spectroscopy and light scattering. The methods involving anion exchange 
chromatography and acid precipitation were shown to be more reliable and selected 
for the purification of all the proteins used in this project. 2D NMR spectroscopy 
demonstrated aS from these two protocols was in a native and monomeric form, 
while protein experiencing boiling procedure was more prone to aggregate (Fig 3.8). 
This was confirmed by the light scattering technique (Fig 3.9). Furthermore, the 
negative peak of far-UV CD spectra for aS purified by boiling protocol was shift to 
208 nm and the [θ]222 nm intensity was much higher, illustrating more secondary 
structure (Fig 3.10). No aggregates were detected by the MALDI mass spectrometry 
(Fig 3.7). This might be due to two reasons: the concentration used for MALDI mass 
spectrometry was only one tenth of that for NMR analysis; the small amount of 
aggregates could be disassembled during the ionization of the experiment.  
 
aS has been identified as a metal-binding protein. Although there is a consensus that 
aS binds copper, it is still controversial about the location of the binding sites and the 
binding affinities. CW-EPR spectroscopy demonstrated that aS bound Cu(II) via two 
binding modes at physiological pH, corresponding to 2N2O and 1N3O (Table 4.2). 
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This is consistent with previous studies on truncated model fragments implying the 
involvement of the N-terminal amine of Met1 and the deprotonated backbone amine 
and carboxylate side chain of Asp2 for the mode 2N2O (Kowalik-Jankowska, 
Rajewska et al. 2005) and the nitrogen of imidazole group of His50 for mode 1N3O 
(Binolfi, Lamberto et al. 2008). However, the modes were not changed for mutants 
H50A aS and aS△1-9 (Table 4.2), suggesting the amino acids involved in the 
coordination could be replaced or/and there were more than one binding site for each 
mode. This was confirmed by the observation that the proportion of the mode 1N3O 
was greatly increased on aS△1-9 H50A. For the C-terminal mutants aS△119-126, 
aS△1-9 H50A△119-126 and aS10-100 H50A, the A∥ and g∥ parameters were 
changed and correlated well with two 3N1O coordination sphere (Table 4.2), 
illustrating the square-planar or tetragonal geometry has been altered. The 
stoichiometry of copper binding to aS was assessed by ITC, showing four binding 
sites for all the N-terminal and C-terminal aS mutants although the affinities were 
different (Table 5.4). This finding confirmed that the residues involved in copper 
coordination could be replaced by the amino acid in the vicinity. There is evidence 
showing that the coordination of Cu(II) may involve the lateral NH2 group of lysine 
residues upstream of His50 (Kowalik-Jankowska, Rajewska et al. 2006), showing that 
lysine could act as a copper anchoring site in the absence of histidine. Similarly, 
Asp2 might be substituted by Glu13 which could also provide nitrogen and oxygen 
ligand in Cu(II) binding mode (Rasia, Bertoncini et al. 2005). Based on these 
findings, it implied that when binding to copper, aS might not act as such protein as 
prion protein where copper binding sites were assigned to certain amino acids, the 
binding sites disappeared when certain amino acids missing or mutated 
(Klewpatinond, Davies et al. 2008).  
 
Similar to aS, its homologues bS and gS displayed two identical copper binding 
modes (Table 4.1). The coordination modes remained the same for H65A bS but 
shifted to two 3N1O modes for bS△1-9 H65A and bS10-100 H65A, suggesting 
His65 might not be involved in the interaction with copper. Nevertheless, it was 
denied by the ITC analysis showing four binding sites for bS and H65A bS with 
reduced affinities for H65A bS (Table 5.5). The affinity constants were altered when 
any of the three regions was mutated or deleted. This suggested that the three regions 
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contributed to the copper binding event. Moreover, there was a manifest decrease in 
the affinity on second binding site on bS∆1-9 (Table 5.5), implying that the 
higher-affinity site on bS was allocated on the residues 1-9 while that was on His50 
for aS (Table 5.4). One binding site was missing for bS10-100 H65A (Table 5.5). 
These observations suggested that the residues in the N-terminus of bS were 
replaceable for the copper cooperation, but the C-terminus was essential for one 
binding event. It was noteworthy that the logKa constants for bS were in the range of 
7.7-8.0, which were higher than those for aS (6.7-7.4). This finding might provide 
some insight into the mechanism by which bS inhibit aS aggregation. It implied that 
the preventive effect of bS on aS aggregation might be related to the higher affinities 
for copper. In that case, bS competes with aS for copper binding and acts as a 
copper-sequestering protein, playing the role of a copper chelator and hence 
preventing or attenuating the subsequent aggregation of aS.  
 
There are several lines of evidence showing redox-active transition metals such as 
copper and iron, may play an important role in the pathogenesis of neurodegenerative 
diseases by increasing oxidative stress and free radical production (Sayre, Moreira et 
al. 2005). The oxidation of proteins could be catalyzed by metals (Cole, Murphy et al. 
2005) and oxidatively modified protein could increase its own tendency toward 
protein aggregation due to the generation of reactive oxygen species (ROS), which 
exert pro-aggregatory effects and turn soluble protein into insoluble forms by either 
inhibiting intracellular proteolysis or causing unusual posttranslational modifications 
(Kowalik-Jankowska, Rajewska et al. 2006). To further explore the role of synucleins 
in PD, the electrochemical property of the copper bound proteins were assessed by 
CV in this study. aS displayed capability of exchanging electrons when bound to 
copper (Fig 6.1). The redox cycling was fully reversible (Table 6.1), suggesting that 
the protein was unaffected by continuous oxidation and reduction. However, this was 
not the case for bS and gS, where the reduction peaks were much less than the 
oxidation peaks (Table 6.1). The finding indicated that some of the copper or protein 
might be oxidized permanently or Cu(I) was not stable on the protein and fell off. 
This observation could explain how bS and gS inhibit aS aggregation: Cu(II) was 
reduced and fell off from bS or gS after it was dragged away from aS and bound to 
bS and gS as they showed higher binding affinities according to ITC (chapter 5).  
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Only one oxidation and reduction peak was observed for the WT aS-Cu species, 
suggesting the copper centres were electronically coupled as four copper were bound 
per molecular of aS according to ITC (chapter 5). The midpoint potential and 
responsive current peak during the redox process on the mutant aS△1-9 H50A was 
quite close to that for WT aS, indicating the amino acids in the proximity might fill 
in the position and form the identical coordination geometry. This confirmed that 
lysine residues upstream of His50 could act as a copper anchoring site in the absence 
of histidine (Kowalik-Jankowska, Rajewska et al. 2006) and Asp2 might be 
substituted by Glu13 in Cu(II) binding mode (Rasia, Bertoncini et al. 2005). The 
integrated reduction peak charge was enormously reduced on aS1-100, indicating the 
presence of the C-terminal region of aS was essential for the reductive 
electrochemistry, which might be involved in the mechanism of inhibition of aS 
aggregation, providing evidence showing C-terminus of aS is a negative regulator of 
self-assembly. The protein might be partially oxidized permanently without the 
C-terminal region, which could lead to self-oligomerization and hence possible 
protein aggregation and neurodegeneration (Paik, Shin et al. 2000). It fits the 
hypothesis that C-terminus truncated aS constructs are more prone to fibrillate in vitro 
than the full-length protein (Crowther, Jakes et al. 1998; Serpell, Berriman et al. 2000; 
Murray, Giasson et al. 2003). In contrast to aS, mutation of His65 on bS enhanced the 
redox activity especially the reduction current, producing reversible electron cycling 
(Table 6.3). This demonstrated that His65 was responsible for the inhibition of the 
electrochemical activity of the protein. This was contrast to aS, where His50 
contributed to the redox activity especially the reduction response which was thought 
to inhibit the protein aggregation (Table 6.2). The difference of the electrochemical 
features on the two proteins indicated two distinct mechanisms for the protein 
aggregation, as no study has reported inhibition of aggregation on the His65 mutant. 
The reductive response was enormously diminished for bS△1-9 and bS10-100 
H65A, indicating the involvement of residues 1-9 and the C-terminus on the redox 
activity. Little has been investigated about bS, this new technique might provide new 
insight into the role of bS on the inhibition of aS aggregation.  
 
To further investigate the role of aS and metals in neurotoxicity, copper and iron 
induced aggregation and toxicity in doperminergic neuron SHSY5Y cells 
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overexpressing synucleins were examined by confocal microscopy and MTT assay. 
High concentration of Cu(II) enhanced the aggregation in aS overexpressing cells 
while Fe(II) had no effect on the formation of aS aggregates (Table 7.1). Intriguingly, 
in cells transfected with H50A aS, there were only 7.1% of cells including aggregates 
in nontreated media and 16.3% in 300 µΜ CuCl2 treated media (Fig 7.6A and Fig 
7.7). The percentages were much less than those for cells overexpressing WT aS 
(12.7% and 37.7% respectively). Again, 17.3% of cells overexpressing aS△1-9 
H50A treated with 300 µΜ CuCl2 were obversed containing aggregates, while none 
was detected in cells overexpressing aS△1-9 or aS10-100 H50A (Fig 7.6 and Fig 
7.7). This finding pointed to the conclustion that copper mediated aS aggregation 
was not only relied on direct binding to the protein as four binding sites were 
detected on all the proteins according to ITC analysis in chapter 5. The other 
hypothesis that metals enhance aS aggregation by increasing the levels of oxidative 
levels stands out. This hypothesis was verified by CV data in chapter 6 showing fully 
reversible redox process on copper bound aS and aS△1-9 H50A, but much less 
reduction peak charge for aS△1-9 and aS10-100 H50A. This disappearance of 
aggregation might be due to the alteration of the electrochemical property of aS. 
 
The PD-related point mutations, A30P and A53T, increase the propensity of aS to 
aggregate in vitro (Conway, Harper et al. 1998; Narhi, Wood et al. 1999; Rochet, 
Conway et al. 2000; Li, Uversky et al. 2001; Uversky, Li et al. 2001; Li, Uversky et al. 
2002). In this study, more aggregates were visualized in cells overexpressing A30P, 
E46K and A53T when treated with 300 µΜ CuCl2 (Fig 7.10). Specifically, the 
percentages of cells increased by 10%, 3% and 6% respectively compared to that in 
cells overexpressing WT aS (Fig 7.10A). This is consistant with the literature 
establishing that E46K mutation is able to increase the propensity of aS to fibrillate, 
but to a less extent than A53T mutation (Greenbaum, Graves et al. 2005). Nevertheless, 
there were only slight increased aggregates in cells overexpressing A30P when 
treated with 300 µΜ FeSO4, and no obvious increase in cells overexpressing E46K 
and A53T aS was observed (Fig 7.10B). This implied that iron mediated aggregation 
could involve different mechanisms compared to copper. Fe
2+
 was reported to induce 
DNA damage in aS transfected human neuroblastoma cells and the susceptibility to 
toxic effects of Fe
2+
 was enhanced with mutant aS associated with inherited forms of 
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PD (Martin, Williamson et al. 2003).  
 
aS was demonstrated to be one of the copper or/and iron transporters as most of the 
overexpressed proteins were bound to the cell membranes in chelex treated media 
where metals were removed by binding to the chelex (Fig 7.3 and Fig 7.6). In 
addition, immunofluorescence revealed that most of the protein was distributed in the 
nuclei in cells overexpressing aS△1-9, aS△1-9 H50A and aS1-100 (Fig 7.11). In 
contrast, most of the proteins were transported to the cytoplasm in cells 
overexpressing aS10-100 H50A (Fig 7.11). These observations suggested that both of 
the amino acids 1-9 and the C-terminus were responsible for the transport of protein 
between the cytoplasm and the nucleus although the mechanism is still elusive.  
 
The copper induced cytotoxicity was assessed by MTT assay which revealed that 
overexpressing cells were less resistant to high concentrations of copper than control 
cells (Fig 7.12). It seemed that cells overexpressing WT aS and the PD-related 
mutants displayed the higher degree of cell death than control cells when treated with 
high concentration of copper (Fig 7.12B), indicating that the copper-aggregate 
complex played a role in the cytotoxicity. However, no toxicity was detected in cells 
overexpressing the aS mutants in which some of the copper-binding sites were 
mutated or truncated when treated with 300 µΜ CuCl2, indicating the overexpression 
of these mutants was not toxic even in the presence of high concentration of copper 
when there was no aggregate. These findings revealed that overexpression of WT and 
PD-related aS mutants enhanced Cu(II)-induced neurotoxicity in SHSY5Y cells and 
copper could mediate the toxicity by interacting with the protein directly which led 
ultimately to aggregation which triggered cell death. In PD patients, there is 
increased expression of aS and high levels of copper in the CSF (Pall, Williams et al. 
1987). This study collates these observations by suggesting that the combination of 
increased aS expression and copper levels causes increased toxicity to neuronal cells. 
 
The mechanism of aS ovexpression induced cell toxicity was not fully defined in this 
study although copper has been proven to be essential during this process. The most 
common hypothesis for the mechanism is that aS oligomers can create pores in 
membranes, which increases permeability of cells to ions from the extracellular space, 
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leading to cell death (Volles and Lansbury 2002; Danzer, Haasen et al. 2007). The 
toxic species are the aS oligomers that are annular or porelike, with outer diameters 
of 10–12 nm and inner diameters of 2 nm (Lashuel, Hartley et al. 2002; Lashuel, 
Petre et al. 2002). These features may lead to the increased but nonspecific ion 
permeability observed with aS-expressing cells (Furukawa, Matsuzaki-Kobayashi et 
al. 2006). This hypothesis is the most popular, particularly given the mechanistic 
similarity to other proteins involved in neurodegenerative diseases, such as Aβ 
(Bhatia, Lin et al. 2000; Kawahara, Kuroda et al. 2000; Zhu, Lin et al. 2000). Our 
research on extracellular aS aggregates showed that the soluble aS oligomers were 
the toxic species to cells in the presence of copper (Wright, Wang et al. 2009). 
Concerning the data from CV, it showed unreversible redox chemistry for the aS 
mutants lacking potential copper-binding sites although ITC analysis demonstrated 
they were capable of binding the same number of coppers with WT aS. This might 
contribute to the absence of aggregates in the SHSY5Y cells overexpressing these 
mutants where the intracellular ROS levels were decreased. CV showed reduced 
reduction response for these mutants, suggesting Cu(II) might be reduced to Cu(I) 
and fell off the protein. The reduced copper could interact with H2O2 and generate 
hydroxyl radical (Sayre, Moreira et al. 2005). There was evidence showing that the 
formation of H2O2 from aS was accelerated in the presence of copper (Paik, Shin et 
al. 2000). Therefore, copper accelerates the formation of aS aggregates by binding to 
the protein directly and increasing intracellular ROS levels. This then leads to 
aggregates induced neurotoxicity and cell death through the pore-creation 
mechanism.   
 
The findings described here illustrate that disruption of the interaction between 
copper and aS and the inhibition of downstream toxic process could be a potential 
target for the development of new therapeutics for PD. In fact, initial studies 
suggested that copper chelators will be effective in the treatment of PD if the 
neurotoxic side effects can be overcome (Gaeta and Hider 2005). Actually, the 
chelation therapies have had some success in improving cognition and lowering Aβ 
levels in Alzheimer’s disease (Ritchie, Bush et al. 2003; Adlard, Cherny et al. 2008; 
Lannfelt, Blennow et al. 2008). 
 
For CV, future research will determine the precise amino acids of aS involved in 
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Cu(II) induced oxidative stress. Furthermore, the characterization of the 
electrochemistry of aS will give a better idea about the physiological and 
pathological functions of the protein. The copper binding property and 
electrochemistry of bS and gS were shown to be different from aS although they 
belong to the same family. The future work can explore the details of redox activity 
of bS and gS, which might provide a novel approach to the treatment for PD. In 
addition, the effect of Cu(I) will be investigated by CV to confirm the mechanism for 
redox stress induced aS aggregation. Also, the interaction between aS and Cu(I) will 
be examined by ITC and EPR to further understand the physiological funcation of 
the protein. In vivo, the intracellular aggregates will be isolated and imaged by 
electron microspy to find the toxic species. In addition, cells overexpressing aS will 
be treated with bS or/and gS to see the effect of the homologues on aS aggregates 

















1. Coding sequence of α-synuclein 
1   ATGGATGTAT TCATGAAAGG ACTTTCAAAG GCCAAGGAGG GAGTTGTGGC TGCTGCTGAG 
61  AAAACCAAAC AGGGTGTGGC AGAAGCAGCA GGAAAGACAA AAGAGGGTGT TCTCTATGTA 
121 GGCTCCAAAA CCAAGGAGGG AGTGGTGCAT GGTGTGGCAA CAGTGGCTGA GAAGACCAAA 
181 GAGCAAGTGA CAAATGTTGG AGGAGCAGTG GTGACGGGTG TGACAGCAGT AGCCCAGAAG 
241 ACAGTGGAGG GAGCAGGGAG CATTGCAGCA GCCACTGGCT TTGTCAAAAA GGACCAGTTG 
301 GGCAAGAATG AAGAAGGAGC CCCACAGGAA GGAATTCTGG AAGATATGCC TGTGGATCCT 
361 GACAATGAGG CTTATGAAAT GCCTTCTGAG GAAGGGTATC AAGACTACGA ACCTGAAGCC 
421 TAA 
 
2. Amino sequence of α-synuclein 
1   MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVATVAEKTK 
61  EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP 
121 DNEAYEMPSE EGYQDYEPEA 
 
3. Coding sequence of α-synuclein A30P 
1   ATGGATGTAT TCATGAAAGG ACTTTCAAAG GCCAAGGAGG GAGTTGTGGC TGCTGCTGAG 
61  AAAACCAAAC AGGGTGTGGC AGAAGCACCA GGAAAGACAA AAGAGGGTGT TCTCTATGTA 
121 GGCTCCAAAA CCAAGGAGGG AGTGGTGCAT GGTGTGGCAA CAGTGGCTGA GAAGACCAAA 
181 GAGCAAGTGA CAAATGTTGG AGGAGCAGTG GTGACGGGTG TGACAGCAGT AGCCCAGAAG 
241 ACAGTGGAGG GAGCAGGGAG CATTGCAGCA GCCACTGGCT TTGTCAAAAA GGACCAGTTG 
301 GGCAAGAATG AAGAAGGAGC CCCACAGGAA GGAATTCTGG AAGATATGCC TGTGGATCCT 
361 GACAATGAGG CTTATGAAAT GCCTTCTGAG GAAGGGTATC AAGACTACGA ACCTGAAGCC 
421 TAA 
 
4. Amino sequence of α-synuclein A30P 
1   MDVFMKGLSK AKEGVVAAAE KTKQGVAEAP GKTKEGVLYV GSKTKEGVVH GVATVAEKTK 
61  EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP 




5. Coding sequence of α-synuclein E46K 
1   ATGGATGTAT TCATGAAAGG ACTTTCAAAG GCCAAGGAGG GAGTTGTGGC TGCTGCTGAG 
61  AAAACCAAAC AGGGTGTGGC AGAAGCAGCA GGAAAGACAA AAGAGGGTGT TCTCTATGTA 
121 GGCTCCAAAA CCAAGAAGGG AGTGGTGCAT GGTGTGGCAA CAGTGGCTGA GAAGACCAAA 
181 GAGCAAGTGA CAAATGTTGG AGGAGCAGTG GTGACGGGTG TGACAGCAGT AGCCCAGAAG 
241 ACAGTGGAGG GAGCAGGGAG CATTGCAGCA GCCACTGGCT TTGTCAAAAA GGACCAGTTG 
301 GGCAAGAATG AAGAAGGAGC CCCACAGGAA GGAATTCTGG AAGATATGCC TGTGGATCCT 
361 GACAATGAGG CTTATGAAAT GCCTTCTGAG GAAGGGTATC AAGACTACGA ACCTGAAGCC 
421 TAA 
 
6. Amino sequence of α-synuclein E46K 
1   MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKKGVVH GVATVAEKTK 
61  EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP 
121 DNEAYEMPSE EGYQDYEPEA 
 
7. Coding sequence of α-synuclein A53T 
1   ATGGATGTAT TCATGAAAGG ACTTTCAAAG GCCAAGGAGG GAGTTGTGGC TGCTGCTGAG 
61  AAAACCAAAC AGGGTGTGGC AGAAGCAGCA GGAAAGACAA AAGAGGGTGT TCTCTATGTA 
121 GGCTCCAAAA CCAAGGAGGG AGTGGTGCAT GGTGTGACAA CAGTGGCTGA GAAGACCAAA 
181 GAGCAAGTGA CAAATGTTGG AGGAGCAGTG GTGACGGGTG TGACAGCAGT AGCCCAGAAG 
241 ACAGTGGAGG GAGCAGGGAG CATTGCAGCA GCCACTGGCT TTGTCAAAAA GGACCAGTTG 
301 GGCAAGAATG AAGAAGGAGC CCCACAGGAA GGAATTCTGG AAGATATGCC TGTGGATCCT 
361 GACAATGAGG CTTATGAAAT GCCTTCTGAG GAAGGGTATC AAGACTACGA ACCTGAAGCC 
421 TAA 
 
8. Amino sequence of α-synuclein A53T 
1   MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVTTVAEKTK 
61  EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP 




9. Coding sequence of α-synuclein H50A 
1   ATGGATGTAT TCATGAAAGG ACTTTCAAAG GCCAAGGAGG GAGTTGTGGC TGCTGCTGAG 
61  AAAACCAAAC AGGGTGTGGC AGAAGCAGCA GGAAAGACAA AAGAGGGTGT TCTCTATGTA 
121 GGCTCCAAAA CCAAGGAGGG AGTGGTGGCT GGTGTGGCAA CAGTGGCTGA GAAGACCAAA 
181 GAGCAAGTGA CAAATGTTGG AGGAGCAGTG GTGACGGGTG TGACAGCAGT AGCCCAGAAG 
241 ACAGTGGAGG GAGCAGGGAG CATTGCAGCA GCCACTGGCT TTGTCAAAAA GGACCAGTTG 
301 GGCAAGAATG AAGAAGGAGC CCCACAGGAA GGAATTCTGG AAGATATGCC TGTGGATCCT 
361 GACAATGAGG CTTATGAAAT GCCTTCTGAG GAAGGGTATC AAGACTACGA ACCTGAAGCC 
421 TAA 
 
10. Amino sequence of α-synuclein H50A 
1   MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVA GVATVAEKTK 
61  EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP 
121 DNEAYEMPSE EGYQDYEPEA 
 
11. Coding sequence of α-synuclein △1-9 
1   ATG_______ __________ _______AAG GCCAAGGAGG GAGTTGTGGC TGCTGCTGAG 
61  AAAACCAAAC AGGGTGTGGC AGAAGCAGCA GGAAAGACAA AAGAGGGTGT TCTCTATGTA 
121 GGCTCCAAAA CCAAGGAGGG AGTGGTGCAT GGTGTGGCAA CAGTGGCTGA GAAGACCAAA 
181 GAGCAAGTGA CAAATGTTGG AGGAGCAGTG GTGACGGGTG TGACAGCAGT AGCCCAGAAG 
241 ACAGTGGAGG GAGCAGGGAG CATTGCAGCA GCCACTGGCT TTGTCAAAAA GGACCAGTTG 
301 GGCAAGAATG AAGAAGGAGC CCCACAGGAA GGAATTCTGG AAGATATGCC TGTGGATCCT 
361 GACAATGAGG CTTATGAAAT GCCTTCTGAG GAAGGGTATC AAGACTACGA ACCTGAAGCC 
421 TAA 
 
12. Amino sequence of α-synuclein △1-9 
1   M________K AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVATVAEKTK 
61  EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP 






13. Coding sequence of α-synuclein △119-126 
1   ATGGATGTAT TCATGAAAGG ACTTTCAAAG GCCAAGGAGG GAGTTGTGGC TGCTGCTGAG 
61  AAAACCAAAC AGGGTGTGGC AGAAGCAGCA GGAAAGACAA AAGAGGGTGT TCTCTATGTA 
121 GGCTCCAAAA CCAAGGAGGG AGTGGTGCAT GGTGTGGCAA CAGTGGCTGA GAAGACCAAA 
181 GAGCAAGTGA CAAATGTTGG AGGAGCAGTG GTGACGGGTG TGACAGCAGT AGCCCAGAAG 
241 ACAGTGGAGG GAGCAGGGAG CATTGCAGCA GCCACTGGCT TTGTCAAAAA GGACCAGTTG 
301 GGCAAGAATG AAGAAGGAGC CCCACAGGAA GGAATTCTGG AAGATATGCC TGTG______ 
361 __________ ________AT GCCTTCTGAG GAAGGGTATC AAGACTACGA ACCTGAAGCC 
421 TAA 
 
14. Amino sequence of α-synuclein △119-126 
1   MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVATVAEKTK 
61  EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPV__ 
121 ______MPSE EGYQDYEPEA 
 
15. Coding sequence of α-synuclein 1-100 
1   ATGGATGTAT TCATGAAAGG ACTTTCAAAG GCCAAGGAGG GAGTTGTGGC TGCTGCTGAG 
61  AAAACCAAAC AGGGTGTGGC AGAAGCAGCA GGAAAGACAA AAGAGGGTGT TCTCTATGTA 
121 GGCTCCAAAA CCAAGGAGGG AGTGGTGCAT GGTGTGGCAA CAGTGGCTGA GAAGACCAAA 
181 GAGCAAGTGA CAAATGTTGG AGGAGCAGTG GTGACGGGTG TGACAGCAGT AGCCCAGAAG 
241 ACAGTGGAGG GAGCAGGGAG CATTGCAGCA GCCACTGGCT TTGTCAAAAA GGACCAGTTG 
301 TAATGA 
 
16. Amino sequence of α-synuclein 1-100 
1  MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVATVAEKTK 









17. Coding sequence of α-synuclein 10-100 H50A 
1   ATG_______ __________ _______AAG GCCAAGGAGG GAGTTGTGGC TGCTGCTGAG 
61  AAAACCAAAC AGGGTGTGGC AGAAGCAGCA GGAAAGACAA AAGAGGGTGT TCTCTATGTA 
121 GGCTCCAAAA CCAAGGAGGG AGTGGTGGCT GGTGTGGCAA CAGTGGCTGA GAAGACCAAA 
181 GAGCAAGTGA CAAATGTTGG AGGAGCAGTG GTGACGGGTG TGACAGCAGT AGCCCAGAAG 
241 ACAGTGGAGG GAGCAGGGAG CATTGCAGCA GCCACTGGCT TTGTCAAAAA GGACCAGTTG 
301 TAATGA 
 
18. Amino sequence of α-synuclein 10-100 H50A 
1  M________K AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVA GVATVAEKTK 
61 EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL 
 
19. Coding sequence of β-synuclein 
1   ATGGACGTGT TCATGAAGGG CCTGTCCATG GCCAAGGAGG GCGTTGTGGC AGCCGCGGAG 
61  AAAACCAAGC AGGGGGTCAC CGAGGCGGCG GAGAAGACCA AGGAGGGCGT CCTCTACGTC 
121 GGAAGCAAGA CCCGAGAAGG TGTGGTACAA GGTGTGGCTT CAGTGGCTGA AAAAACCAAG 
181 GAACAGGCAT CACATCTGGG AGGAGCTGTG TTCTCTGGGG CAGGGAACAT CGCAGCAGCC 
241 ACAGGACTGG TGAAGAGGGA GGAATTCCCT ACTGATCTGA AGCCAGAGGA AGTGGCCCAG 
301 GAAGCTGCTG AAGAACCACT GATTGAGCCC CTGATGGAGC CAGAAGGGGA GAGTTATGAG 
361 GACCCACCCC AGGAGGAATA TCAGGAGTAT GAGCCAGAGG CGTAG 
 
20. Amino sequence of β-synuclein 
1   MDVFMKGLSM AKEGVVAAAE KTKQGVTEAA EKTKEGVLYV GSKTREGVVQ GVASVAEKTK 
61  EQASHLGGAV FSGAGNIAAA TGLVKREEFP TDLKPEEVAQ EAAEEPLIEP LMEPEGESYE 










21. Coding sequence of β-synuclein H65A 
1   ATGGACGTGT TCATGAAGGG CCTGTCCATG GCCAAGGAGG GCGTTGTGGC AGCCGCGGAG 
61  AAAACCAAGC AGGGGGTCAC CGAGGCGGCG GAGAAGACCA AGGAGGGCGT CCTCTACGTC 
121 GGAAGCAAGA CCCGAGAAGG TGTGGTACAA GGTGTGGCTT CAGTGGCTGA AAAAACCAAG 
181 GAACAGGCAT CAGCTCTGGG AGGAGCTGTG TTCTCTGGGG CAGGGAACAT CGCAGCAGCC 
241 ACAGGACTGG TGAAGAGGGA GGAATTCCCT ACTGATCTGA AGCCAGAGGA AGTGGCCCAG 
301 GAAGCTGCTG AAGAACCACT GATTGAGCCC CTGATGGAGC CAGAAGGGGA GAGTTATGAG 
361 GACCCACCCC AGGAGGAATA TCAGGAGTAT GAGCCAGAGG CGTAG 
 
22. Amino sequence of β-synuclein H65A 
1   MDVFMKGLSM AKEGVVAAAE KTKQGVTEAA EKTKEGVLYV GSKTREGVVQ GVASVAEKTK 
61  EQASALGGAV FSGAGNIAAA TGLVKREEFP TDLKPEEVAQ EAAEEPLIEP LMEPEGESYE 
121 DPPQEEYQEY EPEA 
 
23. Coding sequence of β-synuclein △1-9 
1   __________ __________ _______ATG GCCAAGGAGG GCGTTGTGGC AGCCGCGGAG 
61  AAAACCAAGC AGGGGGTCAC CGAGGCGGCG GAGAAGACCA AGGAGGGCGT CCTCTACGTC 
121 GGAAGCAAGA CCCGAGAAGG TGTGGTACAA GGTGTGGCTT CAGTGGCTGA AAAAACCAAG 
181 GAACAGGCAT CACATCTGGG AGGAGCTGTG TTCTCTGGGG CAGGGAACAT CGCAGCAGCC 
241 ACAGGACTGG TGAAGAGGGA GGAATTCCCT ACTGATCTGA AGCCAGAGGA AGTGGCCCAG 
301 GAAGCTGCTG AAGAACCACT GATTGAGCCC CTGATGGAGC CAGAAGGGGA GAGTTATGAG 
361 GACCCACCCC AGGAGGAATA TCAGGAGTAT GAGCCAGAGG CGTAG 
 
24. Amino sequence of β-synuclein △1-9 
1   _________M AKEGVVAAAE KTKQGVTEAA EKTKEGVLYV GSKTREGVVQ GVASVAEKTK 
61  EQASHLGGAV FSGAGNIAAA TGLVKREEFP TDLKPEEVAQ EAAEEPLIEP LMEPEGESYE 







25. Coding sequence of β-synuclein 10-100 H65A 
1   __________ __________ _______ATG GCCAAGGAGG GCGTTGTGGC AGCCGCGGAG 
61  AAAACCAAGC AGGGGGTCAC CGAGGCGGCG GAGAAGACCA AGGAGGGCGT CCTCTACGTC 
121 GGAAGCAAGA CCCGAGAAGG TGTGGTACAA GGTGTGGCTT CAGTGGCTGA AAAAACCAAG 
181 GAACAGGCAT CAGCTCTGGG AGGAGCTGTG TTCTCTGGGG CAGGGAACAT CGCAGCAGCC 
241 ACAGGACTGG TGAAGAGGGA GGAATTCCCT ACTGATCTGA AGCCAGAGGA AGTGGCCCAG 
301 TAGTAA 
 
26. Amino sequence of β-synuclein 10-100 H65A 
1  _________M AKEGVVAAAE KTKQGVTEAA EKTKEGVLYV GSKTREGVVQ GVASVAEKTK 
61 EQASALGGAV FSGAGNIAAA TGLVKREEFP TDLKPEEVAQ 
 
27. Coding sequence of γ-synuclein 
1   ATGGATGTCT TCAAGAAGGG CTTCTCCATC GCCAAGGAGG GCGTGGTGGG TGCGGTGGAA 
61  AAGACCAAGC AGGGGGTGAC GGAAGCAGCT GAGAAGACCA AGGAGGGGGT CATGTATGTG 
121 GGAGCCAAGA CCAAGGAGAA TGTTGTACAG AGCGTGACCT CAGTGGCCGA GAAGACCAAG 
181 GAGCAGGCCA ACGCGGTGAG CGAGGCTGTG GTGAGCAGCG TCAACACTGT GGCCACCAAG 
241 ACCGTGGAGG AGGCGGAGAA CATCGCGGTC ACCTCCGGGG TGGTGCGCAA GGAGGACTTG 
301 AGGCCATCTG CCCCCCAACA GGAGGGTGTG GCATCCAAAG AGAAAGAGGA AGTGGCAGAG 
361 GAGGCCCAGA GTGGGGGAGA CTAG 
 
28. Amino sequence of γ-synuclein 
1   MDVFKKGFSI AKEGVVGAVE KTKQGVTEAA EKTKEGVMYV GAKTKENVVQ SVTSVAEKTK 















trc promoter: base 191-221 
lac operator: base 228-248 
Polyhistidine and enterokinase cleavage site: base 425-504 
Xpress
TM
 Epitope: base 482-505 
Multiple cloning site: base 515-554 








Below is the multiple cloning site and EK cleavage site for pTrcHis A. Synclein is 




413   ATG GGG GGT TCT CAT CAT CAT CAT CAT CAT GGT ATG 




450   GCT AGC ATG ACT GGT GGA CAG CAA ATG GGT CGG  





484   ACT CTG TAC GAC GAT GAC GAT AAG GAT CGA TGG GGA  




521   TCC GAG CTC GAG ATC TGC AGC TGG TAC CAT ATG GGA ATT 
       Ser Glu Leu Glu Ile Cys Ser Trp Tyr His Met Gly Ile 
 
 
Amino sequence of (His)6-aS 
 
MGGSHHHHHHGMASMTGGQQMGRTLYDDDDKDRWGSE 
MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH 
GVATVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL 
GKNEEGAPQE  GILEDMPVDP  DNEAYEMPSE  EGYQDYEPEA 
Polyhistidine (6xHis) region 
Xpress
TM
 epitope EK recognition sequence EK cleavage site 
Xho I Kpn I 
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A: Immunofluorescence staining of SHSY5Y cells expressing pcDNA3.1(-) and 
aS, treated with six different conditions: nontreated media, chelex treated media 
(CM), CM+10µM CuCl2, CM+300µM CuCl2, CM+10µM FeSO4 CM+300µM 
FeSO4, for 48hours. aS was detected using the mouse primary aS antibodyB 
(Zymed Laboratories Inc.). Scale bar represents 10 µm. 
 
B: Immunofluorescence staining of SHSY5Y cells expressing A30P, E46K and 
A53T aS, treated with six different conditions: nontreated media, chelex treated 
media (CM), CM+10µM CuCl2, CM+300µM CuCl2, CM+10µM FeSO4 
CM+300µM FeSO4, for 48hours. aS was detected using the mouse primary aS 
antibodyB (Zymed Laboratories Inc.). Scale bar represents 10 µm. 
 
C: Immunofluorescence staining of SHSY5Y cells expressing H50A aS, aS△1-9, 
and aS△1-9 H50A, treated with six different conditions: nontreated media, 
chelex treated media (CM), CM+10µM CuCl2, CM+300µM CuCl2, CM+10µM 
FeSO4 CM+300µM FeSO4, for 48hours. aS was detected using the mouse 
primary aS antibodyB (Zymed Laboratories Inc.). Scale bar represents 10 µm.  
 
D: Immunofluorescence staining of SHSY5Y cells expressing aS1-100, aS10-100 
H50A and pcDNA3.1(-), treated with six different conditions: nontreated media, 
chelex treated media (CM), CM+10µM CuCl2, CM+300µM CuCl2, CM+10µM 
FeSO4 CM+300µM FeSO4, for 48hours. aS was detected using the sheep 
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0 0 5 - Pos 1 Inject Sample injected 
onto column 
40 0 5 - Pos 1 load Wash column 
with buffer C 
100 0→60 5 1 Pos 1 load Gradient from 
buffer C→D 
20 100 5 1 Pos 1 load Wash column 
with buffer D 

































0 0 5 - Pos 1 Inject Sample injected 
onto column 
100 0 5 - Pos 1 load Wash column 
with buffer A 
200 0→11 5 1 Pos 1 load Gradient from 
buffer A→B 
200 11 5 1 Pos 1 load Wash column 
with buffer B 
400 11→50 5 1 Pos 1 load Gradient from 
buffer A→B 
20 100 5 1 Pos 1 load Wash column 
with buffer B 



























Purification of (His)6-synucleins and their mutants in 12% SDS-PAGE gel.  
    (His)6-A30P aS                     (His)6-E46K aS 







    (His)6- aS                     (His)6-H50A aS 
a  b  c d e  f  g  h  i  j k  l    a  b c  d  e f  g  h  i  j  k l 




A: Lane a, molecular weight standards (kDa); lane b and c, cellular proteins 
before and after (3hours) induction with IPTG; lane d, protein flow through the 
IMAC column; lane e, flow through column after 25 mM imidazole wash; lane 
f-k, fractions eluted with 100 mM imidazole.  
 
B: Lane a, molecular weight standards (kDa); lane b and c, cellular proteins 
before and after (3hours) induction with IPTG; lane d, soluble proteins in urea 
buffer; lane e, protein flow through the IMAC column; lane f, flow through 
column after 25 mM imidazole wash; lane g-l, fractions eluted with 100 mM 
imidazole for (His)6-aS and (His)6-H50A aS, 300 mM imidazole for (His)6-bS and 
(His)6-gS.  
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Purified synucleins and their mutants analyzed in 12% SDS-PAGE. Lane a, 
molecular weight standards (kDa); lane b, aS as control; lane c-p, aS, H50A aS, 
aS△1-9, aS△1-9 H50A, bS, H65A bS, gS, aS△119-126, bS10-100 H65A, bS△







Protein Theoretical isoelectric point (pI) 
aS 4.67 
H50A aS 4.59 
aS△1-9 4.65 
aS△1-9 H50A 4.57 
aS△119-126 4.98 
aS△1-9 H50A aS△119-126 4.85 
aS1-100 9.40 
aS10-100 H50A 9.44 
bS 4.41 
H65A bS 4.35 
bS△1-9 4.40 
bS△1-9 H65A 4.33 
bS10-100 H65A 5.50 
gS 4.97 
 
Isoelectric points of synuclein proteins, calculated from the amino acid 
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